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Immunoglobulin-M (IgM) has been recognized as a diagnostic and therapeutic agent 
and a candidate for stem cell isolation and these have spurred strong interests among 
researchers for its purification. Affinity chromatography, a technique based on the 
principle of molecular recognition, deserves particular attention as it allows for     
several-fold purification of a highly dilute solution in a single step often with a high 
recovery. Despite its potential, the use of affinity chromatography for purification of 
IgMs has been limited due to the unavailability of suitable affinity capture agents. 
Several ligands including C1q, human secretory component, snowdrop bulb lectin, 
mannose binding protein and TG19318 have been investigated. These ligands were, 
however, either non-specific or were isolated from human and animal fluids, 
rendering them unsuitable for biopharmaceutical applications. The present work 
involved designing biomimetic peptidic ligands for affinity purification of IgM at 
high purity and activity.  
Using human polymeric immunoglobulin receptor (hpIgR), a naturally occurring 
protein known for its specific interaction with IgM as template, a systematic approach 
was undertaken to devise novel ligands that showed high specificity for IgM. Two 
peptides, pep12 [ITLI(SSEGY)VSS] and pep14 [CITLI(SSEGY)VSSK], 
incorporating the complementary determining region 2 (CDR2) of Domain 1 (D1) of 
hpIgR, SSEGY, were synthesized. The presence of multiple hydrophobic residues in 
pep14 constituted difficulties in peptide synthesis. An optimized method involving the 
combination of activators, PyBOP and HATU, that facilitated the high production 
yields of peptides was developed. Surface plasmon resonance (SPR) assays were used 
to investigate the interaction of the peptides to immobilized human IgM (hIgM) and 
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human IgG1 (hIgG1). pep12 did not exhibit binding to either of the immunoglobulins 
while pep14 showed specific binding to hIgM. SPR-based binding studies between 
immobilized pep14 and hIgM/ hIgG1/ hIgE/ hIgA1/ bovine serum albumin (BSA) 
suggested no loss in the activity and specificity of pep14 to bind hIgM on 
immobilization. A series of modified peptides, pep13 [ITLI(SSEGY)VSSK], pep5A 
[CITLI(AAAAA)VSSK] and pep14A [CITLI(SSAGY)VSSK], were synthesized and 
investigated for their interaction with hIgM and hIgG1 to obtain an insight into the 
overall binding mechanism of pep14. Cysteine in pep14 was identified to be crucial 
for inducing thiophilic-like interactions between the ligand and hIgM while glutamic 
acid had a significant role in attributing specificity to the ligand to interact with hIgM. 
Circular dichroism (CD) studies were performed to determine the aqueous phase 
structural conformation of the peptides. CD studies suggested the absence of native β-
hairpin structure in pep14. All the ligands exhibited a more flexible conformation 
consisting mainly of a mixture of coil and turn. 
 pep14 was then extensively characterized to evaluate its efficacy as an affinity ligand 
for IgM purification. In order to obtain the best conditions for hIgM binding, the 
mobile phase was optimized. 10 mM HEPES, 150 mM NaCl, pH 7.4 was determined 
to be the optimum binding buffer for pep14-hIgM interaction. Effect of ligand density 
and IgM concentrations (10 μg/mL-300 μg/mL) on the binding characteristics were 
investigated. These studies highlighted the uniqueness of pep14 in capturing hIgM 
even at extremely low concentrations. Exposure of pep14 to a synthetic mixture 
consisting of hIgM, hIgG1 and BSA had no adverse effect on the binding capacity 
and specificity of pep14. SPR-based binding studies between immobilized pep14 and 
fragments of hIgM molecule, namely Fc5µ and Fab, suggested that pep14 was 
binding to a motif in the constant domain 2 of hIgM. Studies were performed to 
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determine the efficacy of immobilized pep14 in isolating IgM molecules derived from 
different species, namely mouse, bovine and rabbit. Rabbit IgM interacted with 
immobilized pep14, though with lower affinity in comparison to hIgM. pep14, 
however, failed to interact with mouse IgM. Bovine IgM showed extensive non-
specific binding to the dextran surface of the CM5 biosensor chip. As a result, no 
conclusive inference could be made for bovine IgM-pep14 interaction. Stability of 
pep14 to common column-sanitizing agents including 20% ethanol, 70% ethanol, 100 
mM sodium hydroxide and 500 mM sodium hydroxide was investigated. Results 
suggested the use of 70% ethanol for rigorous column sanitization while 20% ethanol 
was sufficient for regular cleaning. The above studies collectively established the 
uniqueness of pep14 as a universal affinity ligand for IgM purification.  
During immobilization studies using pep12 on hydrophilic silica matrix, the 
hydrophobicity of the peptide presented challenges, which included: i) pep12 was 
sparingly soluble in the buffers commonly used during conjugation reactions, ii) 
mutual forces of exclusion which arose from the opposing nature of the surfaces of 
the two entities resulted in low immobilization efficiency. A unique method for 
introducing pre-concentration through the use of polyethylene (PEG)-based 
crosslinkers was devised. Immobilization of pep12 to hydrophilic silica matrix at 
three linker densities- 142, 276 and 564 μmole/g of beads, was investigated. The 
results suggested that: i) incorporation of the linker allowed significant improvements 
in the coupling efficiency from 67% (no linker) to 98% (low linker density) ii) a 
decrease in the coupling efficiency resulted from increased linker density. A similar 
approach was used to immobilize pep14 to silica-amine (SA) microspheres. 
Heterobifunctional crosslinker, maleimide-dPEG24-NHS ester (PEG24), containing 
NHS ester at one end and maleimide at the other, was used to facilitate 
 ix 
immobilization. It is important to note that besides serving as immobilization sites, the 
charged surface amino groups on the matrix acted as weak anion-exchangers. 
Acylating agents, acetyl chloride and oxalyl chloride, were investigated as suitable 
quenching agents to selectively block the charged amine functionalities on the matrix 
after linker immobilization. 1H NMR analysis suggested non-reactivity of 
maleimides, present at the linker terminus, to acylating agents. FTIR analysis of SA 
microspheres treated with the acylating agents confirmed the presence of amide 
linkages. Adsorption studies showed that non-specific adsorption of BSA to SA 
microspheres treated with oxalyl chloride and acetyl chloride was reduced by ~95% 
and ~66%, respectively. Since the SA microspheres were soluble in acetyl chloride, 
oxalyl chloride was subsequently used for quenching the free amine moieties on SA 
microspheres after PEG24 immobilization. Successful immobilization of pep14 at a 
coupling efficiency of 34% was achieved. Equilibrium studies were performed to 
determine the equilibrium association constant for the interaction between pep14 and 
hIgM and the (static) binding capacity of pep14-immobilized SA microspheres. The 




 and a binding capacity of 5.9 mg hIgM/g 
of SA microspheres. 
Collectively, these results facilitate the development of a novel chromatographic 
methodology to purify IgM, especially hIgM, on a large scale at high purities and 
yields. The current study demonstrated the uniqueness and competence of biomimetic 
ligands in isolating and purifying large proteins, opening up avenues of research to 
design and develop low molecular weight affinity ligands. This research also allows a 
better understanding of the factors affecting the immobilization of hydrophobic 
peptides to hydrophilic matrices. 
 x 
LIST OF TABLES 
 
Table 2-1 Characteristics of human immunoglobulins     8 
Table 2-2 Properties of human IgM 10 





Contaminants associated with common source materials 
 
Commercially available IgM purification column/ matrix  
  20 
 
 
Table 2-6 Comparison of biospecific and pseudo-biospecific ligands 25 
Table 2-7 De novo designed biomimetic ligands for the affinity  



















Computational tools / equipments / experimental procedures 
and their respective functions 
 
























































Composition of the various buffers used during purification 
 





























Table 4-4 Homology matrix of the constant region domains of human, 


































Comparison of pep14 to biospecific and pseudo-biospecific 
ligands  
 














LIST OF FIGURES 
 







Classification of affinity ligands for chromatographic 














Figure 3-3    
 











Figure 4-2    
 
Structure of the Human Polymeric Immunoglobulin 






Comparison of the deduced amino acid sequences of the 
experimentally interchanged regions A, B and C of human 





Figure 4-4    
 
Schematic diagram of various chimeric domain 1 (D1) 
constructs with a human pIgR backbone (D2–5), and their 
relative binding of I-labeled pentameric-IgM (pIgM) and 
pIgA compared with the relative binding of the two ligands 
to wild-type human or rabbit pIgR (Adapted from Roe et al., 













Secondary structure of hpIgR-D1 as assigned by Stride 




Figure 4-6     
 




Figure 4-7    
 
Representative sensogram for immobilization of hIgM 
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Overlaid reference subtracted sensogram for the interaction 
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The modern age of immunology began in 1890 when Emil von Behring, “The 
Founder of Serum Therapy” and Shibasaburo Kitasato described antibody activity 
against diphtheria and tetanus toxins. Rats, guinea pigs and rabbits were immunized 
with low doses of the infectious agents causing diphtheria and alternatively, tetanus. 
Administration of the sera produced by these animals into non-immunized animals 
infected with the bacteria cured the ill animals. This landmark discovery led to the 
first successful treatment of a child suffering from diphtheria in 1891 (Kornelia,
 
2001). The use of immunoglobulin (Ig) products dates back to 1952 when pooled Igs 
obtained from human plasma were injected intramuscularly to treat immune 
deficiency (Schienfeld and Godwin,
 
2008). At that time, however, Igs separated and 
concentrated from human blood were poorly tolerated when administered 
intravenously. Igs had to be injected intramuscularly in low doses. A major 
breakthrough came when Barandun and coworkers (1962) advocated the need to 
modify Ig preparations to prevent aggregation and thus reduce their serious post-
infusion adverse effects. It was realized that harsh chemical or enzymatic treatment 
could actually denature the molecule and reduce or abolish their natural functional 
ability. 
Since then, advances have been made in purifying and isolating immunoglobulins. 
Today, Igs find vast applications as diagnostic and therapeutic agents. The 
monoclonal antibody (mAb) sector dominates the small molecules market and is the 
highest growth segment within the entire biopharmaceutical industry. With the focus 
of the industry shifting from chimeric and humanized antibodies to fully human 
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antibodies, it has been predicted that the mAbs market will almost triple in value from 
US$ 10.3 billion in 2004 to US$ 30.3 billion in 2010 (Datamonitor, 2005). 
1.1 Applications of IgM 
1.1.1  Therapeutic Agent 
Ongoing efforts to fight life threatening diseases like cancer and AIDS have led to the 
realization of monoclonal IgM as a potential therapeutic agent. Harte et al. (1984) 
performed studies on murine systems and showed that small amounts of specific 
monoclonal IgM could specifically enhance the response to a blood-stage murine 
malaria vaccine. These studies opened up avenues for the probable use of (specific) 
monoclonal IgM as a potent adjuvant in human malarial vaccination. Natural IgMs 
found in the serum of healthy humans have been highly effective in arresting the 
growth of established human neuroblastomas (NB) engrafted into rats (David et al., 
1996). The anti-NB activity of injected cytotoxic IgM was reported to persist for 
several weeks after infusion. Such a finding is important particularly in the United 
States where NB accounts for approximately 7.8% of childhood cancers, which is 
approximately 9.5 cases per million children (Lacayo and Marina, 2007). Ongoing 
efforts saw PAM-1, a fully human IgM antibody being identified as an ideal tool for 
the diagnosis and treatment of the precancerous and cancerous epithelial lesions of the 
breast and the prostate (Brandlein et al., 2004). Work by Irie et al. (2004) led to the 
successful development of a 100% human monoclonal IgM protein (L612 HumAb), 
infusion of which had produced significant antitumor activity in patients with 
metastatic melanoma. [L612 consists of hexameric IgM (about 20%), pentameric IgM 
(pIgM) (about 74%) and other minor IgM molecules]. Irie and co-workers 
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documented that out of the nine patients involved in their study, after mAb infusion 
followed by surgical therapy, two patients were without any signs of disease even 
after five years of treatment. mAb 216, a naturally occurring human IgM, can 
efficiently bind and kill acute lymphoblastic leukemia B-progenitor lymphoblasts 
(Bieber et al., 2007). mAb 216 exhibited an enhanced degree of cytotoxicity when 
introduced in combination with vincristine, a chemotherapeutic agent. mAb 216, 
alone, and in combination with vincentrine are currently under Phase I clinical trials. 
Studies performed by Vollmers et al. (1998) established SC-1, an IgM of human 
origin, as a promising neo-adjuvant therapeutic agent for gastric cancer. IgM 
monoclonal antibodies continue to attract increasing interest, especially in the field of 
cancer therapeutics. This is largely due to their ability to easily discriminate 
glycosylation variants on key antigens that are either unrecognized or poorly 
recognized by IgG (Gagnon et al., 2010). 
Although most of the therapeutic IgM products are either in laboratory or clinical 
trials, the above studies clearly point to the role of monoclonal IgMs as potential 
therapeutic agents. Incidentally, the world‟s first and only IgM-enriched intravenous 
immunoglobulin (IVIGMA) preparation is now available from Biotest, sold under the 
commercial name Pentaglobin.  Owing to its IgM content, Pentaglobin has been found 
to be unique in the elimination of infectious pathogens and neutralization of endo- and 
exo-toxins, far more superior than normal IgG preparations. 
1.1.2 Disease Diagnosis 
Detection of specific IgM antibodies in the sera of patients has been widely used as an 
early and sensitive diagnostic tool for many infectious diseases. Commonly used 
serology techniques like enzyme-linked immunosorbent assay (ELISA), 
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immunofluorescence and precipitation have undergone significant modifications over 
time. Accurate analysis of antigen-specific IgM antibodies can now be performed 
allowing reliable diagnosis of diseases including legionnaires‟ disease (Zimmerman et 
al., 1982), Mycoplasma Pneumoniae infection (Samra and Gadba, 1993), viral 
diseases like measles, rubella, mumps and M. parainfluenzae (Bringuier et al., 1978), 
dengue (Sathish et al., 2003), enteroviral meningitis (Climaker et al., 1992), 
rickettsial disease (Vene, 1989) and cytomegalovirus disease in AIDS patients 
(Boibieux et al., 1992). 
1.1.3 Stem Cell Research 
Cowen and Melton (2006) defined stem cells as “a clonal, self renewing entity that is 
multipotent and can thus generate into several differentiated cell types”. Stem cells 
offer enormous potential as therapeutic agents for curing and treating a wide range of 
human diseases by replacing the existing damaged/diseased host cells. Human body is 
known to contain many different types of stem cells but in minute quantities. The 
surface of each stem cell is coated with unique specialized proteins, called receptors 
or stem cell markers [1]. Developing monoclonal antibodies that can be directed 
against these cell surface receptors can allow the isolation of stem cells. In this 
regards, specific IgMs have been identified which can be directed towards CD15, 
SSEA-1, CDw93 and CD24 stem cell markers, thus opening up completely new 
avenues for research [2]. 
In addition, IgMs have also been used for immunological identification of proteins 
(the Western blot method) and detection of cell secretions [the EISPOT and ELISA 
assays (New World Encyclopedia)]. 
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1.2 IgM Purification  
In order to fully exploit the potential of IgM, large quantities in a highly pure and 
active form must be available for performing clinical trials, characterization studies 
and quantitative-structure activity analyses. In the commercial development of 
biotherapeutics, downstream processing accounts for 50% to 80% of the total 
manufacturing costs (Roque et al., 2007). Elimination of even one of the steps in the 
downstream cycle can significantly reduce operating costs. Cutting downstream 
processing costs would result in reduced treatment costs allowing greater accessibility 
and acceptance of the therapy and finally greater revenues. Traditional approaches for 
purification of IgM have been based on a combination of techniques such as 
precipitation, chromatography and electrophoresis. These methods, however, suffer 
from several serious drawbacks. These techniques are non-specific in their binding 
and thus vulnerable to cross-contaminations. A one stage separation approach has 
been inadequate in providing highly pure IgMs. Multi-step procedures are currently 
adopted, which increases the total cost and time for downstream processing. On the 
other hand, affinity chromatography which is based on biomimetic and biospecific 
ligands, involves specific, reversible and non-covalent interactions between an 
immobilized ligand and the target protein for purification. This technique can be used 
to separate active biomolecules from denatured or functionally different forms, to 
isolate pure IgMs present at low concentration in large volumes of crude sample and 
also to remove specific contaminants [3]. Though highly promising, the application of 
affinity chromatography is limited by the availability of suitable affinity capture 
agents. A comprehensive literature review revealed the application of mannose 
binding protein (MBP) (Nevens et al., 1992), snow drop bulb lectin (Shibuya et al., 
1988), protamine (Wichman and Borg, 1977), C1q (Nethery et al., 1990) and the 
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human polymeric immunoglobulin receptor (hpIgR) (Jones et al., 1987) for 
purification of IgMs. These natural IgM binding proteins, however, are not directly 
amenable for use in affinity chromatography. They suffer from a number of 
disadvantages including high cost of production, their biological origin (they have to 
be isolated from human and animal fluids), the requirement for accurate analytical 
tests to ensure the absence of toxic contaminants and the poor stability to cleaning and 
sanitizing agents (Roque et al., 2004). All these result in their incompatibility with 
industrial scaling up. 
1.3 Research Objectives and Scope 
The objective of this research was to develop an affinity-based chromatographic 
method for the purification of IgM.   
Specifically, the research programme comprised the following: 
A. Design a „universal‟ biomimetic peptidic ligand with specificity to interact with 







 is desirable) and negligible affinity for other proteins. 
B. Obtain an insight into the binding mechanism of the biomimetic ligands to IgM. 
C. Investigate the suitability of the peptide as an affinity ligand for 
chromatographic purification of IgM. 
D. Develop a coupling methodology that would allow for site-directed 
immobilization of the hydrophobic biomimetic ligand to the hydrophilic 
chromatographic matrix at high efficiencies.  
E. Identify a strategy to minimize non-specific interactions between the 
chromatographic matrix and the proteins present in the feed. 
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This research sought to make contributions towards the development of a novel 
chromatographic methodology to purify IgM on a large scale at high purities and 
yields. It would serve to demonstrate the potential of biomimetic affinity peptides in 
the purification of large molecules like IgM. The programme also serves to make 
significant inputs to the existing knowledge on immobilization of hydrophobic ligands 
to hydrophilic matrices. 
1.4 Thesis Organization 
This thesis comprises six chapters. Chapter 1 provides a brief introduction to the topic 
and outlines the research objectives. Published literature on IgM structure, IgM 
purification and the characteristics and application of biomimetic ligands in the 
purification of biomolecules will be extensively reviewed in Chapter 2. Chapter 3 
details the materials and methods used in this research. Chapter 4 encompasses three 
sub-chapters: Chapter 4.1 describes the approach undertaken to design the biomimetic 
affinity ligand for IgM purification followed by a detailed study to determine the 
binding mechanism of the biomimetic peptide to IgM. Ligand synthesis methodology 
and characterization studies to investigate the suitability of the peptide as an affinity 
ligand are presented in Chapter 4.2. Chapter 4.3 discusses the results obtained for the 
various immobilization strategies investigated to couple hydrophobic peptidic ligands 
to hydrophilic matrices. Studies were conducted to minimize non-specific interaction 
of proteins to the chromatographic matrix. Finally, Chapter 5 summarizes the 
important findings and conclusions and describes several recommendations for future 
work. Some preliminary results obtained for the synthesis of domain 1 of human 
polymeric immunoglobulin receptor (hpIgR-D1), a potential biomimetic ligand for 
IgM purification, are also presented in Chapter 5. 




2 LITERATURE REVIEW 
This chapter begins with an introduction to the structure of IgM followed by a 
detailed review on the various approaches currently employed for IgM purification. 
The advantages and disadvantages associated with the different approaches will be 
presented. A discussion on biomimetic ligands, the strategies to design these ligands 
and their application in the purification of biomolecules then follows. The future of 
IgM purification is presented elaborating on the areas that require attention and 
additional contributions.  
2.1 Structure of IgM 
Turner (1981) defined Igs as “a family of structurally dynamic glycoproteins 
responsible for foreign body recognition and isotope elimination”. Based on the 
differences in the constant region of the heavy chains, Ig molecules can be classified 
into five different classes: IgG, IgM, IgA, IgD and IgE. Table 2-1 summarizes the 
characteristics of human Igs (Hamilton, 1997). 
            Table 2-1 Characteristics of human immunoglobulins 
Isotype M.W. (kDa) Occurrence 
% of total serum 
immunoglobulin 









IgD 180 Monomer 0.2 












Perkins and Nealis (1991) have investigated the pentameric structure of human and 
mouse IgM by synchrotron X-ray solution scattering and molecular graphics 
modeling (Figure 2-1). 
 
Figure 2-1 Structure of pentameric IgM (Adopted from Perkins et al., 1991) 
Studies performed on IgM and the four fragments of IgM: the IgM-S monomer, the 
Fc5 central disc, the Fab‟2 arm and the Fab fragment, suggested that the IgM structure 
is essentially planar, with tip-to-tip distance between diametrically opposite Fab arms 
to be approximately 36 nm (Perkins et al., 1991). IgM dominantly exists as a 
pentamer, consisting of five identical subunits of about 180 kDa. Each monomer is a 
"Y"-shaped molecule that consists of four polypeptide chains; two identical heavy 
chains and two identical light chains connected by disulfide bonds. The heavy chain 
consists of one variable (VH) and four constant (Cµl, Cµ2, Cµ3 and Cµ4) domains 
while the light chain consists of one variable (VL) and one constant (CL) domain. Each 
domain has a similar structure consisting of two beta sheets packed tightly against 
each other in a compressed anti-parallel beta barrel. The immunoglobulin fold of a 




constant domain consists of a 3-stranded sheet packed against a 4-stranded sheet. 
Several forces contribute towards the stabilization of the fold structure including 
hydrogen bonding between the beta strands of each sheet, hydrophobic forces 
between residues of opposite sheets in the interior and disulfide bonding between the 
sheets. The folds of a variable domain contain nine beta strands as compared to seven 
in a constant domain fold. These are arranged in two sheets of 4 and 5 strands, 
respectively (Hamilton, 1997; [4]). Pairs of heavy chains are disulphide-linked 
between the Cµ2 and Cµ3 domains and the light chains are disulphide-linked to the 
Cµl domain. Adjacent Cµ3 domains are cross-linked by Cys-Cys disulphide bridges 
as are the adjacent Cµ4 domains (Perkins et al., 1991). In addition to the 70 
immunoglobulin fold domains, the pentameric IgM molecule also contains an 
additional domain, the J or joining chain, with a molecular weight of about 15 kDa 
(Hamilton, 1997). Table 2-2 provides an indication of the physical properties of the 
human IgM molecule (Perkins and Nealis, 1991; Gagnon et al., 2008).  
Table 2-2 Properties of human IgM 
No of residues 7926 
Sedimentation coefficient (S20,w) 17.7 
Carbohydrate ( % by weight) 10 
Biological survival (plasma half life) 5 days 
Diffusion coefficient (cm
2
/sec) 2.6 × 10
-7
 
Molar extinction coefficient (polyclonal) 1.18 
 




2.2 IgM Purification 
Various techniques, either alone or in combination, have been investigated for the 
purification of IgMs.  
2.2.1 Precipitation 
When added at appropriate concentrations, polyethylene glycol
 
(PEG), which is non-
ionic and water-soluble, can cause proteins
 
to precipitate from solution. Neoh et al. 
(1986) employed this technique for purifying mouse monoclonal IgMs from ascitic 
fluid. The technique was successful in providing high yields (~ 80%) but the low IgM 
purity (~90%) reciprocated the need to employ additional purification steps. Gonzalez 
et al. (1988) took the approach of euglobulin precipitation for purifying murine IgG3 
and IgM monoclonal antibodies from ascitic fluid. IgM recovery was less 
reproducible, varying from 40% to 90%. HPLC and radial immuno-diffusion analyses 
showed the presence of IgG contaminants in the purified IgM preparations. Along the 
same lines, Tatum (1993) illustrated the use of a three stage precipitation approach for 
purifying IgM from human plasma obtained by therapeutic plasmapheresis. The first 
stage involved the removal of lipoproteins and fibrinogen by subjecting the plasma to 
a saturated ammonium sulfate (SAS) solution (final concentration 30%), followed by 
immunoglobulin recovery by precipitation with SAS (final concentration 50%). 
Subsequent PEG precipitation of the recovered immunoglobulin fraction led to the 
selective removal of IgM from IgG. The method was effective in handling large 
volumes of the starting material with yields ranging from 65 to 80%. An IgM purity 
of 95% with contaminations from small quantities of IgG, IgA and albumin has been 
documented.  




Precipitation techniques, though simplistic in approach, are slow, non-reproducible, 
non-specific in nature and prone to aggregational losses. Partnership with 
chromatographic methods to attain higher purities is often tried but necessitates an 
increase in the total cost and time of purification. 
2.2.2 Chromatographic Techniques 
Chromatographic techniques are either group-specific in nature, exploiting general 
properties of ionic charge, size or hydrophobicity or are specific to the biochemical 
and biological properties of the target. 
2.2.2a Non-affinity Chromatographic Methods 
Table 2-3 summarizes research encompassing non-affinity type chromatographic 
methods for IgM purification.  
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*NA: Not Available             a  Anion Exchange Chromatography        
b  Hydroxylapatite Chromatography                   c  Thiophilic Adsorption Chromatography    
d  Hydrophobic Interaction Chromatography            e  Cation Exchange Chromatography 
Chromatographic techniques like ion exchange chromatography (IEC), hydrophobic 
interaction chromatography (HIC), hydroxylapatite chromatography (HAC), 
thiophilic adsorption chromatography (TAC) and dye ligand chromatography exploit 
the differences in charge, hydrophobicity and interaction ability with hydroxylapatite, 
thiophilic adsorbent and dye, respectively, for protein purification. These techniques 
are non-specific in their binding and thus vulnerable to cross-contaminations. As 
evident from Table 2-3, a single-stage purification approach has been inadequate in 
providing highly pure IgMs.  




HAC, a mixed mode ion exchange technique, has been quite popular among 
researchers (Stanker et al., 1985; Harshman, 1989; Josic et al., 1991; Tornoe et al., 
1997; Gagnon et al., 2008). Use of mild elution conditions during HAC preserves the 
activity of labile molecules like IgM. However, use of low ionic strength solutions for 
sample preparation and column equilibration can cause IgM precipitation and 
aggregation. Josic et al. (1991) showed almost complete precipitation of IgMs when 
applied to hydroxylapatite column at low ionic concentrations (30 mM sodium 
phosphate, pH 6.8). To overcome these problems, addition of 0.1 M sodium chloride 
to the buffers was suggested. Hydroxylapatite suffers from high risks of microbial 
contamination leading to non-reproducible separations and short column life (Josic et 
al., 1991). Column regeneration problems have been reported and use of fresh 
hydroxylapatite for every batch has been recommended (Tornoe et al., 1997). 
Immobilized pseudo-ligand Cibacron Blue F3GA has been investigated by Johnson et 
al. (1986/1987) for isolation of IgM from murine ascitic fluid. Though considerable 
recoveries were achievable, the purified fraction was found to be contaminated with 
haptoglobin, transferrin and albumin. The non-specific nature of the dye-ligand thus 
necessitated the use of an additional stage of gel filtration. Acetate buffer at pH 5 was 
used for the dialysis of ascitic fluid, for column wash and protein elution. Extensive 
exposure to such low pH values can have a deteriorating impact on IgM activity. 
Furthermore, extremely long purification time of more than 3 days was required to 
process 1.8 mL of ascitic fluid.  
Immobilized pseudo-ligand „T Gel‟, a thiophilic adsorbent, has not been very 
promising either. The method suffers from low recoveries associated with activity 
losses of IgM on adsorption to the chromatographic adsorbent (Belew et al., 1987). 




Modified sulfone-aromatic ligands as thiophilic adsorbents were introduced by 
Knudsen et al. (1992). Low purities (~70%) and low adsorption capacities of 1-1.5 
mg/mL limit their suitability for large scale IgM isolation. 
Owing to the large size of IgMs in comparison to other impurities, size exclusion 
chromatography (SEC) has been used effectively to purify IgMs. However, low 
loading capacity ranging from 2-5% of the total column volume limits its use for large 
scale application. Increasing operational velocities or sample loading can have 
detrimental impact on peak resolution (Josic and Lim, 2001). It is a well known fact 
that SEC exploits the difference in the hydrodynamic volume of proteins for 
separation efficiency. No interactions occur between the proteins and the column 
media. However, an unusual gel filtration technique in which IgMs were actually 
made to interact with the media was demonstrated by Bouvet and Pires (1991). The 
separation was based on introducing ascitic fluid to an SEC column equilibrated with 
a low ionic strength buffer (0.005 M phosphate buffer) followed by a rinse with a high 
ionic strength buffer (0.05 M phosphate, 2 M NaCl). The protocol prolonged the stay 
of IgMs in the column, preventing its elution before albumin, α2 macroglobulin and 
other serum proteins. The method was successful in providing pure IgM with yields 
ranging from 50% to 80% for the sixteen euglobulin monoclonal IgMs tested. 
Multi-step procedures have often been adopted for IgM purification, however, 
multistep procedures are expensive, time consuming and often results in low IgM 
recoveries. Most of the drawbacks associated with the conventional techniques can be 
overcome through the use of techniques like affinity chromatography that involve 
specific interactions with IgM.  
 




2.2.2b  Affinity-based Separation 
Affinity chromatography is a technique based on molecular recognition. The specific 
nature of interaction facilitates the removal of contaminating proteins allowing large 
purity gains in a single step. In addition, the method allows for the separation of 
active IgM biomolecules from denatured or functionally different forms [3]. One of 
the earliest approaches for affinity purification of IgM was based on the adsorption of 
IgM to protamine-Sepharose matrix (Wichman and Borg, 1977). Wichman and Borg 
proposed that the binding was likely electrostatic in nature involving the binding of 
several Fc parts of IgM to suitable portions in protamine. IgA, ceruloplasmin, α2-
macroglobulin among some other serum proteins, were present as contaminants in the 
protamine-Sepharose eluted fraction. Two additional stages of gel filtration 
chromatography had to be conducted to attain 98% pure IgM with a 30% yield. The 
biggest drawback of this technique was probably protamine‟s incompetency to 
specifically bind only IgM. 
Human secretory component (SC), a 75 kDa protein isolated from human milk whey, 
has been evaluated as an affinity adsorbent for IgM purification (Jones et al., 1987). 
Cell culture supernatants of murine and rat hydridomas were purified by the affinity 
matrix. SC specifically bound all polymeric immunoglobulin (IgMs and IgAs) derived 
from different species but did not bind to monomeric or aggregated monomeric 
immunoglobulins, making the process species independent and free from any 
contamination with IgGs. However, generation of pure SC was a cumbersome process 
in itself, involving: i) affinity chromatography using human pentameric IgM-
Sepharose matrix ii) gel filtration chromatography and iii) immuno-affinity 
chromatography using Sepharose anti-human IgA adsorbent. 




Shibuya et al. (1988) advocated the use of a mannose-specific snowdrop (Galanthus 
nivalis) bulb lectin, GNA, as an affinity ligand for IgM purification. GNA coupled to 
Sepharose 4B was employed for purification of IgM from two sources: murine 
hybridoma serum and human serum. The ligand showed high specificity to bind 
murine IgM with no affinity for IgG. The elution of bound IgMs was achieved using 
methyl α-D-mannoside which was costly and impractical for large scale application. 
In addition, the ligand failed to bind human IgMs when human serum was subjected 
to affinity chromatography.  
Use of affinity chromatography for purifying an antigen-specific IgM has also been 
seen in the works of Hibma and Griffin (1990). The technique was highly specific in 
its approach and could not be used to purify all IgMs. Complement protein C1q for 
IgM purification was investigated by Nethery et al. (1990). The purification strategy 
was based on an 18-fold higher affinity of C1q to bind IgM over monomeric IgG. The 
affinity adsorbent strongly bound IgM at 5 ºC while pure IgM was eluted 
isocratically, after two hours of column incubation at room temperature, with the 
column buffer. Isolation of IgM was based on a temperature-dependent interaction 
with no involvement of harsh elution conditions. This served to preserve the immuno-
activity of the IgM molecule. However, the method suffered from low binding 
capacity of 0.4 mg of IgM/mL of gel and product contamination with IgG.  
Nevens et al. (1992) described a method for affinity purification of monoclonal IgM 
utilizing immobilized MBP. MBP, a 650 kDa protein, was isolated from rabbit serum. 
Purification of IgM was temperature and calcium ion dependent. Binding was 
performed at 4 °C in a buffer that contained calcium chloride. Elution was achieved at 
room temperature in a buffer that contained ethylenediaminetetraacetic acid (EDTA) 




in the absence of calcium ions. A binding capacity of nearly 1 mg IgM/mL of support 
has been reported. The affinity matrix was shown to possess the ability to isolate 
IgMs from different species, including mouse, human and bovine, but with varying 
efficiencies. IgMs isolated from ascitic fluid were purer than those obtained from 
serum purification. The method, though highly effective in preserving the biological 
activity of IgMs, suffered from low binding capacity. 
Palombo et al. (1998) used a synthetic ligand PAM (Protein A mimetic, TG19318) for 
affinity purification of IgM from serum, ascitic fluid and cell culture supernatant. 
TG19318 is a low molecular weight peptide consisting of four identical tripeptide 
chains linked to a central polylysine core. The ligand was selected through the 
synthesis and screening of a multimeric peptide library. Palombo and coworkers 
reported a purity of 85-95% when isolating monoclonal IgMs. The advantages offered 
by TG19318 were worthwhile although its use as an affinity ligand for IgM 
purification was probably limited by the fact that the molecule bound not only to IgM 
but also to IgG, IgA, IgE and IgY. The effectiveness of affinity purification relies on 
the ability of an affinity adsorbent to recognize specifically the molecule of interest. 
In the case of the use of TG19318 for purification of IgM from sera and culture 
supernatants, the purified fraction could be contaminated with extraneous antibodies 
present in the feeds. At this point, it is noteworthy to mention that the choice of source 
material can affect the choice of techniques for sample preparation due to the 
differences in specific contaminants and the quantity of target molecule required [5]. 
Table 2-4 summarizes the contaminants associated with some of the most common 
options.  
 




Table 2-4 Contaminants associated with common source materials (Adopted 
from Antibody Purification Handbook, GE Healthcare [5]) 
 Major Contaminants 
Source: Native  
Human serum 
Albumin, transferrin, α2-macroglobulin, 
other serum proteins 
Hybridoma: cell culture supernatant 
with 10% fetal calf serum 
Albumin, transferrin, bovine IgG, α2-
macroglobulin, other serum proteins, viruses 
Hybridoma: cell culture supernatant 
serum free  
Albumin, transferrin (often added as 
supplements) 
Ascites fluid 
Lipids, albumin, transferrin, lipoproteins, 
endogenous IgG, other host proteins 
Source: Recombinant  
Extracellular protein 
Proteins from the host, e.g. E. coli. In 
general low level of contamination 
2.2.2c Immuno-affinity Chromatography 
As early as 1973, one of the articles on IgM purification described the application of 
antisera (containing anti-γ, anti-α, anti-α2-macroglobulin and anti-complement) as 
immuno-adsorbents to obtain pure IgM from Cohn fraction III of normal human 
plasma (Hoven et al., 1973). Immuno-affinity approaches based on anti-IgMs as 
ligands have been described by Cripps et al. (1983) and Huschka et al. (1982). Use of 
antisera as immuno-adsorbent posed practical limitations on the use of this technique 
for large scale purification. Generation of large amounts of purified immuno-
adsorbent required large quantities of highly pure antibodies, antithesis to the very 
task at hand to purify IgMs. In addition, high affinities associated with immuno-
affinity chromatography could result in incomplete column regeneration and thus 
reduced capacity. The use of harsh elution conditions could also denature the 
biomolecules, adversely affecting their biological activity. Cripps et al. (1983) and 
Huschka et al. (1982) used 3 M sodium thiocyante (NaSCN) for eluting the bound 




IgMs from the immuno-adsorbent. This was contrary to the results reported by Lim 
(1987) who showed complete loss of IgM activity on exposure to 3 M KSCN. 
2.3 Commercially Available IgM Purification Columns 
Over the last few years, the commercial market has seen an increase in the number of 
companies offering solutions to IgM purification. Some of these product details are 
tabulated in Table 2-5. Ligands from Pierce Biotechnology, Immunopure and 
Ultralink, though highly selective in their binding to IgM suffer from low binding 
capacities. The large size of the ligand makes it susceptible to denaturation on 
exposure to cleaning and in situ sterilization conditions. In addition, isolation of the 
ligand is costly and labor intensive. Application of thiophilic adsorbents (TA), HiTrap 
(GE) and Thiosorb M (Millipore), is associated with mild elution conditions. 
However, the non-specific nature of the adsorbent allows the capture of all Igs. 
Incidentally, application of TAs is best suited for removal of Igs from hybridoma cell 
culture media. FastMAbs A from Upfront Chromatography A/S is a non-peptidic 
mixed mode chromatographic ligand. The binding of Igs to FastMabs A is performed 
at pH 4.5-5.5. Elution of the bound antibody is performed by changing the pH to 7. 
However, FastMabs are known to bind all IgG subclasses, making it a non-specific 
ligand (Limhe et al., 2000). Kaptiv-M is based on the sequence (RTY)4K2KG 
(TG19318). As discussed earlier, TG19318 is non-specific and binds all 
immunoglobulins. It is noteworthy that many companies offer affinity-based 
purification products. This reflects the significance of affinity-based chromatographic 
methods for IgM purification. 
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2.4 Biomimetic Affinity Chromatography: An Overview 
Due to increasing process economic pressures, monoclonal antibody producers are 
now reconsidering their manufacturing options. As described earlier, precipitation and 
non-affinity chromatographic techniques are non-specific in nature; requiring multi-
step purification processes for IgM manufacture. On the other hand, affinity 
chromatography, a technique based on molecular recognition, involves specific, 
reversible and non-covalent interactions for protein purification. The specific nature 
of binding facilitates increased operational yield and elimination of undesirable 
contaminants allowing several fold purification in a single step (Roque et al., 2007).  
Ligands described in section 2.2 for IgM purification belong to one of the two broad 
groups of affinity ligands: biospecific or pseudo-biospecific ligands. As described by 
Roque and Lowe (2006), “Biospecific ligands are naturally-occurring molecules with 
affinity for the target protein binding site. Pseudo-biospecific ligands, on the other 
hand, can be biological or non-biological in nature and can interact with the target 
protein but do not occur naturally in biological systems”. Figure 2-2 introduces the 
various members belonging to the two groups.   
Biomimetic ligands belong to a new class of pseudo-biospecific ligands that are tailor-
made to mimic the binding dynamics of a naturally-occurring protein-based ligand. 
When introduced, biomimetic ligands were considered as an upgrade of textile dye 
ligands. However, the concept is no longer limited to synthetic biomimetic dyes and 
triazine non-dye ligands (designed de novo ligands), but also includes peptides and 
minimized protein domains (Roque et al., 2004). Among the various ligands 
described for IgM purification, C1q, snowdrop bulb lectin, SC and MBP are 




biospecific ligands while TG19318 falls in the category of biomimetic ligands. Table 
2-6 compares the property of the different affinity ligands. 
 
 
Figure 2-2 Classification of affinity ligands for chromatographic application 
(Adopted from Roque et al., 2006) 
Naturally-occurring protein-based ligands (biospecific ligands) suffer from a number 
of disadvantages including i) their isolation from biological sources is expensive, time 
consuming and labor intensive ii) owing to their biological origin, additional 
analytical testing is required to ensure the absence of toxic contaminants in the final 
purified product iii) the ligands exhibit poor stability to cleaning and sanitizing agents 
(Roque et al., 2004). All these result in their incompatibility with industrial scaling 
up, rendering them unsuitable for biopharmaceutical applications.  
Roque and Lowe (2006) described biomimetic ligands as “tailor-made, low molecular 
weight molecules that are designed to mimic the recognition between a target protein 
and a natural biological ligand”. Low cost of production, increased stability to 
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chemical and biochemical degradation, moderate binding affinities and absence of 
regulatory issues owing to its synthetic nature makes synthetic mimic ligands a viable 
alternative to naturally occurring biospecific ligands (Roque et al., 2007; Sines and 
Velander, 2000). Use of biomimetic ligands thus presents an appealing option for 
downstream processing of proteins. Biomimetic ligands can be classified broadly into 
two classes: biological and non-biological. While peptides and protein domains fall 
into the category of biomimetic biological ligands, the de novo ligands and designed 
dyes are classified as non-biological.  
Table 2-6 Comparison of biospecific and pseudo-biospecific ligands (Adopted 
from Roque et al., 2004) 
Properties 
     Biospecific                       Psuedo-biospecific                                          
                                        Non-mimetic            Biomimetic 
Specificity 
























Selectivity Very High Low to medium High 
Capacity Low High High 
Product Elution Difficult Mild Mild 
Stability Low Very high 
High to very 
high 
Toxicity High Low Low 
Cost High Low Low 
2.4.1  Non-biological Biomimetic Ligands 
A number of chemically synthesized, low molecular weight compounds, mimicking 
the action of biologics have been generated for protein purification. The availability 
of structural information of proteins and complexes through the application of 
crystallographic and NMR techniques and the advancements in computer-based 
molecular modeling techniques have prompted the de novo rational design of affinity 




ligands for several proteins (Roque and Lowe, 2006). Crystallographic, nuclear 
magnetic resonance (NMR) data can be strategically employed to determine a 
potential binding site on the target protein. This information is applied for the design 
of a structure-based combinatorial library, followed by solid-phase synthesis of 
ligands with screening in parallel to generate de novo mimetics for proteins (Lowe et 
al., 1992; 2001). Lowe and co-workers are pioneers in de novo ligand design and 
synthesis of triazine-scaffolded affinity ligands for the purification of different target 
proteins. Table 2-7 summarizes the design approach for some of the de novo designed 
ligands for protein purification. It is not easy and sometimes not even possible to 
crystallize and study the ligand-protein complex. With the introduction of advanced 
software packages for molecular graphics, obtaining three-dimensional structural 
information has become easier and can be exploited for routine ligand design. 
Molecular modeling and bioinformatics have been employed for the design of 
biomimetic dye-ligands for the purification of proteins (enzymes) including L-malate 
dehydrogenase (Labrou et al., 1996a, 1996b) and L-lactate dehydrogenase (Labrou 
and Clonis, 1999).  
Extensive literature is available describing the use of ligands derived through 
screening combinatorial libraries for protein purification. However, most of the 
identified ligands exhibit non-specific binding behavior, recognizing all 
immunoglobulin isotypes. This necessitates the use of alternate ligand design 









Table 2-7 De novo designed biomimetic ligands for affinity purification of 
proteins (Adopted from Roque et al., 2006) 
Protein 
Purified 





Complex kallikrein/ kininogen; 
ligands designed to mimic Phe-








Complex Staphylococcal protein 
A (SpA)-IgG; ligands designed 
to mimic the Phe132–Tyr133 
dipeptide on SpA 
Solution-phase 
synthesis 
(Li et al., 
1998) 
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et al., 2000) 
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2.4.2 Biological Biomimetic Ligands 
Recent years have seen a surge in the application of peptides and protein domains for 
protein purification. Peptidic ligands generally comprise less than 30 amino acid 
residues and assume multiple solution conformations. Considerable literature is 
available on the application of biomimetic peptidic ligands for protein purification 
(Table 2-8), with only a few on the use of protein domains. 
Table 2-8 Peptidic ligands for protein purification 
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1 
b indicates a peptide boronic acid 
2 Ψ(PO2
-




Ac = Acetyl 
4 
c indicates cyclic chain of amino acids 
5 
Cha is the unnatural amino acid β-cyclohexyl-L-alanine 
6
 (3-IAA) = 3-Indolylacetic Acid 
7 (CH2NH) indicates that the peptide bond (CONH) has been replaced by the     
(CH2NH) 
8 






(Note: All modifications that are non-peptidic are highlighted in italics) 
 




2.4.3 Commercially Available Biomimetic Ligands 
The application of biomimetic ligands for large scale affinity purification helps 
overcome the drawbacks associated with the natural proteins. Being more stable, less 
immunogenic and less expensive, biomimetic ligands have garnered attention as 
potential alternates to protein-based ligands. The use of high throughput screening 
techniques, sometimes combined with molecular modeling, has generated new small 
ligands for protein purification (Yang et al., 2005). Some of these ligands have been 
extensively studied and are already commercialized. Table 2-9 lists two biomimetic 
ligands that have found commercial applications. 
MAbsorbent A2P consists of immobilized artificial Protein A (ApA) ligand, 22/8, that 
is known to mimic the IgG binding site of Protein A using triazine framework 
substitutions. Li et al. (1998) described the use of ApA for purifying IgG from human 
plasma and ascitic fluid, with purity of eluted IgG close to 98%. Both pH and ionic 
strength were found to have a significant effect on ApA-IgG binding. Increase in salt 
concentrations had a positive effect, enhancing the interaction between ApA and IgG. 
This could possibly be because the binding between the two entities was stabilized 
predominantly through hydrophobic interactions. MAbsorbent A2P bound all sub-
classes of IgG and depending on the IgG isotype, the capacity of the derivatized 
support ranged from 5 to 12 mg IgG/mL of support. Protein A mimetic peptide 
TG19318 (Fassina et al., 2001; Verdoliva et al., 2005) forms the basis for the ligand 
Kaptiv-GY/M, a tripeptide tetramer (Arg-Thr-Tyr)4-Lys2-Lys-Gly, for antibody 
purification. Kaptiv-GY manifested potential to isolate hIgG from human serum, 
capture IgM, IgA, IgE and IgY from cell culture supernatant, antisera and ascetic 




fluids with purities and recoveries of above 90% and 80%, respectively (Verdoliva et 
al., 2002).  
Table 2-9 Commercially available biomimetic ligands 
Commercial 
Name 





Protein A mimetic 
peptide, 
(RTY)4K2KG 






Wayne, NJ, USA 
Artificial Protein A, 
22/8 
(Newcombe et al., 
2005) 
Bak and Thomas (2007) compared four small ligands, MEP HyperCel, MAbSorbent 
A1P and A2P, FastMabs A and Kaptiv-GY, with several modified Protein A ligands 
for purifying polyclonal rabbit antibodies from clarified antiserum. They concluded 
that of all the small ligands investigated, none were able to match the selectivity and 
purification factors of modified protein A. Most of the ligands exhibited non-specific 
interactions, binding to all immunoglobulin isotypes. New and improved ligand 
design methodologies thus need to be developed that would allow the formation of 
ligands with higher selectivity and affinity.  
5 Future of IgM Antibody Purification 
Manufacturers are constantly looking for ways to streamline IgM recovery and 
purification processes. Strategies can include a) decreasing the number of purification 
steps and b) enhancing the speed of purification. Of all the chromatographic 
techniques employed for bio-separation, biospecific affinity chromatography is 
probably the most powerful since it is directed at the uniqueness of the protein target. 




However, the inherent drawbacks associated with the biological origin of ligands 
limits its application. Biomimetic ligands with their unique ability to mimic the 
biological binding behavior of naturally occurring ligands present the most appealing 
solution to the problem. However, it is time to reevaluate the strategy to design these 
biomimetic ligands. Combinatorial approaches to design biomimetic ligands have 
failed to provide „true‟ mimics of the natural protein ligand. Even though most of 
these ligands were originally designed to mimic the Fc binding character of the 
protein ligands, they have shown affinity for the variable region of antibodies. Most 
of the ligands are non-specific; binding to all immunoglobulin isotypes.  
The initial screening procedure for biomimetic ligands should be based on the criteria 
that i) the ligand binds specifically to the Ig of interest with no affinity for other 
isotypes and ii) the ligand is an Fc receptor to the Ig of interest. As described by Yang 
(2008) “Binding through the Fc portion of an antibody allows the ligand to be a 
universal binder for antibodies and Fc-fusion proteins. Binding through the Fc portion 
also frees the Fab domains for antigen binding, which is desirable when using the 
antibody for immunoassays and diagnostic applications.”  
Another concern is the speed of separation. Most of the literature on IgM separation 
suggests extensive use of chromatographic columns packed with porous beaded 
resins. These conventional chromatographic supports with pore diameters ranging 
from 300-500 Å rely on intraparticle diffusion for mass transport. Diffusion is slow 
and increasingly so for a large molecule like IgM. This is the reason why both 
capacity and resolution decline with increasing flow rate, necessitating the use of low 
superficial velocities. However, low velocities result in prolonged exposure of IgM 
molecules to the matrix material rendering them susceptible to denaturation. Recently, 




Gagnon et al. (2008) and Brne et al. (2007) advocated the use of monolithic columns 
for applications in IgM purification. Monoliths are chromatographic matrices 
containing highly interconnected flow-through pores with diameters ranging from 2-5 
µm. The open porous structure ensures that i) mass transfer is governed by convection 
rather than by diffusion ii) even the largest of biomolecules can be accommodated 
ensuring high binding capacities. Monoliths thus facilitate separations at high flow 
rates and low pressure drops without sacrificing capacity and separation performance 
[7]. Substantial literature is available on the application of monoliths for purification 
of large biomolecules including plasmids (Branovic et al., 2004; Forcic et al., 2005; 
Urthaler et al., 2005; Hanora et al., 2006; Yu et al., 2008) and viruses (Williams et 
al., 2005; Kramberger et al., 2004, 2007; Gutierrez et al., 2008; Smrekar et al., 2008) 
which justifies the application of monoliths for purification of IgM.  
Chromatographic purification in monolithic columns immobilized with biomimetic 
ligands offer a promising solution to IgM isolation and recovery. Extensive research 
has made possible the availability of monolithic columns with a wide range of surface 
functional groups allowing covalent immobilization of affinity ligands. The 
bottleneck now lies in the non-availability of the biomimetic peptides. The present 
work is an attempt to address this problem through the design of novel biomimetic 
peptidic ligands for IgM purification. 
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3 MATERIALS AND METHODS 
Table 3-1 summarizes the various computational tools/equipments/experimental 
procedures used during the research and their respective functions. Details of the 
various methods are provided in the sections that follow.   
Table 3-1 Computational tools/ equipments/ experimental procedures and their 
respective functions 
Computational Tools/ Equipments/ 
Experimental Procedures 
Function 
PEP-FOLD Peptide structure prediction 
Peptide Companion 
Assess the difficulty in synthesizing 
peptides 
Peptide property calculator 
Assess the average hydrophilicity of 
peptides 
Peptide synthesizer 
Solid phase peptide synthesis using Fmoc 
chemistry 
Reversed-phase high performance 
liquid chromatography (RP-HPLC)  
Peptide purification and for determining 
peptide & linker concentration 
Matrix-assisted laser desorption/ 
ionization- Time of Flight (MALDI-
TOF) 
Mass spectrometry analysis of peptides 
Circular dichroism (CD) spectroscopy 
Determination of peptide secondary 
structure 
UV spectroscopy Determination of peptide concentration 
Pepfit Analysis Analysis of the circular dichroism data 
Surface plasmon resonance (SPR) 
Qualitative characterization of interaction 
between biological entities 
Ligand-thiol coupling chemistry 
Immobilization of pep14 to biosensor 
surface 
Amine coupling chemistry 
Immobilization of IgM/ IgG1/ BSA/ 
pep12 to biosensor surface 
Ninhydrin assay 
Determination of PEG11 linker 
concentration 
Glutaraldehyde chemistry 
Immobilization of pep12 to silica-amine 
microspheres in the presence and absence 
of linker 
Fourier transform infrared spectroscopy 
(FTIR) 
Determine the presence of amide linkage 
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1H NMR spectroscopy 
Determine the reactivity between 
acylating agents and maleimide 
Homogenizer Cell lysis 
Equilibrium studies 
Quantitative analysis of pep14-IgM 
binding strength & static binding 





Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) 
To determine the presence of the protein 
of interest 
3.1 Computational Tools 
PEP-FOLD 
PEP-FOLD is an online resource for peptide structure prediction developed by 
Maupetit et al. (2009).  
Peptide Companion  
Peptide Companion software (CoshiSoft, USA) was used to asses the difficulty in 
synthesizing the peptides. 
Peptide Property Calculator 
Peptide Property Calculator (Innovagen, Sweden) was used to assess the average 
hydrophilicity of the peptides and determine the effect of pH on the overall charge of 
the peptide.   
3.2 Peptide Synthesis 
The peptides- pep12 (ITLISSEGYVSS), pep13 (ITLISSEGYVSSK), pep14 
(CITLISSEGYVSSK), pep5A (CITLIAAAAAVSSK) and pep14A 
(CITLISSAGYVSSK) were synthesized by solid-phase peptide synthesis using an 
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automated peptide synthesizer (Intavis AG, Germany) employing 9-
fluorenylmethyloxycarbonyl (Fmoc) chemistry. All experimental procedures were 
carried out in accordance with the manufacturer’s instructions. The Fmoc amino acids 
were purchased from Merck (Darmstadt, Germany) and 4-hydroxymethyl-
phenoxymethyl (HMP) resins from Applied Biosystems (California, USA). 
Consumables for peptide synthesis were purchased from Intavis, Germany. Table 3-2 
summarizes the side chain protecting groups for the various Fmoc amino acids used in 
the study. 
  Table 3-2 Side chain protecting groups of amino acids 
Amino Acid Protecting Group 
Ala (A) -- 
Cys (C) Trt 
Glu (E) OtBu 
Gly (G) -- 
Ile (I) -- 
Leu (L) -- 
Lys (K) Boc 
Ser (S) tBu 
Thr (T) tBu 
Tyr (Y) tBu 
Val (V) -- 
All the solvents/ chemicals were of peptide synthesis grade and purchased from 
Merck. The protocol in the control software was found to be inadequate in providing 
high yields. An optimized protocol for a 50 μmole synthesis scale was designed. 
Three activators PyBOP (benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate), HATU [2-(1H-7-Azabenzotriazol-1-yl)--1,1,3,3-tetramethyl 
uronium hexafluorophosphate methanaminium] and HBTU (O-Benzotriazole-
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N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate) were investigated for their 
efficiency in synthesizing the peptides. Coupling of the first four residues involved 
two deprotection stages with 30% (v/v) piperidine in dimethyl formamide (DMF) and 
a single coupling stage of one hour. Two deprotection steps followed by two coupling 
stages of one hour each was used for coupling the remaining residues. Once 
synthesized the resins were dried for 48 hours in a vacuum dryer and stored at -20 ºC 
till further use. The peptides were simultaneously cleaved and deprotected from the 
resin by a two hour treatment with Reagent R [trifluoroacetic acid (TFA)/ thioanisole/ 
1,2-ethanedithiol (EDT)/ anisole- 90/5/3/2]. Separation of the cleaved peptide was 
achieved by precipitation. To induce peptide precipitation, the cleavage mixture was 
added drop-wise to cold diethylether. The non-peptidic products remained in the ether 
solution while the peptides precipitated out. In order to achieve maximum peptide 
recovery, the ether solution was incubated overnight at -80 ºC. The precipitate was 
collected by centrifugation. The precipitate was then washed three times with cold 
diethylether to remove any residual scavengers. A small volume of water was added 
to the diethylether-washed peptides and the sample was frozen before lyophilization. 
The crude peptides were purified to greater than 95% homogeneity by reversed-phase 
high performance liquid chromatography (RP-HPLC) using an Agilent Zorbax 
300SB-C18 semi-preparative column (particle size: 5 μm, pore size: 300 Å, 
dimensions: 9.4 mm×250 mm [8]. Table 3-3 summarizes the HPLC conditions 
employed during pep14 purification.  
Purified peptide fractions were collected, pooled, frozen and lyophilized before 
storing them in a desiccator at -20 ºC to minimize oxidation and exposure to moisture. 
The stored peptides were brought to room temperature before use. It is important to 
note that the shelf life of a peptide solution is limited. Furthermore, peptides 
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containing cysteine residues could undergo oxidation to form reversible inter-chain or 
intra-chain disulfide bonds. Peptide solutions were therefore prepared just prior to use 
and discarded thereafter.  






Mass spectrometry (MS) analysis of the peptides was performed using an AutoFlex II 
Matrix-assisted laser desorption/ ionization- Time of Flight (MALDI-TOF) (Bruker 
Daltonics, USA). Experimental procedures were carried out in accordance to 
manufacturer’s instructions. 0.54 μL of the peptide sample was injected onto a thin 
layer of α-cyano-4-hydroxycinnamic acid (CHCA). The thin layer was prepared by 
depositing 0.54 μL of CHCA in 33% 2-propanol/ ACN with 0.1% TFA on an 800 μm 
Anchorchip MALDI probe (Bruker Daltonics, USA). Mass specs of the samples 
within the range of [MH]
+
 m/z 1000-3500 were acquired in the reflection mode at a 
laser frequency of 25.0 Hz. Signals from more than 100 laser shots were accumulated 
to obtain reasonable signal to noise (S/N) ratios.  
 
 








            Gradient elution program 
 
Buffer A: Water + TFA (0.1% v/v)  
Buffer B: Acetonitrile (ACN) +  
                TFA (0.1% v/v) 
Flow rate: 1.5 mL/min 
Detector type: UV 
Detector wavelength: 214 nm  
Sample injection volume:  1 mL 
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3.3     Surface Plasmon Resonance Biosensor Assays 
Surface plasmon resonance (SPR) biosensor assays were carried out using a Biacore 
2000 instrument (Uppsala, Sweden) per manufacturer’s instructions. CM5 sensor 
chip, amine coupling kit, thiol coupling kit, and HBS-EP buffer (10 mM HEPES with 
0.15 M NaCl, 3 mM EDTA and 0.005% surfactant P20, pH 7.4) were purchased from 
Biacore. Monoclonal antibodies, human IgM (hIgM), human IgG1 (hIgG1), human 
IgA1 (hIgA1), human IgE (hIgE) were purchased from Merck Biosciences (UK). 
Bovine serum albumin (BSA) was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Rabbit IgM, mouse IgM, bovine IgM and human IgM fragments, Fc5μ and 
Fab, were purchased from Rockland Immunochemicals (Gilbertsville, PA, USA). All 
other reagents used for the binding studies were of analytical grade and purchased 
from Sigma-Aldrich (St. Louis, MO, USA). All experimental procedures were carried  
3.3.1 Immobilization of hIgM/ hIgG1/ BSA to Biosensor Surface 
Figure 3-1 is a schematic representation of the amine coupling procedure used for 
immobilizing hIgM, hIgG1 and BSA to the carboxymethylated dextran (CM5) surface 
of the biosensor chip.  
 
Figure 3-1 Amine coupling procedure (Adopted from [9]) 
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Reagents required for the coupling included: 
 Activators 
 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) in water 
0.1 M N-hydroxysuccinamide (NHS) in water 
 NHS and EDC solutions, in equal volumes, were mixed immediately prior to use. 
 Ligand (hIgM/ hIgG1/ BSA): 20-200 μg/mL in immobilization buffer.  
 Blocking agent: 1 M ethanolamine-HCl, pH 8.5 
 Running buffer: HBS-EP 
Prior to immobilization, the docked sensor chip was equilibrated overnight with the 
running buffer. The CM groups on the sensor surface were then activated with NHS-
EDC solution. This step created highly reactive succinimide esters which readily 
reacted with amines and other nucleophilic groups on the ligands. Ligand, dissolved 
in the immobilization buffer, was then injected onto the activated dextran surface. 
This was followed by blocking the excess active sites with 1 M ethanolamine-HCl 
solution. Ethanolamine also helped to remove any non-covalently bound protein from 
the sensor surface. Studies suggest enhanced immobilization using low ionic strength 
immobilization buffer. High concentration of salt tends to reduce the ionic interaction 
between the protein and the dextran surface. 10 mM sodium acetate at pH 5 was thus 
used as the immobilization buffer for coupling hIgM and hIgG1 while 10 mM sodium 
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Table 3-4 Summary of amine coupling procedure (Adapted from [9]) 
1. Activate the surface 1:1 (v/v) EDC-NHS Flow rate: 5 μL/min 
Contact time: 7 min 
2. Immobilize the 
ligand 
Ligand (hIgM/ hIgG1/ 
BSA) in immobilization 
buffer 
Flow rate: 5 μL/min 
Contact time: Multiple low- 
volume injects till the desired 
ligand density is achieved 
3. Deactivate the 
excess reactive 
groups 
Ethanolamine Flow rate: 5 μL/min  
Contact time: 7 min 
3.3.2 Immobilization of pep14 to CM5 Biosensor Surface 
Figure 3-2 describes the ligand-thiol coupling method for immobilizing cysteine 
bearing ligands.  
 
Figure 3-2 Ligand-thiol coupling procedure (Adopted from Technical Note, 
Biacore, GE [10])  
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Reagents required for coupling included: 
a) Activator 
0.4 M EDC solution in Milli-Q water  
0.1 M NHS solution in Milli-Q water 
NHS and EDC solutions, in equal volumes, were mixed immediately prior to use. 
 
b) 0.12 M 2-(2-Pyridinyldithio)ethaneamine hydrochloride (PDEA) solution in water. 
PDEA and 0.15 M borate buffer at pH 8.5 were mixed in a ratio 2:1 (v/v) just prior 
to use. The diluted PDEA solution was stable for 30 minutes. 
b) Ligand (pep14): 20-200 μg/mL in immobilization buffer. 10 mM sodium acetate, 
pH 4.5 served as the immobilization buffer.  
c)  Blocking agent: 50 mM L-Cysteine solution 
Table 3-5 Summary of ligand-thiol immobilization procedure (Adapted from 
Technical Note, Biacore, GE [10]) 
1. Activate the surface 1:1 (v/v) EDC-
NHS  
Flow rate: 5 μL/min 
Contact time: 3 min 
2. Introduce reactive 
disulfide groups 
PDEA in borate 
buffer 
Flow rate: 5 μL/min 
Contact time: 4 min 




Flow rate: 5 μL/min 
Contact time: Multiple low-
volume injects till the desired 
ligand density is achieved 
4. Deactivate excess 
reactive groups 
L-Cysteine Flow rate: 5 μL/min  
Contact time: 8 min 
3.3.3 Binding Studies 
The SPR Biacore measured the refractive index near the sensor surface which served 
as the floor of a small flow cell. Flow cell (Fc) was the surface through which the 
running buffer (HBS-EP in this case) passed through continuously. After 
immobilization of the ligand on the sensor surface, the analyte sample was passed 
through the flow cell under continuous flow. The binding of the analyte on the surface 
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caused an increase in the refractive index. This change in refractive index was 
measured by the SPR and the sensogram was plotted as resonance units (RUs) versus 
time. Binding experiments were performed at 25 ºC. The first flow cell (Fc1) of the 
biosensor chip served as the reference. Accurate binding responses were obtained by 
subtracting the background (reference) responses from the sensogram. SPR 
experiments are frequently disrupted by small air bubbles trapped in vials with the 
analyte sample. Trapped air bubbles introduce noise in the sensogram. The vials were 
made free of air bubbles before being injected. All studies were performed in 
triplicates. The start injection time for each sample was set to zero on the x-axis. 
Figure 3-3 shows the different phases of an SPR sensogram.   
 
                Figure 3-3 Illustration of an SPR sensogram 
During the association phase, the binding of the analyte to ligand took place and was 
monitored in real time. After analyte injection, running buffer was passed over the 
surface and the dissociation of the analyte-ligand complex was monitored. Finally, 
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regeneration of the ligand surface was achieved through the use of an eluent/ 
regeneration buffer.  
3.3.3a Binding Studies between Immobilized hIgM/ hIgG1/ BSA to 
pep12/ pep13/ pep14/ pep14A/ pep5A 
hIgM, hIgG1 and BSA were immobilized using amine coupling chemistry to CM5 
sensor chips at a density equivalent to 3330, 2960 and 5400 RUs respectively. 16 µM 
analyte samples of pep12/ pep13/ pep14/ pep14A/ pep5A were prepared in HBS-EP 
buffer. Binding studies were performed at a flow rate of 2 µL/min. The SPR 
sensorgrams were overlaid and zeroed on the y-axis to the average baseline. 
3.3.3b Binding Studies on Immobilized pep14  
pep14 bearing an N-terminal cysteine was immobilized using ligand-thiol coupling 
chemistry. The analyte samples of hIgM, hIgG1, hIgE, hIgA1 and BSA were prepared 
in HBS-EP buffer to minimize bulk refractive index contributions. All analyte 
samples were analyzed for any possible precipitation before use. Binding studies were 
performed at a flow rate of 20 µL/min. The SPR sensorgrams were overlaid and 
zeroed on the y-axis to the average baseline.  
While SPR-based biosensor assays can be used to evaluate binding affinity (Ka= 
ka/kd) between two entities, its use for determining avidity is limited to bivalent 
molecules. Avidity is a term used to describe the combined strength of multiple bond 
interactions. Due to the presence of ten identical binding sites in IgM, multiple pep14 
ligands possibly interacted with each IgM molecule resulting in varying dissociation 
rates. SPR studies were thus not used for qualitative determination of binding strength 
between pep14 and IgM. 
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 3.4 Circular Dichroism  
3.4.1 Experimental Setup 
Circular dichroism (CD) studies were performed on a J-810 spectropolarimeter 
(Jasco, USA) in accordance to manufacturer’s instructions. The UV 
spectropolarimeter was purged with nitrogen for 30 minutes before it was turned on. 
The flow rate of nitrogen was maintained at 15 L/min throughout the experiment. 
Peptides were dissolved in ultra-pure water and degassed just prior to sample analysis. 
Degassed ultra-pure water served as the blank for the CD studies. A quartz cell with 
10 mm path length was used for CD studies. Measurements were made with five 
continuous mode scan accumulations from 250 to 190 nm at a scan speed of 20 
nm/min, data pitch of 0.1 nm, response time of 2 seconds and a bandwidth of 1 nm. 
Blank subtracted data were automatically averaged over the five scans by the 
software. The CD spectra measurements were processed by Jasco’s spectra manager 
in millidegrees and were smoothed using the in-built binomial smoothing algorithm. 
The collected data expressed in millidegrees was converted to mean molar ellipticity 
(deg cm
2
/dmol) using the relation: 
[] mean ellipticity = []millidegrees(MRW/10cd) 
where [] is the experimentally measured value,  
MRW is the mean residue molar weight of the peptide,  
c is the concentration of the sample in mg/mL, 
d is the optical path length of the cuvette in centimeters.  
The spectrum was analyzed using the PEPFIT Analysis software kindly provided by 
Dr. Michael Amon (Amon et al., 2008). PEPFIT Analysis is based on the original 
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PEPFIT program developed by Reed and Reed (1997). The original PEPFIT program 
was written in an MS-DOS format while PEPFIT Analysis has been rewritten in an 
excel format and provides for an interactive graphical interface.  
3.4.2 PEPFIT Analysis  
The PEPFIT software, developed by Reed and Reed (1997), is especially suitable for 
analyzing the CD spectra of peptides. The PEPFIT software consists of a set of nine 
reference curves corresponding to the following secondary structures: α-helix, β-
sheet, random coil, β-turn I, II & III, general β-turn, -turn and modified coils. 
Raw data (mean residue ellipticity) from CD spectra measurements, ranging from 240 
to 190 nm, at regular intervals of 2.5 nm were extracted and fitted to the PEPFIT 
Analysis software. The PEPFIT Analysis was interfaced with Microsoft Excel 2003, 
and analyzed using an Intel Pentium 4 desktop operating on Microsoft Windows XP 
Operating System. The raw input values were initially compared with all of the in-
built reference curves at a counter setting of 10. This initial computation served to 
suggest the reference curves to concentrate on, as it was unlikely that a peptide would 
display significant amount of all 9 sample spectra. Subsequently, the analysis was 
repeated with the more probable reference curves along with increased sensitivity 
(counter setting) of the computation. After a series of systematic computations, a 
counter setting of 2 was chosen as the final setting. The “input data scaling factor” 
was set to 100% throughout the analysis. Curve fits with the best correlation 
coefficients, R
2
, were chosen (Amon et al., 2008). 
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3.4.3 Determination of Peptide Concentration 
The concentration of the peptide solution was determined using UV 
spectrophotometry. The residues that contributed significantly to the measured optical 
density at 280 nm were tyrosine and cysteine. The extinction coefficients for the 
peptides were therefore calculated as 
280 = a tyr + b cys 
where a and b are the number of tyrosine and cysteine residues per molecule 
respectively,  










3.5 Ligand Immobilization 
3.5.1     pep12 Immobilization  
3.5.1a     Immobilization to Carboxymethylated Dextran Surface 
Coupling of pep12 to the carboxymethylated dextran surface of the biosensor chip 
was performed using amine-coupling chemistry as described in section 3.3.1. 
Modifications were, however, made in the buffers employed during the process. 
Literature suggests that conversion of carboxyl groups to active NHS esters using 
EDC-NHS mixture can be efficiently carried out in a pH range of 4.5-7.2 
(Hermanson, 1996). NHS and EDC were dissolved in 50 mM 2-(N-
morpholino)ethanesulfonic acid (MES), pH 6 to a final concentration of 100 mM and 
400 mM respectively. NHS and EDC solutions in equal volumes were mixed just 
prior to use. pep12 was dissolved in 20 mM phosphate buffer with the pH of the final 
solution adjusted to 7.3.   
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3.5.1b     Immobilization to Silica-amine Matrix in Absence of Linker 
Non-porous silica-amine (SA) microspheres (diameter 0.97 µm) were purchased from 
Bangs Laboratories (USA). Glutaraldehyde (GA) [50% solution (v/v)] and sodium 
cyanoborohydride [NaBH3(CN)] were supplied by Fluka Chemika (Sigma-Aldrich, 
St. Louis, MO, USA). All other chemicals that were used in the procedure were of 
analytical grade and purchased from Sigma-Aldrich (St. Louis, MO, USA). Ultra-pure 
water was obtained from the Milli-Q system (Millipore, Bedford, USA). 
Centrifugation was performed in an Eppendorf 5810R centrifuge. Sonication was 
performed in a Tru-Sweep 275TAG ultrasound bath from Crest Ultrasonics (USA). 
Mixing was done in an Intelli-mixer RM-2 (Elmi Ltd, Latvia). pep12 immobilization 
strategy was based on a procedure described for coupling amine-containing molecules 
to glutaraldehyde activated agarose beads (Technical Note, Pierce Technology [11]). 
The buffers/ solutions used during this procedure are summarized below: 
 Activation buffer: 100 mM phosphate, pH 6.8 
 Coupling medium: DMF containing acetic acid (AcOH) (1% v/v)  
 Quenching buffer: 1 M Tris-HCl, pH 7.4  
 NaBH3(CN) solution: 5 M, dissolved in 10 mM sodium hydroxide 
 Storage buffer: 20 mM HEPES, 150 mM NaCl, 0.02% sodium azide, pH 7.2 
100 mg of SA microspheres were activated by adding 10 mL of 10% GA solution in 
the activation buffer. Thorough washing was performed with the activation buffer to 
remove any unreacted GA after 4 hours of bead activation. 5.2 mL of 2.5 mg/mL 
pep12 sample in coupling media was added to the GA-activated beads. Reduction of 
Schiff base intermediate was achieved by addition of 200 μL of 5 M NaBH3(CN) 
solution in coupling medium. pep12 coupling was performed at room temperature for 
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12 hours. The residual active sites on the microspheres were blocked by adding 10 
mL of quenching buffer and 200 μL of NaBH3(CN) solution. The suspension was 
mixed for one hour at room temperature. Final washings were performed with 1 M 
NaCl to remove any non-specifically bound peptides. Supernatants were collected 
after each of the coupling, blocking and washing steps. The supernatants were 
analyzed by RP-HPLC to determine the ligand immobilization efficiency.  
3.5.1c     Immobilization to SA Matrix Incorporating a Linker 
Preparation of the Linker Stock Solution  
The linker, mono-N-t-boc-amido-dPEG11 amine (henceforth PEG11), was purchased 
from Quanta BioDesign, USA. L-glutamic acid, dimethyl sulfoxide (DMSO), sodium 
acetate, ninhydrin and hydrindantin were purchased from Sigma-Aldrich. (St. Louis, 
MO, USA). The highly viscous nature of the linker necessitated the use of a diluent. 
200 μL of DMF containing AcOH (1% v/v) was added to the linker sample. The 
diluted sample was aliquoted and stored at -20 ºC till further use. Ninhydrin assay was 
performed to quantify the concentration of the aliquoted sample. 
Ninhydrin Assay 
The described procedure is based on the work of Sun et al. (2006). Ninhydrin solution 
was prepared by dissolving 2 g of ninhydrin and 0.3 g of hydrindantin in 75 mL of 
DMSO under a stream of nitrogen gas followed by addition of 25 mL of 4 N sodium 
acetate buffer. The mixture was bubbled with nitrogen gas for at least 5 minutes and 
used on the same day. Freshly prepared ninhydrin solution assumed a burgundy color 
and turned yellow on oxidation. The solution formed crystals on standing and slight 
heating before use ensured a homogenous solution.  
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Ninhydrin is sensitive to light. All the experiments were therefore carried out in the 
dark. L-glutamic acid was used as a standard in the present study. Standard/ PEG11 
samples (1 mL) and ninhydrin solution (1 mL) were placed in screw-capped test tubes 
and heated in a boiling water bath for 10 minutes. After heating, the tubes were 
immediately cooled in an ice-bath. 5 mL of 50% ethahol was added into each tube and 
thoroughly mixed. The absorbance of the standards/ samples was measured with a 
UV-1601 spectrophotometer (Shimadzu Corporation) at 570 nm. Two independent set 
of experiments were conducted and the reported values were the mean of the two 
experiments. The concentration of the PEG11 sample was obtained using the 
calibration plot of absorbance vs L-glutamic acid concentration (5-50 μg/mL).  
Coupling Procedure 
The linker, PEG11, allowed selective reaction between the available amine terminus 
and GA-activated SA microspheres. Experimental procedure similar to the one used 
for immobilizing pep12 to the matrix (section 3.5.1b) was used. The Boc protected 
terminus was subsequently deprotected using a 1:1 mixture of trifluoroacetic acid and 
dichloromethane, releasing the amine for reaction with pep12. The deprotection 
reaction was carried out for 1 hour at room temperature. The available amine groups 
were subsequently activated with 10% GA solution. The GA-activated linkers were 
then reacted with the amine terminus of pep12. Amine coupling procedure similar to 
the one described in section 3.5.1b was used. pep12 immobilization efficiency at three 
linker densities: 150, 300 and 600 µmoles/gm of support, was determined. The term 
linker density here corresponds to the initial amount of linker that was added to the 
microspheres.  
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Quantification of Unbound Linker Concentration  
NaBH3(CN) was present in the supernatant collected after the linker coupling step. 
Ninhydrin assay could not be used for amine quantification in the presence of a 
reducing agent like NaBH3(CN) in the solution. The linker concentration was thus 
determined by RP-HPLC using a Supelco LC-C18 column (particle size: 5 μm, pore 
size: 180 Å, dimensions: 4.6 mm × 250 mm). RP-HPLC analysis was performed on a 
Waters HPLC system that consisted of a dual λ absorbance detector, controller and an 
autosampler. Conditions used during HPLC analysis are summarized in Table 3-6. A 
calibration plot of peak area vs PEG11 concentration (10 μg/mL-1000 µg/mL) was 
used to quantify the concentration of the unreacted linker in the supernatant. 




3.5.1d Coupling Efficiency and Ligand Stability   
Concentration of unbound peptide in the supernatant(s) collected after peptide 
immobilization, were determined by RP-HPLC. The conditions used during HPLC 
analysis are summarized in Table 3-7. 
 
 
        Gradient elution program 









Buffer A: Water    
Buffer B: ACN 
Flow rate: 1 mL/min 
Detector type: UV 
Detector wavelength: 220 nm  
Sample injection volume: 200 µL 
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NovaPak C18 column (Waters, Ireland) with dimensions of 3.9 mm × 150 mm was 
used. The analysis was performed at room temperature. A calibration plot of peak 
area vs pep12 concentration was used to quantify the concentration of the unbound 
peptide in the supernatant. Ligand immobilization efficiency was determined as: 
Ligand immobilization efficiency (%) =  
(mass of ligand in feed) – (mass of ligand in SN(s) collected after ligand immobilization)   
                                              (mass of ligand in feed)                                                                         
 
pep12 was investigated for its stability in the coupling medium and quenching buffer 
using RP-HPLC analysis in the same manner as described above. 
3.5.2  Minimization of Non-specific Binding of Proteins  
3.5.2a  Adsorption Studies on CIM EDA Monolithic Disc 
Convective interaction media (CIM) ethylene diamine (EDA) disc was purchased 
from BIA Separations (Slovenia). The HPLC conditions used during the study are 
summarized in Table 3-8.  
 







          Gradient elution program 
 
Buffer A: Water + TFA (0.1% v/v)  
Buffer B: ACN + TFA (0.1% v/v) 
Flow rate: 1 mL/min 
Detector type: UV 
Detector wavelength: 214 nm  
Sample injection volume: 20 µL 
 
×100 
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3.5.2b  Reactivity between Maleimide and Acylating Agents 
N-ethyl maleimide (NEM) was used as a representative maleimide in this study. Each 
of the vials containing 4.1 mg of NEM, labelled as NEM1 and NEM2, were mixed 
with 1025 μL of acetyl chloride (Sigma-Aldrich, M.W.- 78.5 Da, ρ = 1.105 g/mL)  
and 1025 μL oxalyl chloride (Alfa Aesar, M.W.- 126.93 Da, ρ = 1.4785 g/mL), 
respectively. The samples were incubated for 1 hour at room temperature before they 
were analyzed 
1
H NMR. The 500 MHz 
1
H NMR spectra were acquired using Bruker 
(Billerica, MA, USA) Avance 500 spectrometer per manufacturer’s instructions. 
While CDCl3 served as the solvent, acetyl chloride, oxalyl chloride and NEM in 
CDCl3 were used as controls.  
3.5.2c  Acylation of Silica-amine Microspheres  
Acylation of SA microspheres was performed with acetyl chloride and oxalyl 
chloride. Three sets of vials, each containing 17 mg of SA microspheres, were 
sonicated for 10 minutes. The three sets of samples, labeled SA1, SA2 and SA3, were 
then treated with 250 μL of acetyl chloride, oxalyl chloride and HBS buffer (10 mM 
HEPES + 150 mM NaCl, pH 7.4), respectively. The samples were incubated for 1 
Time (min) % A % B 
0 100 0 
2 100 0 
2.01 0 100 
10 0 100 
10.01 100 0 
14 100 0 
 
 
Buffer A: Binding buffer (10 mM 
HEPES + 150 mM NaCl. pH 7.4) 
Buffer B: Elution buffer (10 mM 
HEPES + 1 M NaCl, pH 7.4) 
Flow rate: 1.5 mL/min 
Detector type: UV 
Detector wavelength: 280 nm  
Sample injection volume: 20 μL 
 
           Gradient elution program 
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hour at room temperature. After an hour of incubation, acetyl chloride in SA1 was 
removed by vaporization in a fume hood. Oxalyl chloride in SA2 was removed by 
centrifuging the beads at 5700 g for 10 minutes. 900 μL of HBS was added to SA1 
and SA2 while 750 μL of HBS was added to SA3. All the samples were sonicated for 
10 minutes followed by centrifugation at 5700 g for 10 minutes. The samples, SA1 
and SA2, were then subjected to several wash cycles. Each wash cycle involved 
resuspension of the microspheres in 900 μL of HBS buffer, mixing for 5 minutes, 
centrifugation at 5700 g for 5 minutes followed by removal of the supernatant. SA1 
and SA2 samples were washed until the recovered supernatants exhibited absorbance 
values less than 0.003 AU.  
Fourier transform infrared spectroscopy (FTIR) spectroscopic study of the samples, 
SA1, SA2 and SA3, was conducted for the presence of amide linkage. FTIR spectrum 
was obtained using a Bio-Rad FTIR model-400 spectrophotometer with a deuterated 
triglycine sulphate detector. All experimental procedures were performed in 
accordance with manufacturer’s instructions. The spectrum was obtained by 
accumulating 128 scans at a resolution and sensitivity of 6 cm
-1
 and 1 respectively. 
Transmittance-mode configuration was employed with a bare KBr pellet used as the 
background. The sample compartment was fully purged with nitrogen to avoid 
disturbances from water and carbon dioxide. The samples were analyzed at a speed of 
10 kHz within a scan range of 4000 cm
-1
 and 400 cm
-1
. 
3.5.2d   Adsorption Studies 
SA1, SA2 and SA3 samples were resuspended in 600 μL of 0.1 mg/mL BSA-HBS 
solution. The suspensions were mixed gently for 2 hours at room temperature. After 
incubation, the samples were centrifuged at 1120 g for 10 minutes. Waters’ HPLC 
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system was used to analyze the recovered supernatants. The UV detector was set to 
280 nm. No column was used during the analysis. HBS at a flow rate of 1 mL/min 
served as the mobile phase. Sample injection volume was equal to 40 μL.  
3.5.3 pep14 Immobilization   
3.5.3a Coupling to Silica-amine Microspheres 
Coupling of pep14 to SA microspheres was performed by incorporating a hetero-
bifunctional PEG linker with amine and sulfhydryl reactive terminals. The linker, 
maleimide-dPEG24-NHS ester (henceforth PEG24), was purchased from Quanta 
Biodesign (Ohio, USA). A 250 mM linker stock solution was prepared by dissolving 
100 mg of the linker in 187 μL of anhydrous DMSO. 192 μL of linker stock solution, 
diluted with 50 mM HEPES at pH 7.25 to a final concentration of 10 mM, was added 
to 150 mg of pre-equilibrated SA microspheres. The amount of linker added 
corresponded to a density of ~350 μmole/g of support. Coupling of the cross-linkers 
to the silica microspheres took place through the reaction between the NHS esters and 
the amine functionalities on the silica surface. Coupling was performed for 60 
minutes at room temperature. After an hour of gentle mixing, the microspheres were 
centrifuged at 3500 g for 10 minutes. The supernatant was recovered and analyzed by 
RP-HPLC to determine the amount of unbound PEG24 (section 3.5.3c). Selective 
blocking of the free amine functionalities on the SA microspheres was achieved by 
incubating the microspheres in 2.2 mL of oxalyl chloride for 1 hour at room 
temperature. Two washings with 17:3 mixture of 2 mM HEPES and DMSO were then 
performed. pep14, dissolved in a 17:3 mixture of 2 mM HEPES and DMSO to a final 
concentration of 1 mg/mL was added to the SA microspheres. The amount of pep14 
added corresponded to a density of ~100 μmole/g of support. The pH of the solution 
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was adjusted to pH 7.2 with 1 M NaOH. Coupling was performed for 12 hours at 
room temperature. The silica microspheres were recovered by centrifugation at 3500 g 
and washed twice with DMSO. Three washings with HBS (10 mM HEPES, 150 mM 
NaCl, pH 7.4) were performed before preserving the beads in HBS containing 0.02% 
sodium azide.  
3.5.3b Degradation of PEG24 Linker 
NHS ester and maleimide groups in the linker hydrolyzed rapidly in an aqueous 
media, within hours at pH 7-7.5. Degradation of a 2 mM PEG24 sample in 50 mM 
HEPES buffer, pH 7.25, was monitored. RP-HPLC was used to analyse the sample at 
different time intervals (30, 60, 150, 300, 450, 1080 and 1140 minutes). Table 3-9 
summarizes the conditions used during HPLC analysis of PEG24. Phenomex C4 
column (250 mm x 4.6 mm, 5 μm particles) was used for the analysis.  







3.5.3c Quantification of Unbound PEG24 Concentration 
Supernatant collected after linker immobilization was incubated in the dark at room 
temperature for 18 hours to allow degradation of PEG24. After incubation, the 








          Gradient elution program 
 
Buffer A: Water    
Buffer B: ACN 
Flow rate: 1 mL/min 
Detector type: UV 
Detector wavelength: 210 nm  
Sample injection volume: 10 μL 
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samples were analyzed with RP-HPLC. HPLC analysis was performed in the same 
manner as described in section 3.5.3b. Phenomex C4 column (250 mm x 4.6 mm, 5 
μm particles) was used for analysis. A calibration plot of peak area vs PEG24 
concentration (0.05 mM-10 mM) was used to quantify the concentration of the 
unbound linker in the supernatant. 
3.5.3d Coupling Efficiency  
Concentration of unbound peptide in the supernatant(s) collected after peptide 
immobilization was determined by RP-HPLC. The conditions used during HPLC 
analysis are summarized in Table 3-2. Ligand immobilization efficiency was 
determined in the same manner as described in section 3.5.1d. 
3.5.3e  Equilibrium Studies 
Adsorption studies were performed on pep14-immobilized SA microspheres (ligand 
density- 34 μmole/g of microsphere). 250 μL of hIgM samples in HBS buffer, at 
concentrations ranging from 0.15 mg/mL to 1.25 mg/mL, were added to the 
microspheres. The samples were gently mixed overnight at room temperature. The 
concentration of unbound hIgM was determined by measuring the absorbance of the 
supernatant at 280 nm.    
3.6 hpIgR-D1: Expression, Purification and Refolding 
The procedures described herein for the expression, purification and refolding of 
hpIgR-D1 were based on the work of Hamburger et al. (2004).  
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3.6.1 Recombinant Plasmid  
The recombinant plasmid, pET20b-pIgR D1-H6, containing the gene that codifies 
hpIgR-D1 was supplied as a stab culture by Addgene (USA). The plasmids were 
extracted and re-transformed into strain BL21 (Invitrogen, USA) for better cell 
growth and protein expression (Extraction and retransformation experiments were 
kindly performed by Dr. Nian Rui, NUS). The recipes for the different culture media 
used in the work are listed in Table 3-10. The media together with their containers 
were autoclaved at 121 °C for 20 minutes before use. 
Table 3-10 Recipe for 1 L Luria Broth (LB) and agar plate culture media 
Cell culture 
media 
Tryptone (g) Yeast extract (g) NaCl (g) Agar (g) 
LB 10 5 10 0 
Agar Plate 10 5 10 15 
Ampicillin was added to the culture media to control plasmid loss in recombinant 
protein expression. Ampicillin stock solutions at 100 mg/mL were prepared and kept 
at -20 °C till needed. The stock solution was diluted 1000 fold i.e. 1 mL of ampicillin 
stock solution was added to 1 L of culture media for use. The transformed cell culture 
was streaked on agar plates containing ampicillin and incubated upside down at 37 °C 
for 16-20 hours. Thereafter, a colony was picked and inoculated into 3 mL of LB 
medium containing ampicillin. The culture was then shaken overnight (12-16 hours) 
at 200 rpm and 37°C. The cells were recovered by centrifugation and lysed. SDS-
PAGE analysis of the lysate was performed to confirm the expression of the protein of 
interest. Once confirmed, glycerol stocks of the cells were prepared and the aliquots 
were stored at -80 ˚C till needed.  
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3.6.2 Cell Culture and Protein Expression  
Two mL of inoculum raised in 3 mL of LB medium was inoculated into 400 mL of 
fresh LB medium containing ampicillin. As the gene encoding the target protein was 
guarded by T7 promoter, the expression of recombinant protein was initiated by 
induction at OD600= 0.5-0.6, with the addition of isopropyl-β-D-thiogalactoside 
(IPTG) to a final concentration of 0.4 mM. The culture was shaken for another 5 
hours at 37 ºC. 
3.6.3 Cell Lysis 
The cells were harvested by centrifuging the culture at 10000 rpm and 4 °C for 20 
minutes. The supernatant was discarded and the harvested pellet was stored at -80 °C 
till further use. When required, the cell pellet was first thawed on ice and resuspended 
in 5 mL of phosphate buffered saline (PBS) buffer. Lysis of the resuspended cell 
culture was accomplished using a high pressure homogenizer at 18.9 MPa for 40 
seconds. Shear, cavitation and impact caused the cell wall to rupture releasing the 
intracellular contents into the lysate. The lysate was centrifuged at 18,000 g for 5 
minutes and the pellet was collected for purification. 
3.6.4 Protein Purification 
hpIgR-D1, expressed as inclusion bodies, was solubilized in PBS buffer containing    
10 mM imidazole, 8 M Urea, 300 mM NaCl and 40 mM dithiothretol (DTT). The 
inclusion bodies containing the target protein were unfolded and stabilized by the urea 
in the buffer. The pellet was allowed to stand for one hour followed by 20 minutes of 
mixing. The mixture was then centrifuged at 18,000 g for 5 minutes. The supernatant 
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thus obtained was filtered using a 0.2 μm filter and diluted with the binding buffer to 
obtain a final DTT concentration of 5 mM. The diluted supernatant was loaded onto a 
Ni-immobilized affinity column (Sepharose 6 Fast Flow Media, GE) equilibrated with 
5 column volumes (CV) of the binding buffer. His-tagged hpIgR-D1 got bound to the 
metal-ion ligand while most of the remaining components in the supernatant passed as 
flowthrough. To remove any contaminants trapped inside the matrix, the column was 
washed with 10 CV of wash buffer. Recovery of bound recombinant proteins was 
achieved by step elution with a buffer containing 500 mM imidazole. Imidazole, at 
such high concentration, competed with histidine for the Ni
2+
 ligand, thus forcing the 
target protein to move into the effluent. All the collected samples were pooled and 
subjected to SDS-PAGE to determine the presence of the target protein. Table 3-11 
lists the composition of the buffers used during purification. The pH of all the buffers 
was adjusted to pH 7.4. 
Table 3-11 Composition of the various buffers used during purification 
 Denaturing Buffer Wash Buffer Elution Buffer 
Imidazole 10 mM 20 mM 500 mM 
NaH2PO4 50 mM 
NaCl 300 mM 
Urea 8 M 
 
Removal of imidazole and sodium chloride, from affinity-purified denatured protein 
fraction, was achieved using a Hiprep 26/10 desalting column (GE Healthcare).        
50 mM sodium phosphate containing 8 M urea served as the desalting buffer. 
3.6.5 Protein Refolding 
Concentration of the protein in the desalted sample was determined by UV 
spectrophotometry at 280 nm. (hpIgR-D1 has an extinction coefficient of 13,370       






). Rapid dilution technique was employed to refold hpIgR-D1; the desalted 
protein sample was added dropwise (1 drop per 20 seconds) into the refolding buffer 
(100 mM Tris, 400 mM L-Arginine, 2 mM EDTA, 0.5 mM oxidized glutathione, and 
5 mM reduced glutathione, pH 8.0) under rapid mixing conditions at room 
temperature. The final concentration of the protein in the diluted sample was kept 
below 100 μg/mL. The solution was gently mixed for 52 hours at 10 ˚C. The refolded 
protein sample was concentrated using Amicon Ultra Centrifugal Filter (Millipore, 
Molecular weight cut-off 3000 Da). Size exclusion chromatography of the 
concentrated sample was then performed in a Superdex 75 26/60 column (Amersham 
Biosciences). TBS (20 mM Tris at pH 8.0, 150 mM NaCl) was the mobile phase 
during size exclusion chromatography. Fractions containing hpIgR-D1 were pooled 
and stored at 4 ºC till further use. 
It was important to establish if the recovered protein had adopted a native-like 
conformation after the refolding process. With the possible exception of enzymes, this 
could be easily done by confirming that the refolded protein bound to its natural 
ligands. Biacore is particularly well suited to evaluate the binding of recombinant 
proteins to their natural ligands. Pentameric IgM is a natural ligand to pIgR-D1. SPR-
based binding studies were performed between hpIgR-D1 and hIgM to investigate the 
activity of the refolded protein. 
3.6.6 SDS-PAGE 
The samples to be analyzed were mixed with 4X sample buffer in the ratio 4:1 i.e. a 
50 μL SDS-PAGE sample contained 40 μL of diluted protein sample and 10 μL of the 
sample buffer. The mixture was heated for 5 minutes at 95 ˚C followed by 
centrifugation at 20,800 g for 5 minutes to remove any precipitate. 10 μL of protein 
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standard was added into the 1
st
 well. 15 μL of the supernatant (around 10 μg of 
protein) was then loaded into the adjacent wells of a 4-14% PAGE gel. Table 3-12 
shows the recipe for preparing a 4-14% SDS-PAGE gel. 





















6.4  1  2.5  0.1  50  10  
Resolving gel 
solution, 14% 
3.9  3.5  2.5  0.1  50  5 
 
* Gel buffer for the stacking gel: 0.5 M Tris solution at pH 6.8 
   Gel buffer for the resolving gel: 1.5 M Tris solution at pH 8.8 
 ** APS- ammonium persulfate 
The apparatus was then hooked up to a power source and a constant voltage of 200 V 
was applied to separate the protein bands. The system was run for 40-45 minutes to 
ensure that the proteins do not reach the other side of the gel. The gel was washed 
three times with deionized water, each time for 5 minutes with gentle rocking. 20 mL 
of Coomassie Blue G250 stain (Biorad) was pooled and the gel was stained for 1 hour 
(in the rocking platform). After staining, the staining buffer was replaced with 
deionized water and destained overnight.  
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4.1 BIOMIMETIC AFFINITY LIGAND DESIGN 
4.1.1 Introduction 
In the last few years, biomimetic peptidic ligands have gained recognition as a viable 
alternative to natural binding partners. Peptidic ligands are commonly obtained 
through screening combinatorial libraries or derived from N-terminal, C-terminal, or 
internal sequences of native proteins. Application of peptide libraries for identifying 
affinity ligands has been investigated extensively in recent years. Various strategies 
have been developed for the synthesis of peptide repertoires including biological 
(phage display) and chemical (“split synthesis”, “peptides on beads”, “synthetic 
peptide combinatorial libraries”, and photolithography) (Houghten et al., 1991; 
Houghten and Dooley, 1993; Clackson, 1994; Houghten, 1995; Bradbury, 2000) 
synthesis. Constrained peptide libraries have also assumed considerable recognition as 
these peptides are thought to better mimic the in-vivo binding of a receptor to its 
target (Rudolf et al., 1998). Circularization, generally achieved via formation of a 
disulfide bond between the N and C terminal of the peptide, allows increased 
resistance to enzymatic degradation and is believed to stabilize the native-like 
antigenic conformation in the synthetic peptide (Carter, 1996).  
Most of the ligands identified through screening combinatorial libraries show non-
specific binding behavior, recognizing all immunoglobulin isotypes. The approach, 
though novel, has not been successful in imparting binding specificity, a uniquely 
distinguishing property observed in natural immunoglobulin binding proteins. Fassina 
et al. (1996) designed a tetrameric peptide library to search for a Protein A mimetic 
ligand. TG19318 coupled to Eupergit C30N has been employed for one-step 
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purification of IgG antibodies directly from crude sera. However, TG19318 affinity 
columns are not specific in their binding to IgG and interact with IgM (Palombo et al., 
1998), IgA (Palombo et al., 1998), IgE (Palombo et al., 1998), and IgY (Verdoliva et 
al., 2000). Similarly, a hexameric ligand, HWRGWV, has been investigated by Yang 
et al. (2006) for human IgG purification. The peptide had a broad binding spectrum 
with affinity for all subclasses of hIgG, hIgD, hIgE, hIgM and to a lesser extent, 
human secretory IgA. In addition, most of the biomimetic ligands that have been 
designed to mimic the Fc-protein A binding behavior bound to the Fab (and Fc) 
fragment(s) of IgG.  
Purification of monoclonal antibodies by epitope chromatography also has been 
investigated. Sepharose coupled pentameric peptide, PDTRPAP, was found to be 
highly efficient in purifying anti-epithelial mucin mAbs from hybridoma tissue 
cultures (Murray et al., 1997; Murray et al., 1998) and ascites fluids (Price et al., 
1991). The pentameric peptide interacts with the Fab region of anti-epithelial mucin 
mAb. This apparently renders the ligand unsuitable for purifying other mabs 
belonging to the same class.  
IgA-binding proteins of Streptococcus pyogenes are members of the M protein family. 
Studies on such IgA-binding M proteins have suggested that a sequence of 29 amino 
acid residues is sufficient for IgA-binding (Johnsson et al., 1994). Sandin et al. (2002) 
described the successful application of a 50-residue synthetic peptide, comprising the 
29-residue region, for single-step affinity chromatography of human IgA from serum 
and saliva. The ligand showed specificity in isolating IgA with negligible interaction 
with IgG and IgM. The above strategy motivated us to investigate a similar approach 
for affinity purification of IgM, albeit using a smaller ligand. The work described in 
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this chapter focuses on designing a biomimetic peptide that is specific in its binding to 
IgM and can thereafter be employed as an affinity ligand for IgM purification. The 
second part of this chapter is an attempt to investigate the mechanism of the 
interaction of the biomimetic ligand to IgM.  
4.1.2 Approach to Ligand Design 
Figure 4-1 describes the systematic approach involved in the design and development 
of a „universal‟ affinity chromatographic system utilizing immobilized biomimetic-
peptidic ligands for IgM purification. The entire process can be divided into two 
parts- ligand design and chromatographic studies. Ligand design is a systematic 
multistage procedure that begins with the critical step of developing a rationale to 
create the ligand. Determination of the nature of interaction between the analyte and 
the ligand, ligand synthesis at low costs and high yields, quantitative/ qualitative 
evaluation of the ligand performance and immobilization of the ligand to form a 
homogenous chromatographic matrix follows. The success of an affinity purification 
process depends vastly on the success of the ligand design process. 
We sought to identify a “universal” biomimetic ligand for IgM thus requiring the 
peptide to be an Fc receptor of IgM and not a Fab receptor. With the intent of using 
the interactions between IgM and the naturally-occurring protein as the template for 
the design of the biomimetic ligand, it was important to identify a protein that is a 
natural Fc receptor to IgM. At the same time, it was necessary that the naturally 
occurring Fc receptor exhibited affinity for IgMs from different species, in particular 
human IgM. In recent years, the focus of the industry has largely shifted on generating 
chimeric, humanized and fully human IgMs for therapeutic applications. This is 
because mabs produced by hybridoma technology are of mouse origin. Mouse 
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antibodies are seen by the human immune system as foreign and the human patient 
mounts an immune response against them, producing HAMA („human anti-mouse 











A thorough literature survey suggested that dimers and larger polymers of human IgA 
(collectively called pIgA) and human pIgM bound specifically to the human 
polymeric immunoglobulin receptor (hpIgR)/ transmembrane secretory component 
(SC) (Brandtzaeg et al., 1985). Besides binding to human IgM, hpIgR is also known 
to bind murine IgM and rat IgM (Jones et al., 1987). Interactions between hIgM and 
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Figure 4-1 Stages in the development of an affinity chromatography system 
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hpIgR thus appeared suitable to be used as the template for the design of the 
biomimetic ligand. Figure 4-2 is a schematic representation of the structure of hpIgR 
(Kaetzel, 2001). hpIgR is a 100-120 kDa type 1 transmembrane protein with five Ig 
like extracellular domains and a long cytoplasmic tail containing signals for 
intracellular sorting and endocytosis. Once formed, the hpIgR-pIg complex undergoes 
endocytosis in human body and is transported to the apical face of the cell. At this 
site, the extracellular ligand binding segment of hpIgR gets proteolytically cleaved. 
The released portion of the receptor, referred to as SC, remains associated with the 
polymeric Ig to form secretory IgA or IgM. (Musil and Baenziger, 1987). Interaction 
studies between free SC and J chain containing pIgM suggests the binding constant 






 (Brandtzaeg, 1977).  
 
Figure 4-2 Structure of the Human Polymeric Immunoglobulin Receptor 
(Adopted from Kaetzel, 2001)  
Studies carried out by Goldblum et al. (1996) revealed that binding of human pIgM to 
hpIgR depends preferentially on a strong interaction with domain 1 (D1). This was 
further investigated by Roe et al. (1999), who exploited the difference in the 
interaction of human polymeric immunoglobulins (pIgs) with rabbit and human pIgR 
to characterize the sites of interaction of pIgM with hpIgR. hpIgR interacts with pIgs 
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with high affinity. On the other hand, rabbit pIgR interacts primarily with pIgA and 
has negligible affinity for pIgM. A series of chimeras were constructed to assess the 
relative role of the various regions. It was found that replacing D1 of rabbit origin 
with human D1 established pIgM-binding properties in rabbit pIgR. On the other 
hand, human chimeric receptor containing rabbit D1 exhibited reduced binding 
affinity for pIgM. These results established the critical role of D1 in initiating non-
covalent forces of interaction between pIgM and hpIgR. hpIgR-D1 consists of three 
complimentary determining regions (CDR)-like loops. To evaluate the relative role of 
the regions containing the different CDR-like loops, Roe et al. (1999) divided domain 
1 into three regions A, B, and C that contained the CDR-like loop 1, 2, or 3, 
respectively (Figure 4-3).  
    
Figure 4-3 Comparison of the deduced amino acid sequences of the 
experimentally interchanged regions A, B and C of human (H) and rabbit (R) 
pIgR domain1 (Adopted from Roe et al., 1999) 
A series of chimeras were constructed to assess the relative role of the various 
regions. The human regions were replaced alone, or in combination, with the same 
region(s) from rabbit D1, resulting in six different mutants. Binding studies between 
pIgM/pIgA and the various chimeric constructs suggested that the region containing 
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the CDR2-like loop is the most important in the pIgM-binding process and replacing 
this region in the human receptor with the rabbit counterpart will significantly reduce 
the pIgM-binding capacity (Figure 4-4). It was also concluded from the studies that 
combining the two human D1 regions that contained the CDR1- and CDR2- like 
loops can reconstitute pIgM binding to a level approaching that of human receptor 
(Roe et al., 1999).  
 
Figure 4-4 Schematic diagram of various chimeric domain 1 (D1) constructs with 
a human pIgR backbone (D2–5), and their relative binding of I-labeled 
pentameric IgM (pIgM) and pIgA compared with the relative binding of the two 
ligands to wild-type human or rabbit pIgR (Adopted from Roe et al., 1999) 
The above mentioned observations motivated us to investigate the suitability of a 
peptide incorporating the CDR2-like loop (SSEGY) for IgM isolation and 
purification. Several other factors that were accounted for during ligand design were: 
1)  Most peptides, 20 residues or less, can be synthesized without major difficulty. As 
peptide length increases, yield of correct peptide sequence becomes a major 
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consideration. Long sequences contribute to synthesis as well as purification 
difficulties [12].  
2) Peptide sequences containing 10-20 residues can assume some degree of 
secondary structure [13].  
3) An important factor in ligand design is to make provision for site-directed 
oriented immobilization of the ligand. The most common coupling methods rely 
on the presence of free amino (α-amino or Lysine), sulfhydryl (Cysteine) or 
carboxylic acid groups (Aspartic acid, Glutamic acid or terminus carboxyl). The 
residue involved in coupling i) should be a terminal residue and ii) should not be 
present in multiple numbers. If multiple reactive sites are present, the peptide 
should be shortened (if possible) [13]. 
Figure 4-5a shows the ribbon diagram of hpIgR-D1. The CDR2-like loop (res 51-55) 
is a part of the β-hairpin structure adopted by residues 47 to 56. Serine (res 52), 
glutamic acid (res 53), and glycine (res 54) constitute the turn region while serine (res 
51) and valine (res 55) are part of the two anti-parallel beta strands C (res 47-51) and 






 Figure 4-5a Ribbon diagram of hpIgR-D1 (Adopted from Hamburger et al., 2004) 
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Figure 4-5b Secondary structure of hpIgR-D1 as assigned by Stride (PDB Code: 
1XED) 
On the basis of the above observations and considerations, two ligands 
a) pep12, a12 amino acids (aa) long peptide with a sequence ITLISSEGYVSS 
b) pep14, a14 aa long peptide with a sequence CITLISSEGYVSSK 
were examined.  
pep12 
Residues 47-56 were deemed essential as this would allow the proposed ligand to i) 
incorporate the CDR2-like loop ii) possibly adopt the native β-hairpin structure in 
aqueous phase. Residues 57 (serine) and 58 (serine) were added to enhance peptide 
solubility. Residue 59 (lysine), though highly hydrophilic, was not incorporated as 
lysine at the C-terminus would introduce an additional amine moiety. With amines 
present at N- and C-terminus, it is likely that the peptide would exhibit multiple 
orientations on immobilization, rendering the matrix heterogeneous. 
pep14 
With a view to increase ligand hydrophilicity, pep14 was synthesized. Cysteine 
(residue 46) was added onto the pep12 sequence at the N-terminus to make provision 
for site-directed immobilization of the ligand. Any residue additions were possible at 
the C-terminus thereafter. Peptide length, as mentioned earlier, is restricted by 
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constraints of solubility and difficulty in peptide synthesis. Peptide companion 
software was used to estimate the difficulty in peptide synthesis. It was found that for 
all the proposed sequences (Table 4-1), synthesis difficulty was relatively identical. 




 residue from N-terminus, respectively, 
were predicted as the steps with highest difficulty level. The focus was thus shifted to 
determine the solubility of the various proposed peptides. Peptide Property Calculator 
was used to evaluate the average hydrophilicity and the percentage of the hydrophilic 
residues in each sequence.  












46-58 CITLI(SSEGY)VSS 13 -0.5 38% 
46-59 CITLI(SSEGY)VSSK 14 -0.2 43% 
46-60 CITLI(SSEGY)VSSKY 15 -0.4 40% 
46-61 CITLI(SSEGY)VSSKYA 16 -0.4 38% 
46-62 CITLI(SSEGY)VSSKYAG 17 -0.4 35% 
46-63 CITLI(SSEGY)VSSKYAGR 18 -0.3 39% 
The 14 aa peptide, res 46-59 with the sequence CITLI(SSEGY)VSSK, was found to 
have the highest hydrophilicity and the highest percentage of hydrophilic residues and 
was chosen for further investigation. Secondary structure prediction of pep12 and 
pep14 was performed using PEP-FOLD, an online tool to predict peptide 3D 
conformation. The results suggested that pep12 and pep14 adopted the native β-
hairpin conformation (Figure 4-6).   
                                                                                                               Biomimetic Affinity Ligand Design 
 77 
                     
                        (A)             (B) 
Figure 4-6 Predicted secondary structure of A) pep12 B) pep14 
4.1.3 Results and Discussion 
4.1.3a   Binding Studies 
Evaluation of pep12 binding activity was performed through adsorption studies 
between pep12-immobilized SA microspheres and hIgM. No binding was observed 
between the entities suggesting negligible affinity of pep12 for hIgM. High costs 
associated with the adsorption studies (requirement of large quantities of peptide, 
linker and immunoglobulins) necessitated the adoption of SPR assays for further 
evaluation of ligand performance. Studies were performed on an hIgM/ hIgG1-
immobilized CM5 biosensor chip. Successful immobilization of hIgM/hIgG1 was 
performed by using amine coupling chemistry (Figure 4-7). 16 µM pep12 and pep14 
samples prepared in HBS-EP served as analytes. Interaction studies were performed at 
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25ºC at a flow rate of 2 μL/min. CM5-immobilized hIgM and hIgG1 (ligand) density 
was equivalent to 3330 and 2960 RU respectively. 
 
  
Figure 4-8 shows the overlaid reference-subtracted sensogram obtained for the 
interaction between the proposed ligands and hIgM. Flat profiles obtained during the 
association and dissociation phases of interaction between pep12 and immobilized-
hIgM suggests the absence of physical interactions between the two entities. 
Exponential nature of the curves obtained during the association and dissociation 
phases for the interaction between pep14 and immobilized hIgM suggests binding 
between the two entities.  
The results of the binding studies performed between immobilized hIgG1 and the 
proposed ligands are shown in Figure 4-9. Flat profiles were obtained for the 
interaction between hIgG1 and pep12 and hIgG1 and pep14. These results suggest 
 1 
Figure 4-7 Representative sensogram for immobilization of hIgM (myeloma) 
using amine coupling chemistry. Stages of coupling: (i) Injection of NHS-EDC 
sample (ii) Injection of hIgM-sodium acetate sample (iii) Injection of 1 M 
ethanolamine solution 
 
(i)  (ii) (iii) 
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that pep14 was highly specific in its interaction to hIgM with negligible affinity for 







Figure 4-8 Representative reference-subtracted sensogram for binding between 
immobilized hIgM and A) pep14 and B) pep12. Flow rate: 2 µL/min. Flow 
channel 1 (Fc1) served as a reference surface. Temperature: 25ºC     
 
Figure 4-9a SPR-based binding studies between immobilized hIgG1 and pep12 
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Figure 4-9b SPR-based binding studies between immobilized hIgG1 and pep14 
CD studies were performed to assess the aqueous phase secondary structure of pep12 
and pep14. Figure 4-10 shows the CD results obtained for pep12 and pep14. The CD 
results, as analyzed by PEPFIT Analysis, suggest the absence of native β-hairpin 
structure in pep12 and pep14. Both the ligands exhibited a flexible conformation, 
consisting mainly of a mixture of coil and turn. Table 4-2 shows the results of PEPFIT 
Analysis. The experimental and predicted data were in good agreement with each 
other as inferred from high R
2
 values. 
The failure of pep12 to bind hIgM was quite unexpected as both pep12 and pep14 
contained the residues present in the CDR2-like region of hpIgR-D1. It became 
apparent, however, that removal of lysine or cysteine or both could result in the loss 
of binding activity of pep14. Critical-residue-identification was performed through 
SPR-based binding studies between pep13 and immobilized hIgM/hIgG1. pep13, a 
13-mer peptide had an amino acid sequence of ITLI(SSEGY)VSSK. It differed from 
pep14 with regards to a deleted cysteine residue. Identical experimental conditions 
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were maintained as used during pep12/pep14-hIgM studies. Flat profiles were 
obtained during the association and dissociation phases of interaction between pep13 
and immobilized hIgM (Figure 4-11a) and pep13 and immobilized hIgG1 (Figure 4-
11b). These results suggest the absence of affinity between the entities.  
  
Figure 4-10 CD spectra of (A) pep12 (B) pep13 and (C) pep14. The dots are 
experimental data while the solid lines represent the predicted data as generated 
by PEPFIT Analysis 
















pep12 ITLISSEGYVSS 0 3 22 0 0 43 0 32 0 100 0.99 
pep13 ITLISSEGYVSSK 0 0 30 0 0 44 0 26 0 100 0.98 
pep14 CITLISSEGYVSSK 0 0 40 0 0 39 0 21 0 100 0.98 
pep14A CITLISSAGYVSSK 0 0 30 0 0 30 0 28 12 100 0.98 
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Figure 4-11a SPR-based binding studies between pep13 and immobilized hIgM 
 
 
Figure 4-11b SPR-based binding studies between pep13 and immobilized hIgG1. 
CD studies were performed to determine the aqueous phase secondary structure of 
pep13 (Figure 4-10). The CD results as analyzed by PEPFIT Analysis suggest a 
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conformation similar to pep12 and pep14 (Table 4-2). These results ascertained that 
lysine was not the critical residue and cysteine in pep14 was necessary for pep14-
hIgM interaction.   
4.1.3b Mechanism of pep14-IgM Interaction 
Based on the results presented in the previous section, together with published data, 
the following key points with regards to pep14-hIgM binding mechanism could be 
derived: 
1) Studies by Roe et al. (1999) have shown that CDR2-like loop in hpIgR-D1 is 
essential for hIgM binding. However, pep12 and pep13 containing the CDR2-like 
loop did not exhibit any interaction with hIgM. pep14, on the other hand, 
interacted with hIgM. It can thus be inferred that the CDR2 region alone was not 
sufficient for binding.  
2) Thiophilic adsorbents are a class of sulfur-containing immobilized ligands with 
high affinity for immunoglobulins. Though the mechanism of interaction is 
unknown, it is well established that Fc, Fab, and F(ab')2 immunoglobulin 
fragments are thiophilic in nature. The interaction is group-specific and not 
directed towards any particular immunoglobulin (Hutchens, 1992). Experiments 
had shown that the presence of cysteine in pep14 was essential for hIgM binding. It 
is thus evident that group-specific thiophilic-like forces arising from the presence 
of sulfur atom in pep14 was crucial for ligand activity.   
3) CD analysis has shown pep14 to exhibit a flexible conformation, consisting mainly 
of a mixture of coil and turn. Regan (1997) suggested that different amino acids 
might have varying abilities to adopt a particular conformation. The propensity of 
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amino acids for different secondary structure is listed below (Constantini et al., 
2006). 
a) Alanine, leucine, methionine, glutamic acid, glutamine, lysine and arginine 
have intrinsic α-helix forming propensity.  
b) Tyrosine, tryptophan, isoleucine, valine, threonine, phenylanaline and cysteine 
are β-sheet preference amino acids.  
c) Glycine, proline, aspartic acid, asparagine, histidine and serine disrupt 
secondary structures, α-helix and β-sheet, and are known as secondary structure 
breakers. 
With reference to the above, it is likely that residues at position 6 (Ser), 7 (Ser), 8 
(Glu) and 9 (Gly) form an integral part of the solvent-exposed reverse turn in pep14. 
The role of the residues SSEGY in pep14 was evaluated through SPR-based 
interaction studies between immobilized hIgM and pep5A. pep5A 
[CITLI(AAAAA)VSSK] was similar to pep14 except for the replacement of the 
residues of the CDR2-like loop (SSEGY) with alanine (A). A 16 µM sample of 
pep5A in HBS-EP buffer was used in the study. Experimental conditions were 
identical to those used during pep14-hIgM studies. pep5A showed no binding to hIgM 
(Figure 4-12). It was thus hypothesized that residues- SSEGY in pep14 could be 
involved in hIgM interaction. CD studies were performed to determine the aqueous 
phase secondary structure of pep5A. The CD results as analyzed by PEPFIT Analysis 
suggest a conformation similar to pep14 (Table 4-2). It can thus be ascertained that 
the residues SSEGY had a significant role to play in pep14 activity. These results are 
in close agreement to the observations of Roe et al. (1999). The authors had suggested 
that residues, SSEGY, constituting the CDR2-like loop in hpIgR-D1 were necessary 
for hpIgR-hIgM complex formation.  
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Figure 4-12 Representative sensogram for the interaction of pep5A to CM5-
immobilized hIgM  
4) Sequence comparison of the CDR2-like loop of human, bovine, rabbit, rodent and 
chicken pIgR shows the absence of the charged residue, glutamic acid, in the 
CDR2-like loop of rabbit, chicken and rat (Figure 4-13). Incidentally, these are 
also the species that do not interact with pIgM (Hamburger et al., 2004). The data 
suggests that glutamic acid may have a key role to play in attributing specificity to 
pIgR-D1 to interact with IgM.  
Rabbit    A   S   T   G Y 
Rat    S   S   N   G Y 
Mouse    S   S   N   G Y 
Bovine    S   S   E   G Y 
Human    S   S   E   G Y 
Figure 4-13 Comparison of the CDR2-like loop of different species 
The role of glutamic acid in pep14 was evaluated through SPR-based interaction 
studies between immobilized hIgM/ hIgG1 and pep14A. pep14A was identical to 
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pep14 except for the substitution of glutamic acid with alanine. A 16µM sample of 
pep14A in HBS-EP buffer was used in the study. Experimental conditions were 
identical to those used during pep14-hIgM studies. pep14A showed no binding to 




Figure 4-14b Representative sensogram for interaction of pep14A to CM5-
immobilized hIgG1  
Figure 4-14a Representative sensogram for interaction of pep14A to CM5-
immobilized hIgM  
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CD studies were performed to determine the aqueous phase secondary structure of 
pep14A. The CD results as analyzed by PEPFIT Analysis suggest a conformation 
similar to pep14 (Table 4-2). These results suggest that solvent exposed glutamic acid 
was possibly serving as a point of electrostatic attraction and its presence was vital for 
ligand specificity. Serine, glycine and tyrosine did not interact with IgM, rather they 
played a key role in governing the secondary structure of pep14. 
Considerable degree of likeness is evident in the binding mechanism exhibited by 
pep14 and hpIgR-D1 in their interaction to hIgM. hpIgR-D1 contains three CDR-like 
loops, which together form the binding region for pIgs. hpIgR-D1 structure (PDB ID: 
1XED) reveals that CDR3 is positioned away from the other CDRs. Therefore, a 
protein contacting the CDR1 and CDR2 regions of hpIgR-D1 may find it difficult to 
simultaneously contact CDR3 (Hamburger et al., 2004). Similar observations can be 
seen in the works of Roe et al. (1999). The authors suggested that the region 
containing the CDR2-like loop is the most essential for pIgM binding. The region 
containing the CDR1-like loop also contributed substantially to this interaction, 
whereas only little contribution was provided by the region containing the CDR3-like 
loop. CDR1 is a highly conserved region of D1 among different species of pIgR and 
has been proposed to make essential contacts with dIgA. Interaction between SC(15-
37), a 23 aa long synthetic peptide fragment containing the CDR1 region of pIgR-D1, 
to immunoglobulins has been studied. The peptide bound Igs indiscriminately, that is, 
it bound to pIgs as well as monomeric IgA and IgG (Bakos et al., 1991). While 
SC(15-37) bound all Igs, pIgR-D1 recognizes only pIgs. This implies that though 
CDR1-like loop could generate group-specific forces of attraction (pre-concentration), 
only those immunoglobulins that were able to interact with CDR2-like loop were 
successful in forming a complex.  
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The forces between CDR1 and Igs appear to be electrostatic. Point mutations in the 
CDR1 region of the rabbit pIgR-D1 highlighted the importance of three charged 
residues (two arginines and a lysine). Substitution of these residues with alanine 
abolished pIgR binding to dIgA (Coyne et al., 1994). In case of pep14, however,    
pre-concentration appears thiophilic-like in nature, attributable to the presence of the 
cysteine residue in pep14. Glutamic acid, located in the CDR2-like loop, appears to 
induce specificity in hpIgR-D1 and pep14 through electrostatic interactions with IgM. 
The binding mechanism between pep14 and hIgM can therefore be summarized as- 
Cysteine in pep14 is critical for inducing thiophilic-like interactions between the 
ligand and IgM while glutamic acid has a significant role in attributing specificity to 
the ligand to interact with IgM.  
Most peptides of biological interest are derived from N-terminal, C-terminal, or 
internal sequences of native proteins [14]. Many peptides corresponding to protein α-
helical sequences adopt native helices in aqueous environments (Francisco et al., 
1994). However, as seen here and several reported in the literature, peptides derived 
from a protein region with β-hairpin structure do not assume the same configuration 
in the aqueous phase. This brings us to an interesting observation that the interaction 
between IgM and pep14 biomimetic ligand was possibly governed primarily by the 
primary structure of the ligand and was less dependent on the secondary structure of 
the ligand.  
4.1.4 Concluding Remarks   
As described by Sousa et al. (2008) “Peptide-based affinity chromatography 
represents a particularly promising approach because it combines the selectivity of a 
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naturally-occurring biological interaction with the simplicity of a single small 
molecule”. Interactions between naturally-occurring hpIgR and hIgM were used as 
template to design a peptidic ligand with affinity for IgM. Several synthetic peptides 
incorporating the complementarity determining region 2 of domain 1 of hpIgR-D1 
were investigated for their interactions with hIgM and hIgG1. pep14, a 14mer peptide 
with the sequence CITLI(SSEGY)VSSK, showed specific interactions with hIgM and 
negligible affinity for hIgG1. CD studies suggested the absence of native β-hairpin 
structure in pep14. The ligand exhibited a more flexible conformation, consisting 
mainly of a mixture of coil and turn. Alanine substitution studies were conducted to 
obtain an insight into the overall binding mechanism of pep14 and hIgM. Cysteine in 
pep14 was found to be responsible for generating pre-concentration while glutamic 
acid was responsible for inducing specificity for IgM.  
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4.2 Binding Characteristics of pep14  
4.2.1 Introduction 
Label-based and label-free techniques are two commonly used strategies for 
investigating the binding characteristics of biomolecules. The label-based techniques 
require labelling of molecules with labels such as fluorescent dyes, epitope tags, 
radioisotopes, etc. The label-free methods, on the other hand, depend on the 
measurement of an inherent property of the molecule itself (e.g. mass and dielectric 
property) (Espina et al., 2004, Li et al., 2004). While easy availability of reagents and 
simple instrument requirements have resulted in wide spread application of label-
based techniques, the techniques suffer from several drawbacks including i) possible 
alteration of surface characteristics and ii) the labelling procedure is laborious and 
lengthy. The label-free techniques, however, do not involve any surface modifications 
and thus avoid any interference due to tagging molecules. In recent years, many label-
free techniques such as SPR, carbon nanotubes, nanowires, interferometry, etc., have 
been developed and are rapidly emerging as potential alternatives to labelling 
methods (Yu et al., 2006). In the present research, SPR, a label free technique, was 
used extensively for pep14 characterization. Advantages offered by the SPR 
technique include i) real time measurement ii) qualitative and quantitative 
measurements and iii) multiplex analysis (Ray et al., 2010).  
Chapter 4.1 described the design of a peptidic ligand, pep14, a 14mer peptide that 
bound selectively to human IgM (hIgM) and showed negligible affinity for human 
IgG1 (hIgG1). The mechanism of interaction was explored to better understand the 
forces prevalent in a small peptide-large protein pair system. This chapter describes 
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the various characterization studies that were performed to evaluate the efficacy of 
pep14 as an affinity ligand for chromatographic purification of IgM. A procedure for 
synthesis of pep14 in high yields and low costs is described. Physical properties of 
pep14, determined using Peptide Property Calculator, are listed below: 
(i)  Molecular Weight: 1486.7 Da    (ii)   Net charge at pH 7: 0 (Figure 4-15a)  
(iii) Iso-electric point, pI: 6.3 (iv)  Average hydrophilicity: -0.2 (Figure 4-15b)  
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4.2.2 Characterization Studies 
4.2.2a  Ligand Orientation and Specificity  
As described by Carter (1996) “Orientation of the peptide sequence, as immobilized 
to an affinity matrix, is a significant regulator in modulating antibody recognition and 
specificity. It is thus important to conjugate the peptide in a manner that will 
encourage appropriate native-like binding”. Studies were performed by Murray et al. 
(1997) to determine the effect of the orientation of the mimotope, KSKAVGC. The 
mimotope retained its binding activity when coupled through the N-terminus. 
However, the C-coupled mimotope peptide matrix failed to bind the antibody. 
Chapter 4.1 described the interaction between immobilized hIgM/ hIgG1 and pep14. 
pep14 interacted specifically to immobilized hIgM but did not exhibit affinity for 
hIgG1. Immunoglobulins do not contain free cysteine while BSA is a thiol-bearing 
protein (Kaplan et al., 1980). It was hypothesized that cysteine in pep14 might 
interact non-specifically to BSA through disulfide bond formation. Binding 
experiments were performed between immobilized BSA and pep13/ pep14. pep13, 
ITLI(SSEGY)VSSK, is a 13 mer peptide identical to pep14, expect that it is devoid of 
cysteine at N-terminus. No binding was observed between pep13 and immobilized 
BSA. On the other hand, interactions were observed between immobilized BSA and 
pep14 (Figure 4-16).  




These results suggest that cysteine in pep14 was interacting with BSA. Coupling of 
pep14 to chromatographic matrix should thus be performed through the sulfhydryl 
group in cysteine. Figure 4-17 shows the sensogram obtained for the immobilization 
of pep14 to CM5 biosensor chip using ligand-thiol coupling chemistry. Leaching of 
non-specifically bound pep14 took place slowly after the coupling procedure. pep14-
immobilized sensor surface was allowed to attain a stable response level before 
conducting the binding experiments. As mentioned earlier, a pH of 4.5 was 
maintained during pep14 immobilization. Under these conditions, pep14 and carboxyl 
surface would have assumed a positive and negative charge, respectively. Ionic 
interactions between oppositely charged pep14 and the carboxymethylated biosensor 
surface could be responsible for the non-specific binding between the entities. 
Figure 4-16 Overlaid reference-subtracted sensogram for the interaction of 
immobilized BSA to A) pep14 B) pep13. Concentration of analyte ~16 µM. 
Mobile phase: HBS-EP. Flow rate: 2 µL/min  
 




Figure 4-17 Representative sensogram for the immobilization of pep14 to CM5 
biosensor chip using ligand-thiol coupling chemistry 
Several reports suggest the loss of ligand activity upon immobilization. SPR-based 
binding studies were thus performed between immobilized pep14 and hIgM/ hIgG1/ 
hIgE/ hIgA1/ BSA to ascertain the behavior of pep14 upon coupling to the matrix 
surface. Figure 4-18 shows the overlaid reference-subtracted sensogram obtained for 
the interaction of immobilized pep14 to the analyte molecules. The concentration of 
each of the analyte samples used in this study was 50 nM. The exponential nature of 
the curve obtained during the association and dissociation phases for the interaction 
between pep14 and hIgM suggests binding between the entities. On the other hand, 
flat profiles were obtained during the association and dissociation phases of the 
sensograms for the interaction between immobilized pep14 and hIgG1/ hIgA1/ hIgE/ 
BSA. Binding studies were also performed between IgG obtained from human sera 
and immobilized pep14. No binding was observed between the entities (data not 
shown). Though mammalian cell culture allows the production of monoclonal 
   Slow leaching 
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antibodies on a large scale, their purification can encounter problems due to low 
antibody concentration in culture supernatants or interference due to the presence of 
other proteins. Albumins are the major contaminants present. Non-specific 
endogenous antibodies that are either produced by the host animal or added as 
supplements to the culture media (fetal calf serum) are also occasionally encountered 
(Josic and Lim, 2001). The above results established the retention of activity and 
specificity of pep14 for hIgM on immobilization and negligible affinity for 
contaminating proteins. pep14 exhibited a binding behavior similar to its parent 
protein, hpIgR, in interacting specifically with IgM. (hpIgR interacts specifically with 
polymeric immunoglobulins i.e. pIgM and pIgA). hIgA1 used in the study was 
monomeric in nature. Therefore, failure of pep14 to bind hIgA1 is justified.  
 
Figure 4-18 Interaction of immobilized pep14 to A) hIgM B) hIgE C) BSA         
D) hIgA1 E) hIgG1. Ligand density: 422 RU. Flow rate: 20 μL/min  
One of the reasons for the wide acceptance of affinity chromatography lies in its 






                                                                                                               Binding Characteristics of  pep14 
 96 
of IgM in culture supernatants can be as low as 10 μg/mL. Experiments were thus 
conducted to evaluate the effect of analyte concentration on the recognition ability of 
pep14. The results obtained suggest that pep14 continued to recognize IgM at 
concentrations as low as 10 nM (~10 μg/mL) (Figure 4-19). 
 
Figure 4-19 Effect of hIgM concentration on the binding response A) 315 nM B) 
210 nM C) 157 nM D) 105 nM E) 52 nM F) 10 nM G) interaction profile of hIgM 
to the reference carboxymethylated dextran surface of the biosensor chip. pep14 
density was equivalent to 2545 RU  
 
Binding responses of 38 RU (Figure 4-18) and 124 RU (Figure 4-19) were obtained 
for a 50 nM hIgM sample interacting with immobilized pep14-CM5 sensor surfaces at 
ligand densities of 422 RU and 2545 RU, respectively. Ligand density thus has an 
important role in defining the binding capacity. It should, however, be realized that a 
high ligand density could possibly promote non-specific interactions. In order to 
simulate the interaction of hIgG1 (contaminant) in the crude feed to an actual high 
ligand density chromatographic column, it was decided to perform binding studies 
between immobilized hIgG1 and concentrated pep14 samples. hIgG1 immobilization 
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was performed using amine coupling chemistry on a CM5 sensor chip. An hIgG1 
density equivalent to 2965 RU was used. Figure 4-20 shows that pep14, even at high 
concentration, did not lose its binding specificity and showed negligible interaction 
with hIgG1. It can thus be inferred that high ligand densities could be employed for 
the actual chromatographic studies with no loss in specificity.  
 
Figure 4-20 Interaction between immobilized hIgG1 and A) 64.3 µM pep14 B) 32 
µM pep14. Mobile phase: HBS-EP buffer, Flow rate 2 μL/min 
All studies conducted so far involved interaction between pep14 and feeds containing 
only a single protein. Presence of large quantities of proteins, besides IgM, in the 
culture supernatant can result in a significant loss of binding capacity of pep14. This 
can be attributed to the steric hindrance/ crowding of the ligand sites by protein-based 
contaminants present in the feed mixture. It was thus vital to ascertain the behavior of 
pep14 when exposed to a mixture of proteins. SPR-based interaction studies were 
performed between immobilized pep14 and i) 100 μg/mL hIgM ii) protein mixture 
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containing BSA, hIgG1 and hIgM at a concentration of 1 mg/mL, 100 μg/mL  and 
100 μg/mL, respectively. The results obtained are shown in Figure 4-21.  
 
Figure 4-21 Representative sensogram for the interaction between immobilized 
pep14 and A) 100 μg/mL hIgM B) protein mixture containing BSA, hIgG1 and 
hIgM at a concentration of 1 mg/mL, 100 μg/mL and 100 μg/mL, respectively. 
Ligand Density: 422 RU, Flow rate 20 μL/min 
Comparison of the sensograms suggests only a 16% reduction in the binding capacity 
on exposing pep14 to a mixture of proteins. It is noteworthy that the present studies 
were conducted at a low ligand density (422 RU). High ligand densities can be 
employed successfully to overcome this loss in binding capacity. It was, however, 
necessary to verify if pep14 continued to retain its specificity when contacted with the 
above protein mixture; the molecules bound to the immobilized-pep14 surface was 
subsequently collected and analyzed by SEC. During SPR studies, non-specific 
interactions occurred between the proteins and the carboxymethylated dextran 
surface. In order to account for non-specific binding of the proteins, binding studies 
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were performed between Fc1 (reference surface) and protein mixtures Molecules 
bound to Fc1 and pep14 were collected and analyzed by SEC. Figure 4-22 shows the 
overlaid chromatograms obtained from SEC analysis.  
  
pep14 did not exhibit any loss in binding specificity and continued to bind only IgMs. 
The above studies instilled confidence in pep14‟s ability to isolate IgM, with minimal 
loss in binding capacity, and no loss in specificity even when contacted with protein 
mixtures like culture supernatants. 
4.2.2b Mobile Phase Selection  
Nature of Mobile Phase 
In order to obtain the best conditions for hIgM binding, the mobile phase needs to be 
optimized. Among many potential applicable buffers for chromatography, phosphate 
and HEPES buffer were selected in this research. These two buffers differ 




















Figure 4-22 SEC separation profile. Samples were separated by Superdex 200 
10/300GL. Flow rate: 0.25 mL/min. λ = 214 nm 
hIgG1 
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the matrix, thus influencing protein binding. Furthermore, they are biologically 
compatible. The compositions of the two buffers used were: i) 10 mM HEPES, 150 
mM NaCl, pH 7.4 (HBS) ii) 10 mM phosphate, 150 mM NaCl, pH 7.4 (PBS). 50 nM 
hIgM samples prepared in respective buffers were investigated for their binding to 
pep14. The biosensor chip was equilibrated with the binding buffer for two hours 
prior to the binding experiment. The results obtained are shown in Figure 4-23. hIgM 
samples prepared in PBS showed significantly lower and more erratic binding to 
immobilized pep14. Comparison of the sensograms suggests HEPES to be a more 
appropriate buffer. Phosphate buffer is an inorganic buffer and it is likely that buffer 
cations and anions interfered with the biological interaction of pep14 to hIgM. 
HEPES, on the other hand, is an organic zwitterionic buffer. The fact that anionic and 
cationic sites in HEPES are present as non-interacting groups could possibly explain 
for the low interference from HEPES during pep14-hIgM interaction [15].  
 
Figure 4-23 Interaction between immobilized pep14 and 50 nM hIgM sample 
with A) HBS B) PBS as mobile phase. Ligand density: 422 RU, FR: 20 µL/min  
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pH of Mobile Phase 
Proteins tend to aggregate at a pH equal to or near their isoelectric points, 
necessitating the working pH to lie away from this range. hIgMs have a pI in the 
range of 5.5-6.7 (Prin et al., 1995). Extensive exposure to pH conditions below 5.5 or 
above 8.5 can have an adverse impact on the bioactivity of IgM (Lim, 1987). The 
binding of hIgM to pep14 was thus investigated in a pH range of 7.4-8.5. 50 nM hIgM 
samples prepared in HBS-EP having a pH of 7.4, 8 and 8.5 were examined to 
determine the effect of pH. The results obtained are shown in Figure 4-24. 
 
Figure 4-24 Interaction between immobilized pep14 and 50 nM hIgM sample 
prepared in 10 mM HBS-EP buffer having a pH of A) 7.4 B) 8.0 and C) 8.5. 
Ligand density 422 RU. Flow rate 20 μL/min 
The results suggest a decrease in the binding response with an increase in the pH of 
the binding buffer. IgM and pep14 have an isoelectric point of 5.5-6.7 and 6.3, 
respectively. This means that any increase in the pH of the mobile phase beyond 6.7 
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would render pep14 and IgM negatively charged. Increased forces of repulsion 
between negatively charged pep14 and IgM could have possibly resulted in a decrease 
in the binding efficiency with an increase in the pH values. 
Ionic Strength of Mobile Phase  
Experiments were performed to determine the optimum ionic strength of the binding 
buffer for pep14-hIgM interaction. 50 nM hIgM samples were prepared in 10 mM 
HEPES, pH 7.4 with varying sodium chloride (NaCl) concentrations of 80 mM, 150 
mM and 300 mM. The CM5 sensor surface was equilibrated for two hours with the 
respective binding buffers before interaction studies. At low salt concentration (80 
mM), hIgM bound non-specifically to the dextran surface suggesting unsuitability of 
the binding buffer (Figure 4-25a). Besides non-specific binding, IgMs also tend to 
precipitate in low ionic strength solutions. A significant decrease in the binding of 
hIgM to pep14 occurred on increasing the NaCl concentration from 150 mM to 300 
mM (Figure 4-25b). Mutual forces of attraction between the biological entities 
possibly got disrupted on application of a high ionic strength buffer suggesting the 
involvement of ionic forces in pep14-hIgM interaction. In Chapter 4.1, it was shown 
that glutamic acid in pep14 served as a point of electrostatic interaction. The above 
results reaffirm our observation that ionic interactions arising from negatively charged 
glutamic acid (in pep14) indeed facilitated pep14-hIgM interaction.  
Results obtained collectively suggested that 10 mM HEPES, 150 mM NaCl, pH 7.4 
was the optimum binding buffer for pep14-hIgM interaction. 










Figure 4-25b Interaction between immobilized pep14 and 50 nM hIgM sample in 
10 mM HEPES, pH 7.4 containing A) 150 mM NaCl and B) 300 mM NaCl 
Figure 4-25a Interaction between 50 nM hIgM sample in 10 mM HEPES 
containing 80 mM NaCl, pH 7.4 to A) reference surface and B) pep14. Ligand 
density: 422 RU. Flow rate 20 μL/min 
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4.2.2c Binding Region in hIgM 
pep14 was derived from the amino acid sequence of a 120 kDa protein, human 
polymeric immunoglobulin receptor. hpIgR is an Fc receptor to hIgM and 
demonstrates binding to the heavy chain constant region (Cμ) of the hIgM molecule 
(Braathen et al., 2002). Binding to Fc fragment renders a ligand a „universal binder‟ 
for antibodies and can possibly diminish the optimization process for a new antibody 
of the same isotype and from the same species (Yang et al., 2005). We sought to 
ascertain in this part of the research, the region in hIgM that was interacting with 
pep14. SPR-based binding studies were performed between immobilized pep14 and 
fragments of hIgM molecule, namely Fab and Fc5μ. The fragments purchased from 
Rockland Immuochemicals Inc. (USA) had been obtained from hIgM myeloma 
protein by digestion with trypsin followed by column chromatography. The hIgM 
whole molecule has an average M.W. of 950 kDa, while Fab and Fc5μ fragments 
have an average M.W. of 45 kDa and 340 kDa respectively (Figure 4-26) [16].  
 
Figure 4-26 IgM whole molecule and fragments (Adapted from [16]) 
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HBS-EP was used for preparing the analyte samples. The results obtained are shown 
in Figure 4-27. No binding was observed for either of the hIgM fragments to pep14.  
 
Figure 4-27 Interaction between immobilized pep14 and A) hIgM whole molecule 
B) hIgM Fc5 fragment and C) hIgM Fab fragment. A 50 nM concentration for 
each of the analyte molecules was used 
Literature suggests that trypsin digestion results in a 15% loss in total IgM mass. An 
early report by Zikan and Bennett (1973) suggested that the portion lost during trypsin 
digestion was a polypeptide cleaved from the hinge area. IgM does not contain a 
formal hinge region as that found in IgG; instead, it contains an additional domain 
(C2) at the hinge site. Perkins et al. (1999) reported that digestion of hIgM with 
trypsin resulted in only a portion of the C2 domain to remain attached to the Fc5 
fragment. It is thus evident that a portion of the C2 domain is not present in either of 
the Fab or Fc5μ fragments tested. The sensogram (Figure 4-26) suggests binding 
between hIgM whole molecule and pep14 while no interaction was observed for 
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either of the two fragments to pep14. These results imply that pep14 is possibly 
binding to the Cμ2 region of hIgM. 
It is interesting to note that the Cμ2 domain of IgM is quite unique. While IgG, IgA 
and IgD contain three constant domains in the heavy chain (CH) region, four domains 
exist in IgM and IgE. Amino acid sequencing shows that CH1, CH2 and CH3 
domains of the γ/α chain correspond to CH1, CH3 and CH4 domains of the µ chain. 
The hinge region in IgG and IgA correlates to the CH2 domain in IgM. While the 
hinge region of IgG and IgA are proline rich, the CH2 domain of IgM is rich in 
carbohydrates (Pathak and Palan, 2005). Even though IgM and IgE contain the CH2 
domain, a mere 27% homology exists between the two. These observations make the 
CH2 domain of IgM stand apart from others and explain the specificity of pep14 to 
interact with IgM only. Essentially, pep14, being an Fc receptor to IgM, has the 
potential to be employed as a universal affinity ligand for IgM purification.  
4.2.2d  Effect of Ligand Density 
Each hIgM molecule can bind to a maximum of ten immobilized ligands at the same 
time. The term „avidity‟ has been used to describe the combined strength of such 
multiple bond interactions. It should, however, be noted that avidity is the combined 
synergistic strength of bond affinities rather than the sum of bonds [17]. SPR-based 
binding studies were performed between hIgM and high ligand density surfaces. Two 
CM5 biosensor surfaces, with pep14 density equivalent to 2545 and 3795 RU, were 
prepared. Coupling of pep14 was done using ligand-thiol chemistry. Figure 4-28 
shows the results obtained from the study. The results suggest higher hIgM binding 
response with increased ligand loading. However, the hIgM binding response did not 
increase linearly with ligand density. This is quite expected because when small 
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ligands are immobilized onto a matrix at high density, only a certain percentage of the 
binding sites contribute to the interaction with the target molecule. A significant 




Figure 4-28 Binding study between 50 nM hIgM and immobilized pep14 at a 
density equivalent to A) 3795 RU B) 2545 RU C) 422 RU D) reference surface. 
Flow rate 20 μl/min 
A typical affinity purification process consists of three steps; sample loading, washing 
and elution. To achieve high process yields, it is vital that the bound protein 
molecules do not dissociate during the washing stage. Figure 4-29 compares the rate 
of dissociation of hIgM from three pep14-immobilized CM5 surfaces. The ligand 
densities on the biosensor surfaces were equivalent to 422, 2545 and 3795 RUs, 
respectively. The results suggest that at high ligand densities, more number of ligands 
were able to interact with each molecule of hIgM resulting in slow rates of 
dissociation. On the other hand, higher rate of hIgM dissociation was observed for the 
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ligand density on the chromatographic matrix should be optimized to obtain high 
ligand utilization percentage and optimal binding strength between the interacting 
species.  
 
Figure 4-29 Effect of ligand density on the strength of interaction between hIgM 
and immobilized pep14 at a ligand density equivalent to A) 3795 RU B) 2545 RU 
C) 422 RU 
4.2.2e Choice of Eluent 
One of the major limitations associated with affinity chromatography is the loss of 
bioactivity of the target protein on exposure to elution conditions. The choice of an 
eluent should be based on the fulfillment of three criteria: (a) complete recovery of the 
bound molecules, (b) retention of the bioactivity of the target protein and (c) retention 
of the bioactivity of the immobilized ligand. 
IgM is a highly labile molecule and susceptible to denaturation on exposure to harsh 
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to assess the efficacy of fifteen possible eluents (Table 4-3). pep14 dissolved in HBS-
EP buffer served as the analyte. 100 mM Glycine-NaOH buffer at pH 9 was most 
effective for eluting bound pep14 without loss of IgM bioactivity.  










1 1 M Sodium Chloride 6 10 mM HCl 11 
50% Ethylene Glycol,       
pH 8.5 
2 4 M Magnesium Chloride 7 
10 mM Sodium Hydroxide,     
pH 9.0 
12 
25% Ethylene Glycol,  
pH 10 
3 
2 M Pottasium 
Thiocyanate in 1X PBS, 
pH 7.0 
8 1 M Ethanolamine, pH 8.0 13 
0.1 M Glycine-NaOH,  
pH 8.0 
4 
0.1 M Acetate Buffer,  
pH 3 
9 
0.1 M Sodium Bicarbonate,     
pH 8.5 
14 
0.1 M Glycine-NaOH,  
pH 8.5 
5 
10 mM Glycine-HCl,  
pH 2 
10 0.1 M Sodium Bicarbonate, pH 9 15 
0.1 M Glycine-NaOH, 
pH 9 
The next set of studies involved the use of 100 mM Glycine-NaOH, pH 9 to elute the 
bound hIgMs from pep14-immobilized CM5 surface (Ligand density~ 3795 RUs). A 
93% regeneration of the sensor surface was achieved.  
4.2.2f Interaction of pep14 to IgM from Different Species  
Studies were performed to determine the efficacy of immobilized pep14 in isolating 
IgM molecules derived from different species, namely mouse, bovine and rabbit. 
HBS-EP was used to prepare the analyte samples, each at a concentration of 50 nM. 
The results obtained are shown in Figure 4-30. Rabbit IgM interacted with 
immobilized pep14, though with lower affinity in comparison to human IgM. No 
interactions were seen between mouse IgM and pep14. It was observed that bovine 
IgM showed extensive non-specific binding to the dextran surface of the CM5 
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biosensor chip (Data not shown). As a result, no conclusive inference could be made 
for bovine IgM-pep14 interaction. 
 
Figure 4-30 Binding of pep14 to A) human IgM B) rabbit IgM and C) mouse 
IgM. Flow rate 20 µL/min  
As has been shown earlier, pep14 bound itself to the Cµ2 domain of human IgM. 
Comparison of the amino acid sequence of the Cμ2 domain of different species 
suggests a 43% homology between human and mouse and a 62% homology between 
human and rabbit (Bernstein et al., 1984) (Table 4-4). A lower degree of homology 
between human IgM and mouse IgM possibly explains the failure of mouse IgM to 
interact with pep14.  
Table 4-4 Homology matrix of the constant region domains of human, mouse and 
rabbit μ chains (Adapted from Bernstein et al., 1984) 
 C1 C2 C3 C4 
Human 
vs. Mouse 
27% 43% 53% 70% 
Human 
vs. Rabbit 
73% 62% 64% 80% 
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4.2.2g Stability of pep14 
One of the principal concerns in adapting affinity media to process scale is the 
stability of the ligand to the conditions used for cleaning- or sterilizing-in-place. 
Common column-sanitizing agents include ethanol (20-70%) and sodium hydroxide 
(100 mM-1 M). 20% ethanol is the most commonly used sanitizing agent, although it 
has no sporicidal effect and has only a partial viral inactivation effect. 70% ethanol, 
on the other hand, has the best germicidal efficiency. NaOH is commonly used at 
concentrations of 100 mM to 1 M (Ahuja, 2000). In order to evaluate ligand stability, 
pep14 samples (100 µg/mL) were prepared in each of the following solvents: HBS-
EP, 20% ethanol, 70% ethanol, 100 mM NaOH and 500 mM NaOH. The samples 
were gently shaken for 12 hours and RP-HPLC was used to analyze the samples every 
4 hours. Chromatograms obtained for pep14-HBS-EP sample at t= 0 and t= 12 hours 
are shown in Figure 4-31. Figure 4-31b shows the presence of 2 peaks. The peaks 
were identified as pep14 (t~ 9.7 minute) and its corresponding dimer (t ~10.1 
minutes) using MALDI-TOF analysis.  
HPLC analysis of the samples prepared in 20% and 70% ethanol and incubated for 
different time durations suggested that 20% ethanol and 70% ethanol had no adverse 
effect on pep14 stability. Chromatograms similar to the ones observed for pep14-
HBS-EP sample were obtained.  
HPLC results of the samples prepared in 100 mM and 500 mM NaOH, and incubated 
for 4 hours, are presented in Figure 4-32. Exposure of pep14 to 100 mM NaOH 
resulted in an additional peak at t~ 9.4 minutes. MALDI-TOF analysis suggested the 
molecular weight of the component to be 1292 Da, indicating the presence of a 
hydrolyzed product. Exposure of pep14 to 500 mM NaOH resulted in extensive 
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hydrolysis of pep14, as evident from the multiple number of peaks in the 
chromatogram. The use of 100 mM and 500 mM NaOH as sanitizing agents should 
therefore be avoided to prevent ligand loss.  
These results collectively suggest that 20% ethanol could be safely employed as a 







Figure 4-31 HPLC analysis of pep14-HBS-EP sample after incubation for (a) t= 
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Figure 4-32 HPLC analysis of pep14 in (a) 100 mM NaOH (b) 500 mM NaOH, 
after incubation for 4 hours 
4.2.3 pep14 Synthesis 
The characterization studies discussed in the preceding sections have established the 
suitability of pep14 for IgM purification. Subsequent to these, we sought to examine 
the possibility of synthesizing the peptide at low costs to conduct further studies. 
Previous synthesis approach employing PyBOP as the coupling agent suffered from 
low yields; with pep13 [ITLI(SSEGY)VSSK] being identified as the major deletion 
peptide in the crude. The MALDI-TOF results showed that the major hindrance to 
pep14 synthesis occurred at the stage of cysteine coupling (Figure 4-33). These results 
are comparable to that predicted by the Peptide Companion software (Figure 4-34) 
which estimates the relative difficulty in coupling a particular residue during peptide 
(a) 
  (b) 
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synthesis. The use of multiple numbers of deprotection and coupling stages even 


































Figure 4-33 MALDI-TOF results of the synthesized crude peptide using PyBOP 
as coupling agent.  pep13*- pep13 with substituted sodium ions. 
 
          Intermediate coupling 
               Difficult coupling 
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The use of alternative activators, namely HATU and HBTU, was attempted. HATU 
was found to be highly efficient in coupling cysteine and dramatic improvement in the 
yield of pep14 was obtained. HBTU, on the other hand, did not prove effective 
providing a low yield of pep14. HATU, however, is an expensive coupling agent and 
thus the total cost of synthesis was relatively high. Table 4-5 provides a comparison 
of the prices of three coupling agents (Source: NovaBiochem). 
Table 4-5 Price of coupling agents 
Chemical Quantity Price (USD) 
HATU 5 g $ 85.00 
HBTU 5 g $ 20.00 
PyBOP 5 g $ 28.00 
 
In order to minimize the synthesis cost, an attempt was made to perform peptide 
synthesis employing PyBOP for coupling the first twelve residues followed by the use 
of HATU for coupling cysteine. The MALDI-TOF results clearly demonstrate the 
efficacy of the designed protocol and its suitability for large scale synthesis (Figure     
4-35).  
Purified peptides must be rigorously tested for their purity. Purity greater than 80% is 
considered suitable for monoclonal antibody purification [18]. HPLC analysis of the 
purified pep14 sample suggested a purity of 95.7% (Figure 4-36). An average peptide 
synthesis yield of 65% was obtained. 
 
 




Figure 4-35 MALDI-TOF results of the synthesized crude peptide using PyBOP 
and HATU as coupling agents. 
 
 
           Figure 4-36 HPLC analysis of purified pep14 
4.2.4 Concluding Remarks 
pep14 was extensively characterized to evaluate its efficacy as an affinity ligand for 
IgM purification. In order to obtain the best conditions for hIgM binding, the mobile 
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the optimum binding buffer for pep14-hIgM interaction. Effect of ligand density and 
hIgM concentrations (10 μg/mL-300 μg/mL) on the binding characteristics were 
investigated. These studies highlighted the uniqueness of pep14 in capturing hIgM 
even at extremely low concentrations. Exposure of pep14 to a synthetic mixture 
consisting of hIgM, hIgG1 and BSA had no adverse effect on the binding capacity 
and specificity of pep14. SPR-based binding studies between immobilized pep14 and 
fragments of hIgM molecule, namely Fc5µ and Fab, suggested that pep14 was 
binding to a motif in the constant domain 2 of hIgM. This is the first known instance 
in which a small peptidic ligand is shown to bind specifically to the Fc fragment of 
IgM, a property normally associated with large ligands such as hpIgR. Studies were 
performed to determine the efficacy of immobilized pep14 in isolating IgM molecules 
derived from different species, namely mouse, bovine and rabbit. Rabbit IgM 
interacted with immobilized pep14, though with lower affinity in comparison to 
human IgM. pep14, however, failed to interact with mouse IgM. Stability of pep14 to 
common column-sanitizing agents including 20% ethanol, 70% ethanol, 100 mM 
sodium hydroxide and 500 mM sodium hydroxide was investigated. Results 
suggested the use of 70% ethanol for rigorous column sanitization while 20% ethanol 
was sufficient for regular cleaning. The above studies collectively established the 
uniqueness of pep14 as a universal affinity ligand for IgM purification.  
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4.3 Immobilization of Hydrophobic Peptidic Ligands 
to Hydrophilic Matrices  
4.3.1 Introduction 
One of the major concerns during peptidic ligand design pertains to the 
immobilization strategy that will eventually be used to covalently couple them to the 
chromatographic matrix [13]. Besides high coupling efficiency, the strategy should 
allow for site-directed, oriented immobilization of the peptides forming a 
homogenous matrix (Rusmini et al., 2007). The groups „available‟ in the peptide 
govern the coupling chemistry that can be used to conjugate it to the matrix. It is 
essential that the moieties crucial for antigenic determinance should not get involved 
in the coupling procedure (Betancor et al., 2006). Conjugating a peptide through its 
terminal amino acid is often the best choice as it avoids steric problems in epitope 
presentation rendering interactions with the antibody more permissible. In addition, it 
is important that the peptide be conjugated in an orientation that will encourage it to 
mimic the binding activity of the native protein (Carter, 1996).  
Immobilization of peptides through terminal amine or cysteine is a popular choice. 
Groups including isothiocyanates, isocyanates, acyl azides, NHS esters, sulfonyl 
chlorides, aldehydes, epoxides and oxiranes react rapidly with amine containing 
peptides to form stable amide or secondary amine bonds. Covalent immobilization of 
peptides to these reactive groups proceeds by one of the two chemical pathways: 
acylation or alkylation (Hermanson, 1996). Historically, cyanogen bromide activated 
matrices have been very popular. Their ability to efficiently couple amine 
functionalities under mild conditions is, however, offset by problems of ligand 
leaching and ionic properties associated with this chemistry [19]. Supports pre-
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activated with glutaraldehyde, epoxy or NHS esters are now more common for 
coupling amine containing peptides. Coupling of peptides containing N-terminal 
cysteine can be performed through the introduction of thiol reactive groups on the 
chromatographic matrix. The primary coupling reactions for modification of 
sulfhydryls proceed by one of the two routes: alkylation or disulfide-interchange, 
forming thioether and disulfide bonds, respectively. Groups showing reactivity 
towards cysteine/ thiols include haloacetyl and alkyl halide derivatives, maleimides, 
aziridines, acryloyl derivaties, arylating agents, thiol-disulfide exchange reagents 
(Hermanson, 1996). It is important to note that disulfide linkages are reversible in 
nature. Ligands coupled to the matrix using the disulfide exchange reaction are 
susceptible to leaching upon exposure to disulfide reducing agents and high pH 
conditions (Brocklehurst and Little, 1973). Chapter 4.2 described the use of 100 mM 
glycine-NaOH buffer at pH 9.0 as an eluent to recover bound hIgMs. Under the given 
pH conditions, slow leaching of pep14 might occur if a disulfide exchange reaction 
were used to couple it. It is thus vital to use a coupling technique that allows non-
reversible covalent immobilization for pep14.   
Pre-concentration is the mechanism of drawing a ligand molecule closer to the 
vicinity of the binding surface through i) physical forces of attraction or ii) 
minimization of forces of repulsion or mutual exclusion, between the entities 
(BIAapplications Handbook, GE). Pre-concentration, especially through ionic forces 
of attraction, play a vital role in influencing ligand immobilization. Notwithstanding, 
in the absence of such forces, coupling of ligands particularly hydrophobic ones could 
be difficult. Hydrophobicity of the peptides present challenges as: i) the peptides tend 
to be insoluble in the buffers commonly used during conjugation reactions, ii) a 
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highly hydrophilic surface or region tends to mutually exclude hydrophobic 
molecules, resulting in low coupling efficiency.  
Chapter 4.2 demonstrated the potential of pep14 as a universal affinity ligand for IgM 
purification. However, before pep14 could be investigated for large scale affinity 
purification of IgM, it was necessary to develop an immobilization strategy that 
would allow non-reversible covalent attachment of hydrophobic pep14 to the 
hydrophilic chromatographic matrix.  
Chapter 4.1 described the use of pep12-immobilized silica-amine matrix for pep12-
hIgM adsorption studies. Our results during coupling of hydrophobic pep12 to 
hydrophilic matrices (see Section 4.3.2a,b,c) established the importance of pre-
concentration in the immobilization of hydrophobic peptides to hydrophilic matrices. 
The use of matrix-spacer-ligand system has been the classical approach in designing 
affinity chromatography adsorbents. The use of spacers to distance an immobilized 
peptide from the surface of a support matrix introduces flexibility. Flexibility vests 
the immobilized peptide with increased mobility leading to higher protein capture 
efficiency (Weimer, 2000). Hydrophilic spacer molecules serve to alter the solubility 
properties of the immobilized peptides resulting in enhanced binding to protein 
molecules. Nevertheless, the effect of the crosslinkers in introducing pre-
concentration has not been studied. A unique way of introducing pre-concentration 
through the use of PEG-based linkers was developed during pep12 immobilization 
studies on hydrophilic SA matrix (see Section 4.3.2c). Coupling of pep14 was 
subsequently performed in the manner similar to pep12. 
One of the parameters crucial for the success of affinity chromatography is minimal 
non-specific interactions between the proteins and chromatographic support. Blocking 
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the free functional groups on the matrix surface after ligand immobilization is thus an 
integral part of most coupling procedures. Several functional groups are available that 
do not promote non-specific interactions. However, amine functionalities, if present 
on the matrix surface, can result in considerable non-specific binding of proteins. 
Coupling of cysteine-bearing ligands to amine-functionalized matrices using 
heterobifunctional crosslinkers containing NHS ester at one end and maleimide at the 
other is common. To date, no method to selectively block the free amine groups on 
the matrix after linker immobilization has been reported. Acylating agents, acetyl 
chloride and oxalyl chloride, were investigated as suitable quenching agents to 
selectively block the charged amine functionalities on the matrix. Table 4-6 
summarizes the physical properties of pep12 and pep14. The physical properties were 
determined using Peptide Property Calculator.  
Table 4-6 Properties of pep12 and pep14 
Property pep12 pep14 
Isoelectric point, pI 3.3 6.3 
Average Hydrophilicity (Hopp-Woods Scale) -0.4 -0.2 
Net charge at pH 7.0 -1 0 
4.3.2 Results and Discussion 
4.3.2a   Immobilization of pep12 to Carboxymethylated Dextran Surface 
Figure 4-37 shows the results obtained for immobilization of pep12 onto the 
carboxymethylated dextran surface using conventional amine coupling chemistry. The 
sensogram suggests negligible coupling of pep12 to the sensor surface.  
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Figure 4-37 Immobilization of pep12 to CM5 biosensor chip using amine 
coupling chemistry. (I) represents the baseline level after surface activation, (II) 
represents the baseline level at the end of the coupling process. Amount of ligand 
immobilized is equivalent to [(II) – (I)] = 57 RU 
Coupling of proteins to NHS esters is commonly performed at pH above 7. Such 
conditions facilitate the existence of amines in a deprotonated state allowing them to 
undergo nucleophilic substitution reaction with the NHS esters [20]. In the present 
study, pep12 dissolved in phosphate buffer, pH 7.3, was reacted with an activated 
carboxyl surface. Negligible coupling was observed. It is important to note that 
pep12, with a pI of 3.3, is acidic in nature and assumes an overall negative charge at 
pH above 3.3. Similarly, the carboxymethylated dextran surface with a pI of 3.5 
assumes an overall negative charge at pH above 3.5. Studies suggest that nearly 30-
40% of the carboxyl groups on the biosensor surface should have been activated with 
the present activation procedure and the remaining carboxyl groups would have 
assumed a negative charge (Johnson et al., 1991). It is thus possible that mutual forces 
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groups on the sensor prevented the entities from approaching each other for coupling. 
These results suggest that pre-concentration has a significant role in facilitating ligand 
immobilization; coupling of negatively charged pep12 should therefore be performed 
on a positively charged matrix and/or in a non-aqueous medium.  
4.3.2b Immobilization of pep12 to SA Matrix in Absence of Linker 
pep12, bearing an N-terminal amine, was coupled to SA microspheres using the two-
step glutaraldehyde chemistry in a DMF-acetic acid (1% v/v) medium. Low solubility 
of pep12 in phosphate, HEPES and MES buffers necessitated the use of an organic 
solvent as coupling medium. DMF, a polar organic solvent, dissolved pep12 
efficiently to concentrations up to 2.5 mg/mL. Addition of small volumes of buffer/ 
water to pep12 dissolved in DMF resulted in precipitation. Figure 4-38 describes the 
glutaraldehyde-mediated ligand coupling method. Schiff base formation constitutes 
the first stage of the two-step method; reduction of Schiff base to form a stable 
secondary amine linkage follows next (Hermanson, 1996).  
 
 
Figure 4-38 Glutaraldehyde-mediated ligand coupling (Adopted from 
Hermanson, 1996) 
Schiff base formation is an acid-catalyzed reaction and proceeds through an 
intermediate of the carbonyl conjugate acid (McMurry and Begley, 2005). Acetic acid 
was thus added to DMF to a final concentration of 1% (v/v). Strong acids such as 
hydrochloric acid or sulfuric acid hydrolyze DMF back into formic acid and 
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dimethylamine and therefore were not used [21]. Coupling of pep12 to GA-activated 
SA microspheres in DMF-AcOH medium resulted in an immobilization efficiency of 
~ 67%.  
4.3.2c Immobilization of pep12 to SA Matrix Incorporating a Linker 
Coupling of pep12 to SA microspheres was performed by incorporating PEG-based 
crosslinkers at varying densities. The linker, mono-N-t-boc-amido-dPEG11-amine 
(PEG11), was a 37 atom molecule with a molecular weight of 644.79 Da and 
introduced a spacer arm of 42.8 Å [22]. RP-HPLC analysis of the supernatants 
collected after linker coupling suggested the average PEG11 density to be equivalent 
to 142, 276 and 564 μmole/g of SA, respectively. Figure 4-39 shows the effect of 
ligand density on the coupling efficiency of pep12.  
 
Figure 4-39 Effect of PEG11 density on pep12 coupling efficiency 
The results suggest that: i) incorporation of the linker allowed significant 
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density), ii) a decrease in the coupling efficiency resulted from increased linker 
density. A decrease in pep12 immobilization efficiency with an increase in surface 
linker density might be attributed to the varying degree of mutual exclusion between 
hydrophilic and hydrophobic moieties at different linker densities. The above 
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Figure 4-40 Illustration of the varying degree of exclusion between hydrophobic 
pep12 and the hydrophilic coupling sites when (a) no PEG linkers (b) PEG11 at 
low densities (c) PEG11 at high densities, were present on SA microspheres 
Figure 4-40(a) shows that in the absence of PEG linkers, the glutaraldehyde activated 
coupling sites were close to the hydrophilic SA surface. As a result, the coupling sites 
were shielded by strong mutual exclusion between hydrophilic SA surfaces and 
hydrophobic peptide. Coupling of hydrophobic peptides to the SA surface was 
therefore less favorable. A 21 carbon spacer arm was introduced between the matrix 
and pep12 on using the PEG11 linker. Introduction of the linker thus extended the 
coupling sites away from the hydrophilic surface. Weak mutual exclusion between 
hydrophilic linkers (at low density) and hydrophobic peptide allowed pep12 to reach 
the vicinity of the active termini of the linker (Figure 4-40b). The coupling efficiency 
was thus higher when low linker densities were used. Figure 4-40c demonstrates that 
at high linker density, the crowding effect of PEG linkers might have hindered the 
coupling process. Since the PEG chain was hydrophilic, when PEG chains were 
densely packed near the SA surface, they would have collectively formed a “shell” of 
hydrophilic moieties resulting in strong mutual exclusion between pep12 and the 
Strong mutual 
exclusion between 
pep12 & linker 
(GA-activated 
coupling sites were 
present at the linker 
terminus) 
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linkers. Consequently, a low coupling efficiency was observed despite a higher linker 
density.  
The stability of pep12 in DMF-AcOH and quenching buffer was subsequently 
investigated. The peptides were found to be stable and peak areas as analyzed by RP-
HPLC were comparable for freshly prepared and incubated samples. The above 
studies suggest that PEG linkers at low density can introduce pre-concentration 
allowing enhanced immobilization of hydrophobic peptides to hydrophilic matrices.  
4.3.2d  Minimization of Non-specific Binding of Proteins to Matrix 
The nature of the functional group on the support matrix governs the extent of non-
specific binding between the proteins and the matrix. While several functional groups 
do not cause significant non-specific binding, surface groups like amine promote 
significant non-specific interactions. It is important to note that besides serving as 
immobilization sites, the charged surface amino groups act as weak anion-exchangers 
[23]. Fig. 4-41 shows the results of the binding experiment performed to assess the 
extent of non-specific binding of 1 mg/mL BSA sample to 0.34 mL CIM EDA disk. 
CIM EDA disks are amine activated monolithic supports obtained by reacting the 
native epoxy groups with ethylene diamine [23].  
 
Figure 4-41 Adsorption studies on CIM EDA disc 
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The chromatogram suggests that more than 40% of the BSA that was injected into the 
column got adsorbed to the matrix though non-specific ionic interactions. Blocking 
the free charged amine functionalities on the matrix is thus necessary for minimal 
non-specific interactions. Coupling of pep14 to SA microspheres through the use of 
heterobifunctional linker, maleimide-dPEG24-NHS ester (PEG24), was proposed. To 
date, no method to selectively block the free amine groups on the matrix after PEG24 
immobilization has been reported. It was thus necessary to develop a methodology 
that would allow the blocking of free amine functionalities on the matrix. 
Amine groups were present in pep14, at the terminus and as a side chain moiety. It is 
obvious that if the amine functionalities on the matrix are blocked after pep14 
immobilization, the quenching agent will not only react with amines on the matrix but 
it will also react with the amines in the ligand. This could adversely affect the ligand 
bioactivity. It was thus decided that blocking of amines should be performed 
immediately after PEG24 immobilization. Acylation of amine groups on a PEG24-
coupled matrix was proposed as the strategy to reduce non-specific binding. Acylating 
agents, acetyl chloride and oxalyl chloride, were investigated for their suitability 
(Figure 4-42). 
                                                                                          
    
        
 
          (a)                                      (b)                                      (c) 
Figure 4-42 Structure of (a) acetyl chloride (b) oxalyl chloride (c) NEM 
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 The non-reactivity of maleimides (present at PEG24 terminus) to acylating agents 
was a critical criterion before acylation could be considered as a strategy to suppress 
non-specific binding. NEM (Figure 4-42c) was used as a representative maleimide to 
investigate the reactivity between maleimides and the acylating agents. The proton 
positions in NEM are labelled as 1, 2, 3 and 4. 1H-NMR results for the reaction 
between NEM and acylating agents are shown in Figure 4-43. 
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Figure 4-43 1H-NMR analysis of a) NEM b) acetyl chloride c) oxalyl chloride d) 
NEM in acetyl chloride e) NEM in oxalyl chloride 
1 2 3 4 6 5 7 8 9 ppm 
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Figure 4-43a shows the presence of 4 major peaks. The peaks at 1.195, 3.561, 6.684 
ppm corresponded to NEM proton positions (1 & 2), 3 and 4, respectively. The peak 
at 1.567 ppm possibly corresponded to trace quantities of moisture in NEM. The 
occurrence of additional peaks in 4-43d & 4-43e could be attributed to the trace 
amount of impurities found in acetyl chloride and oxalyl chloride. 4-43b and 4-43c 
confirm the presence of impurities in acetyl chloride and oxalyl chloride. Comparison 
of the proton peaks and the corresponding peak area ratios suggested that no reaction 
occurred between NEM and acetyl chloride and NEM and oxalyl chloride. Adsorption 
studies were then performed on SA microspheres pretreated with the acylating agents 
to determine the efficacy of the acylating agents in blocking the amine functionalities. 
The results are summarized in Table 4-7.  
Table 4-7 Adsorption studies on treated SA microspheres 
Sample Pre-treatment with 
 % BSA adsorbed 
to matrix 
SA1 Acetyl chloride 25.5 ± 15.0 
SA2 Oxalyl chloride 3.5 ± 2.3 
SA3 
(Control) 
HBS, pH 7.4 75.2 ± 5.0 
Reduction in non-specific binding of BSA to SA microspheres treated with oxalyl 
chloride and acetyl chloride was ~95% and ~66%, respectively. A large standard 
deviation was however observed for sample SA1. The reduced reproducibility could 
be attributed to the solubility of SA microspheres in acetyl chloride. SA matrix, being 
soluble in acetyl chloride, was recovered via precipitation. Precipitation might have 
caused the formation of a heterogeneous mixture of silica masses with varying surface 
areas. This possibly explains the large standard deviations observed during the 
                                                Immobilization of Hydrophobic Peptidic Ligands to Hydrophilic Matrices 
 132 
binding experiments. The solubility of the SA matrix thus made it difficult to 
determine the efficacy of acetyl chloride as a quenching agent. Notwithstanding this, 
we expect acetyl chloride to function equally well as a quenching agent for matrices 
that are insoluble in it.  
FTIR analysis of SA microspheres treated with the acylating agents indicated the 
presence of amide linkages (Figure 4-44). The results suggest that oxalyl chloride and 
acetyl chloride had successfully reacted with the amine groups on the silica surface, 
resulting in the formation of amide bonds. The reactions between amines and 
acylating agents are demonstrated in Figure 4-45. 
 
Figure 4-44 FTIR absorbance spectra for A) untreated SA microspheres B) SA 
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Figure 4-45b Acylation of surface amine groups on silica matrix with oxalyl 
chloride.  
 
Carboxyl moieties are created on the silica microspheres after treatment with oxalyl 
chloride. However, since binding of analyte molecules to affinity ligands is 
commonly performed at or near physiological conditions, surface carboxyls do not 
pose problems. Under physiological conditions, most of the proteins assume an 
overall negative charge [24]. Mutual forces of repulsion between negatively charged 
proteins and negatively charged carboxyl groups minimize the non-specific 
interactions. It can be concluded that acetyl chloride or oxalyl chloride can be used to 
SA SA 
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selectively quench the free amine functionalities on the matrix without affecting the 
activity of the maleimide group on the PEG24 linker.  
4.3.2e  Immobilization of pep14 to SA Matrix  
Hydrophobic pep14, bearing an N-terminal cysteine, was immobilized on the same 
lines as pep12. pep14 was coupled to SA microspheres using a heterobifunctional 
crosslinker with amine and sulfhydryl reactivity. The linker, maleimide-dPEG24-NHS 
ester (PEG24), was an 82 atom molecule with a molecular weight of 1394.55 Da and 
it introduced a spacer arm of 95.2 Å [22]. The linker served a dual purpose: (a) 
provided means to conjugate the peptide to the matrix and (b) introduced pre-
concentration by distancing the hydrophobic peptide from the hydrophilic SA matrix. 
A low linker density was used to minimize the exclusion of hydrophobic pep14 from 
the binding sites.  
As suggested by Hermanson (1996) “The maleimide functionality is specific for 
coupling to sulfhydryls when the reaction pH is in the range of 6.5-7.5. At pH 7, the 
reaction of the maleimide group with sulfhydryls proceeds at a rate 1000 times greater 
than its reaction with amines. At more alkaline pH values, however, its reaction with 
amines becomes more evident.” pep14, with a pI of 6.3, showed limited solubility in 
the buffers suitable for this range of pH. Attempts were made to dissolve pep14 in 
water, PBS, HEPES and MES but with no success; pep14 showed good solubility in 
basic buffers. However, the high pH associated with these buffers limited their use. 
Addition of HCl to lower the pH of pep14 sample dissolved in borate buffer at pH 8.5 
resulted in precipitation. pep14 showed high solubility in organic polar solvents- 
DMF, DMSO and NMP. The rate of reaction between maleimides and reduced 
sulfhydryls is extremely low in a reaction medium that is deficient of proton-acceptor. 
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Unlike water, DMF, DMSO and NMP are poor proton-acceptors. Therefore, 
triethylamine (TEA)/ triethanolamine (TEOA) / N,N-diisopropylethylamine (DIEA) 
to a final concentration of 50 mM was added to pep14 dissolved in the organic 
solvents. The peptides, unfortunately, precipitated. Lowering the TEA concentration 
to 15 mM allowed moderate solubility of pep14 in DMSO; concentration of 1 mg/mL 
was achievable. HPLC analysis of pep14 dissolved in DMSO-TEA was conducted 
every 30 minutes. The results suggested that more than 80% of the sulfhydryl groups 
in pep14 got oxidized to form disulfide bonds within 1 hour of incubation. Lowering 
the concentration of TEA to as low as 2 mM had no significant effect. A combination 
of NMP and water (1:1 v/v) showed promising results in dissolving pep14. However, 
SA microspheres were found to be soluble in this solvent mixture. At first, it appeared 
that the non-visibility of the silica microspheres in this medium was possibly due to 
refractive index matching. However, centrifugation at 20,000 g for thirty minutes 
yielded no pellet. A 3:1 mixture of 3 mM HEPES and DMSO (final pH adjusted to 
6.9-7.0) was thus investigated. Though pep14 exhibited moderate solubility in the 
organo-aqueous solvent, SA microspheres were found to dissolve in it as well. A 17:3 
mixture of 3 mM HEPES and DMSO (final pH adjusted to 6.9-7.0) was then 
investigated. SA microspheres did not dissolve in this mixture. FTIR spectroscopic 
studies were performed to examine if HEPES-DMSO (17:3 v/v) mixture had any 
effect on the chemical morphology of SA microspheres. These results are shown in 
Figure 4-46. The HEPES-DMSO mixture did not have any adverse effect on the SA 
microspheres and was hence chosen as the medium to perform the coupling reaction 
between pep14 and maleimides. Table 4-8 summarizes the results obtained from the 
use of different solvents for solubilizing pep14. 
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Figure 4-46 Overlaid FTIR spectra for A) SA microspheres B) SA microspheres 
incubated in a 17:3 mixture of 3 mM HEPES and DMSO for 12 hours. 
 
Table 4-8 Solubility of pep14 in different solvents (Volume of solvent added 
corresponded to a final pep14 concentration of 1 mg/mL) 
 
Solvent Observations 
HEPES/ MES/ PBS/ water Sparingly soluble 
0.05 M borate buffer at pH 8.5  Soluble 
0.05 M borate buffer at pH 8.5 + HCl (to reduce the pH to 7.3) Turbid solution 
DMF/ DMSO/ NMP Soluble 
DMF + TEA/ TEOA/ DIEA (final concentration 50 mM)   Turbid solution  
NMP + TEA/ TEOA/ DIEA (final concentration 50 mM)   Turbid solution 
DMSO + TEA/ TEOA/ DIEA (final concentration 50 mM)   Turbid solution 
DMF + TEA/ TEOA/ DIEA (final concentration 15 mM)   Turbid solution  
NMP + TEA/ TEOA/ DIEA (final concentration 15 mM)   Turbid solution  
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DMSO + TEA/ TEOA/ DIEA (final concentration 15 mM)   
Soluble but high 
rates of oxidation 
of pep14 to its 
corresponding 
dimer  
DMSO + TEA/ TEOA/ DIEA (final concentration 2 mM)   
Soluble but high 
rates of oxidation 
of pep14 to its 
corresponding 
dimer 
NMP + water (1:1 v/v) 
Soluble but SA 
microspores were 
also soluble  
3 mM HEPES + DMSO (3:1 v/v) 
Soluble but SA 
microspores were 
also soluble 
3 mM HEPES + DMSO (17:3 v/v) 
Soluble & SA 
microspheres 
were insoluble 
The supernatant collected after linker immobilization was analyzed for the amount of 
unbound PEG24 using a unique strategy as described in Chapter 3. While PEG did 
not degrade in solution, NHS and maleimide moieties at the linker terminus 
hydrolyzed gradually with time (Thomson, 2004). This resulted in the formation of a 
mixture exhibiting marked variation in concentration with time; making it difficult to 
get reproducible results. Studies were conducted to obtain the incubation time 
necessary to decompose nearly all of the PEG24 linkers in the solution. It was found 
that after 18 hours of incubation at room temperature, the rate of change in mixture 
concentration was negligible allowing reproducible quantification of linker 
concentration (Figure 4-47). PEG24 density on SA beads as determined by this assay 
was equivalent to 162 μmoles/gm of SA. pep14 exhibits a net zero charge at pH 6.9-7. 
In the absence of ionic forces of attraction between pep14 and matrix, it was vital to 
minimize mutual exclusion between hydrophobic pep14 and coupling sites. This was 
achieved by using a low linker density of 162 μmoles/gm. The blocking of the amine 
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functionalities on the SA matrix was performed by the use of oxalyl chloride. A 
pep14 coupling efficiency of 34% was achieved as determined by RP-HPLC. pep14 
density on the SA microspheres was equivalent to 34 μmole/g of microspheres.  
 
              (A) 
   








      (D) 
 
 
      (E) 
 
Figure 4-47 RP-HPLC chromatograms of PEG24 at different time intervals (A) 0 
min  (B) 30 min (C) 450 min (D) 1080 min. (E) 1140 min. Absorbance measured 
at λ= 210 nm     
Moderate coupling efficiency of 34% could be achieved for pep14 in comparison to 
98% for pep12. Several factors might have contributed to the lower coupling 
efficiency:  
1) DMSO is a weak oxidizing agent and oxidized the sulfhydryls in pep14 to form 
disulfide bonds. HPLC analysis of pep14 dissolved in HEPES-DMSO (17:3 v/v) 
mixture was performed at different time intervals. The results are summarized in 
Table 4-9. More than 50% of pep14 was oxidized in 3 hours. Since maleimides 
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only react with reduced sulfhydryls, a major portion of the pep14 could not react 
with maleimide.  
                     Table 4-9 Disulfide bond formation on oxidation of pep14 







2) Concentration of pep14 in the coupling medium was 2.5 times lower than the 
concentration of pep12. Low solubility of pep14 in DMSO-HEPES mixture could 
be attributed to the non-ideal behavior exhibited by DMSO upon addition of 
water. Addition of water to DMSO causes the liquid phase to become highly 
structured due to hydrogen bonding. The solute solubility is minimum in a 1:2 
molar mixture of water and DMSO (Lipinski, 2006). Low concentration of pep14 
in turn affected the coupling rates. 
4.3.2f  Equilibrium Studies 
Equilibrium studies were performed to determine the equilibrium association constant 
for the interaction between pep14 and hIgM and the static binding capacity of pep14- 
immobilized SA microspheres (ligand density: 34 μmole/g of microspheres). The 
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where,  
C is the equilibrium (unbound) hIgM concentration (M), 
q is the amount of hIgM adsorbed per gram of SA microspheres (mg hIgM/g 
SA microspheres), 
 qmax is the static binding capacity, 
 Ka is the equilibrium association constant, M
-1
  
A plot of q vs C is shown in Figure 4-48.  
 
Figure 4-48 Graph of q vs C 
Rearranging the previous equation gave:   
q/C = -Kaq  + Kaqmax 
 
A graph of q/C vs q was plotted to obtain the association constant and the binding 




 was obtained. The binding constant 
obtained for pep14-hIgM interaction was one order of magnitude lower than that 
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SA microspheres was obtained. Minimal non-specific binding occurred between hIgM 
and the pep-14 immobilized SA microspheres (treated with oxalyl chloride). 
 
Figure 4-49 Graph of q/C vs q 
4.3.3 Concluding Remarks 
This is likely the first report that demonstrates the use of PEG-based linkers to 
introduce pre-concentration. PEG-based linkers at low density could facilitate the 
immobilization of hydrophobic peptidic ligands to hydrophilic surfaces by weakening 
mutual exclusions between the entities. Several reports have demonstrated the use of 
DMF in conjugation with a buffer as the coupling medium. However, a non-aqueous 
mixture consisting of DMF and acetic acid can be used successfully as a coupling 
media for immobilizing hydrophobic peptidic ligands to glutaraldehyde-activated 
















q (mg hIgM adsorbed/g of SA microspheres)
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effect on peptide stability. Traditionally, HPLC with Evaporative Light-Scattering 
Detector (ELSD) is used for quantification of maleimide-dPEG24-NHS ester 
crosslinkers. However, high costs limit the availability of ELSD in laboratories. The 
assay described here allows for easy quantification of the linkers. An effective 
procedure for selectively quenching the free amine functionalities on the surface of 
SA microspheres has been demonstrated. The strategy not only allowed the coupling 
of pep14 to the maleimide group on the NHS-PEG-maleimide linkers but also 
minimized non-specific binding of the proteins to the matrix. This strategy might be 
equally useful when crosslinkers like succinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC), sulfo-SMCC, m-
maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) and sulfo-MBS are used. 




 and a binding capacity 
(static) of 5.9 mg hIgM/g of SA microspheres. These results serve to establish the 
uniqueness of pep14 and its suitability for large scale purification of IgM.  
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5   CONCLUSIONS AND RECOMMENDATIONS  
5.1 Conclusions 
IgMs, designed for therapeutic applications, are required to fulfill stringent purity and 
quality criteria set forth by the regulatory and approval agencies. An effective way to 
purify IgM is through affinity chromatography, which currently is limited by the 
availability of ‘suitable’ capture agents. Peptide-based affinity chromatography 
represents a particularly promising approach because it combines the selectivity of a 
naturally-occurring biological receptor with the simplicity of a single small molecule 
(Sousa et al., 2008). The focus of the present research was to develop biomimetic 
peptidic ligands which can mimic the binding activity of hpIgR, a naturally-occurring 
Fc (‘universal’) receptor to IgM. Several synthetic peptides incorporating the 
complementarity determining region 2 of domain 1 of hpIgR were investigated for 
their interactions with hIgM and other hIgs. pep14, a 14mer peptide, emerged as a 
unique ligand exhibiting specificity in its interaction to hIgM with negligible affinity 
for hIgG1, hIgA1, hIgE and BSA. pep14-hIgM interactions were characterized that 
provided an insight into the overall binding mechanism. Cysteine in pep14 was found 
to be responsible for generating pre-concentration while glutamic acid induced 
specificity for hIgM. CD studies suggested the absence of native β-hairpin structure in 
pep14. The ligand exhibited a flexible conformation, consisting mainly of a mixture 
of coil and turn. Effect of pH, ionic strength and nature of the binding buffer on 
pep14-hIgM interaction was examined. Optimal binding performance was obtained in 
a 10 mM HEPES, 150 mM NaCl, pH 7.4 binding media. SPR-based binding studies 
suggested pep14 to be an Fc receptor to hIgM, binding to the CH2 domains of hIgM. 
Effect of ligand density on the strength of interaction, binding capacity and non-
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specific binding was determined. The results suggested that at high densities, multiple 
number of ligands were interacting with each molecule of hIgM. 100 mM Glycine-
NaOH at pH 9 permitted easy recovery of bound IgMs without loss in biological 
activity. No loss in binding capacity or selectivity was observed on exposing pep14 to 
a mixture of proteins containing hIgM, hIgG1 and BSA. Stability of peptides to 
common sanitizing agents- 20% ethanol, 70% ethanol, 100 mM NaOH and 500 mM 
NaOH was investigated. While 20% ethanol appeared more suitable for regular 
column clean up, 70% ethanol was found adequate for rigorous sanitization. An 
optimized method for synthesizing pep14 at high yields and low costs was devised. 
Table 5-1 compares pep14 to biospecific, non-mimetic and biomimetic ligands. It is 
evident that pep14 fulfills the requirements of being a biomimetic ligand. The ligand 
shows promise to produce pure, biologically active IgMs, especially hIgMs, on a large 
scale for therapeutic purposes.   
Mutual exclusion between hydrophobic peptidic ligands and hydrophilic matrices 
adversely affect coupling efficiency. A unique method of introducing pre-
concentration through the use of PEG-based linkers was devised. Coupling of pep12 
to silica-amine matrix was performed in the absence and presence of PEG-based 
linkers. A significant increase in the coupling efficiency, from 67% to 98%, could be 
achieved on incorporating the linker at low density. Hetero-bifunctional crosslinker, 
maleimide-dPEG24-NHS ester (PEG24), containing NHS ester and maleimide at their 
terminals were used to couple pep14 to silica-amine microspheres. A novel method to 
selectively quench the amine functionalities on the matrix surface after PEG24 
coupling was developed. Acylating agent, oxalyl chloride, showed promise in 
blocking the charged amines on the surface, minimizing non-specific interactions 
between the proteins and surface amine groups up to 95%. A pep14 coupling 
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efficiency of 34% was achieved. pep14 density on silica-amine microspheres was 
equivalent to 34 μmole/g of microspheres.  
Table 5-1 Comparison of pep14 to biospecific and pseudo-biospecific ligands 
(Adapted from Roque et al., 2004) 
Properties 
                                                             Psuedo-biospecific 
                                     Non-mimetic          Biomimetic              pep14 
Specificity 




































hIgG1 & BSA. 
Capacity Low High High 




capacity)   
Product 
Elution 
Difficult Mild Mild 
IgM was eluted 
using 100 mM 
Glycine-NaOH, 
pH 9.0 
Stability Low Very high 






NMP. It can 
withstand 
acidic buffers 
(pH≥ 1.3) and 
alkaline buffers 
(pH≤ 10.5)   
Cost High Low Low 
pep14 was 
synthesized in 
high yields at 
purities >95%  
at low costs 
The research demonstrates the uniqueness of pep14 and its suitability for large scale 
purification of IgM. The study demonstrates the competence of biomimetic ligands in 
isolating and purifying large proteins, opening up avenues of research to design and 
     
Biospecific                            
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develop affinity ligands that can mimic the bioactivity of naturally-occurring binding 
partners. Coupling of hydrophobic ligands to hydrophilic matrices incorporating PEG-
based linkers (at low density) introduces the novel concept of pre-concentration. This 
study also allows a better understanding of the factors affecting immobilization and 
sets the stage to devise new pre-concentration techniques that will allow enhanced 
coupling efficiency.  
5.2 Recommendations for Future Work 
Although considerable success has been achieved in developing the biomimetic 
peptidic ligand, much work still remains to be done. Several potential avenues of 
research are discussed below:  
(1) Studies may be conducted on pep14-immobilized monolithic column to 
demonstrate the suitability of pep14 for large scale purification of IgM. Studies 
need to be performed to optimize the ligand density on the matrix. The optimized 
ligand density should provide for high ligand utilization percentage and optimal 
binding strength between the interacting species. Monolithic studies would aim 
at optimizing the chromatographic conditions with respect to peak resolution, 
column efficiency and dynamic binding capacity.  
(2) The hydrophobic nature of pep14 limited its solubility in the buffers commonly 
used during covalent immobilization. Low concentration of pep14 in the coupling 
medium resulted in moderate immobilization efficiencies of 34%. Substituting 
the hydrophobic residues in pep14 with hydrophilic residues or inclusion of 
additional hydrophilic residues at the terminus of pep14 can be investigated. 
However, caution needs to be exercised to assure no loss in the biological activity 
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of the ligand. Enhanced hydrophilicity would improve the solubility of the 
peptides in the coupling media allowing higher coupling efficiency.  
(3) Peptidic ligands are prone to degradation by enzymes which limit their 
application in industry. There are several ways to improve the stability of a 
peptidic ligand. Using D-amino acids to construct the peptide, the proteolysis 
resistance of the ligand can be improved (Tugyi et al., 2005). Cyclic peptides can 
be another choice. Cyclic peptides are more resistant to protease degradation due 
to the lack of conformational freedom and display high affinity (Mantzourani et 
al., 2008).  
(4) The designed ligand, pep14, exhibited affinity for human IgM and rabbit IgM. 
However, its inability to bind mouse IgMs limits its application for purifying 
hybridoma-derived monoclonal IgMs. Protein domain-based biomimetic ligands 
could possibly allow a solution to this. hpIgR-D1, an Fc receptor to IgM, binds 
IgMs from different species and can be investigated for its suitability as an 
affinity ligand.  
The results described in this thesis lay the foundation for the proposed future work. 
Preliminary synthesis of hpIgR-D1 was performed using the method described by 
Hamburger et al. (2004). Details of the method are provided in Chapter 3. Figure 5-1 
shows the SDS-PAGE results obtained for the various stages of hpIgR-D1 synthesis. 
Figure 5-2 shows the results for SPR-based binding studies between hpIgR-D1 and 
hIgM. The binding profile suggests that the refolded protein hpIgR-D1 was 
biologically active.  
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- 
Lane A: Standards                                     Lane B: Crude protein  
Lane C: IMAC purified sample                   Lane D: Desalted IMAC purified sample    
Lane E: SEC 1st Peak (52 hrs refolding)   Lane F: SEC 2nd Peak, hpIgR-D1 (52 hrs refolding)  
Figure 5-1 SDS-PAGE results 
 
Figure 5-2 Representative sensogram illustrating the interaction between 
synthesized hpIgR-D1 and hIgM 
In the present work, refolding of denatured hpIgR-D1 was performed through dilution 
refolding. This method is time-consuming and buffer consuming and thus not optimal 
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for large-scale production as extensive concentration is required after renaturation. In 
addition, the protein concentration needs to be carefully controlled to prevent 
aggregation. In this regards, on-column refolding of hpIgR-D1 can be investigated to 
determine its efficacy. The method is attractive as it prevents protein aggregation and 
can be easily automated using preparative chromatographic systems. 
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REFERENCES 
1 Appendix E: Stem Cell Markers . In Stem Cell Information [World Wide Web 
site]. Bethesda, MD: National Institutes of Health, U.S. Department of Health and 
Human Services, 2009 http://stemcells.nih.gov/info/scireport/appendixe.  




4 http://www.wipo.int/pctdb/fr/wo.jsp?WO=2007062474&IA=EP2006050059& DI 
SPLAY=DESC 




7 BIA Separations. CIM: Convective Interaction Media for Biochromatography.     
http://www.biaseparations.com/subpage.asp?FolderId=198.  











16  http://www.piercenet.com/products/browse.cfm?fldID=01010505 
 152 





C46E0 1232683#nhsester  
21 http://en.wikipedia.org/wiki/Dimethylformamide 
22 http://www.quantabiodesign.com/shop/  
23 http://www.biaseparations.com/pr/248/307/specific-informations 
24 class.fst.ohio-state.edu/FST822/lectures/Denat.htm 
Adams PA, Goold RD, Thumser AA. Heme-peptide/ protein interactions: The binding 
of heme octa and undecapeptides, and microperoxidase-8 and -11, to human serum 
albumin. J. Inorg. Biochem. 1989; 37: 91-103. 
Amatschek K, Necina R, Hahn R, Schallaun E, Schwinn H, Josic D, Jungbauer A. 
Affinity Chromatography of Human Blood Coagulation Factor VIII on Monoliths 
with Peptides from a Combinatorial Library. J. High. Resolut. Chromatogr. 1999; 23: 
47-58. 
Amon MA, Ali M, Bender V, Hall K, Aguilar MI, Aldrich-Wright J, Manolios N. 
Kinetic and conformational properties of a novel T-cell antigen receptor 
transmembrane peptide in model membranes. J. Pept. Sci. 2008; 14: 714-724. 
Anagli J, Vilei EM, Molinari M, Calderara SC. E. Purification of active calpain by 
affinity chromatography on an immobilized peptide inhibitor Eur. J. Biochem. 1996; 
241: 948-954. 
Baigent SM, Lowry PJ. Unrocortin is the principal ligand for the corticotrophin-
releasing factor binding proetein in the ovine brain with no evidence for a sauvigne-
like peptide. J. Mol. Endocrinol. 2000; 24, 53-63. 
Bak H, Thomas ORT.  Evaluation of commercial chromatographic adsorbents for the 
direct capture of polyclonal rabbit antibodies from clarified antiserum. J. Chromatogr. 
B. Biomed. Sci. Appl. 2007; 848: 116-130. 
 153 
Barandun S, Kistler P, Jeunet F. Intravenous administration of human 
gammaglobulin. Vox Sang 1962; 7: 157-174. 
Belew M, Juntti N, Larsson A, Porath J. A one-step purification method for 
monoclonal antibodies based on salt promoted adsorption chromatography on a 
„thiophilic‟ adsorbent. J. Immunol. Meth. 1987; 102: 173-182. 
Betancor L, Lopez-Gallego F, Alonso-Morales N, Dellamora G, Mateo C, Fernandez-
Lafuente R, Guisan JM. Glutaraldehyde in Protein Immobilization A Versatile 
Reagent, in: Guisan JM  (Ed.) Methods in Biotechnology: Immobilization of Enzymes 
and Cells, Humana Press, Totowa, New Jersey, 2006, pp. 57-64. 
Bieber MM, Twist CJ, Bhat NM, Teng NNH. Effects of Human Monoclonal 
Antibody 216 on B-Progenitor Acute Lymphoblastic Leukemia In Vitro. Pediatr 
Blood Cancer 2007; 48: 380-386. 
Blanco FJ, Rivas G, Serrano L. A short linear peptide that folds into a native stable 
beta-hairpin in aqueous solution. Nat Struct Biol. 1994; 1: 584-90. 
Boibieux A, Tardy JC, Simplot A, Peyramond D, Aymard M. Amplified ELISA anti-
CMV IgM antibodies for early diagnosis of cytomegalovirus disease in AIDS 
patients. Int. Conf. AIDS 1992; 8: 57.  
Bouvet JP, Pires R. One-step purification of murine monoclonal antibodies of the IgM 
class. J. Immunol. Meth. 1991; 145: 263-266. 
Braathen R, Sorensen V, Brandtzaeg P, Inger S, Johansen Finn-Eirik. The Carboxyl-
terminal Domains of IgA and IgM Direct Isotype-specific Polymerization and 
Interaction with the Polymeric Immunoglobulin. J. Biol.Chem. 2002; 277: 42755-
42762.  
Bradbury A. Molecular library technologies at the millenium. Trends Biotechnol. 
2000; 18: 131-133. 
Brandlein S, Eck M,  Ströbel P, Wozniak E, Hermelink HKM, Hensel F, Vollmers 
HP. PAM-1, a natural human IgM antibody as new tool for detection of breast and 
prostate precursors. Human Antibodies 2004; 13: 97-104.   
Brandtzaeg P. Human secretory component-VI Immunoglobulin-binding properties 
Immunochemistry 1977; 14: 179-188.  
 154 
Brandtzaeg P. Role of J chain and secretory component in receptor-mediated 
glandular and hepatic transport of immunoglobulins in man. Scand. J. Immunol. 1985; 
22: 111-146. 
Branovic K, Forcic D, Ivancic J, Strancar A, Barut M, Gulija TK, Zgorelec R, 
Mazuran R. Application of short monolithic columns for fast purification of plasmid 
DNA. J. Chrom. B 2004; 801: 331-337.  
Bringuier JP, Andre J, Sohier R. The Use of IgM Antibody Responses in the 
Diagnosis of Primary Infections to Measles, Rubella, Mumps, and M. Parainfluenzae 
Viruses. Med. Microbiol. Immunol.1978; 64: 299-305.  
Brne P, Podgornik A, Peterka M, Strancar A, Kalin N, Bencina K. In a Minute 
Separation of IgG from IgM and Human Serum Albumin in Human Serum using CIM 
Monolithic Column. 2004 Poster Presentation, Monolithic Summer School, Slovenia. 
Brne P, Podgornik A, Peterka N, Strancar A, Kalin N, Bencina K. Purification of IgM 
on CIM monolithic Column. 2004 Poster Presentation, Monolithic Summer School, 
Slovenia. 
Brocklehurst K, Little G. Blochem. J. 1973; 133: 67-80. 
Buettner JA, Dadd CA, Baumbach GA, Masecar BL, Hammond DJ. Int. Peptide 
Protein Res. 1996; 47: 870. 
Burton NP. Design of novel affinity adsorbents for the purification of trypsin-like 
proteases. J. Mol. Recognit. 1992; 5: 55-68. 
Byeon WH, Weisblum B. Affinity adsorbent based on combinatorial phage display 
peptides that bind α-cobratoxin. J. Chrom. B 2004; 805: 361-363. 
Camperi SA, Iannucci NB,  Albanesi GJ, Eberhardt MO, Etcheverrigaray M, 
Messeguer A, Albericio F, Cascone O. Monoclonal antibody purification by affinity 
chromatography with ligands derived from the screening of peptide combinatory 
libraries. Biotechnol. Lett. 2003; 25: 1545-1548. 
Carter JM. Conjugation of Peptides to Carrier Proteins via Glutaraldehyde, in: J.M. 
Walker (Ed.) The Protein Protocols Handbook, Humana Press, Totowa, New Jersey, 
1996, pp. 679-688. 
 155 
Chen T, Su S, Nie H, Zhu L. Phage display: Design and selection of functional 
binding peptides ligands application for isolation of bromelain using affinity 
chromatography. J. Biotech. 2008; 136S. 
Clackson T, Wells JA. In-vitro selection from protein and peptide libraries. Trends 
Biotechnol. 1994; 12: 173-184. 
Climaker M, Samuelson A, Magnius L, Ehrnst A, Olcen P, Forsgren M. Early 
diagnosis of enteroviral meningitis by detection of specific IgM antibodies with a 
solid-phase reverse immunosorbent test (SPRIST) and μ-capture EIA. J. Med. Virol. 
1992; 36: 193-201.  
Collinsova M, Castro C, Garrow TA, Yotakis A, Dive V, Jiracek J. Combining 
Combinatorial Chemistry and Affinity Chromatography: Highly Selective Inhibitors 
of Human Betaine: Homocysteine S-Methyltransferase. Chem. Biol. 2003; 10: 113-
122. 
Cowen C, Melton DA. “Stemness”: Definitions, Criteria, and Standards. In: Lanza R, 
Gearhart J, Hogan B, Melton D, Pedersen R, Thomson J, Thomas ED, West M, 
editors. Essentials of Stem Cell Biology. Elsevier Academic Press; 2006. xxv-xxx. 
Cripps AW, Neoh SH, Smart IJ. Isolation of Human IgA and IgM from Normal 
Serum Using Polyethylene Glycol Precipitation and Affinity Chromatography. J. 
Immunol. Meth. 1983; 57: 197-204. 
Datamonitor. Monoclonal Antibody Therapies: Evolving Into a $30 Billion Market. 
2005.  
David K, Ollert MW, Juhl H, Vollmert C, Erttmann R, Vogel CW,  Bredehorst R. 
Growth arrest of solid human neuroblastoma xenografts in nude rats by natural IgM 
from healthy humans. Nature Medicine 1996; 2: 686-689.  
Drucker A, Skedgel C, Virik K, Rayson D, Sellon M, Younis T. The cost burden of 
trastuzumab and bevacizumab therapy for solid tumours in Canada. Curr. Oncol. 
2008; 15: 136-142.  
Ehrlich GK, Bailon P. Identification of model peptides as affinity ligands for the 
purification of humanized monoclonal antibodies by means of phage display. J. 
Biochem. Biophys. Meth. 2001; 49: 443-454. 
 156 
Ehrlich GK, Bailon P. Identification of peptides that bind to the constant region of a 
humanized IgG(1) monoclonal antibody using phage display. J. Mol.Recognit. 1998; 
11: 121-125. 
Ericsson C, Hjerten S. Reversed-Phase Electrochromatography of Proteins on 
Modified Continuous Beds Using Normal-Flow and Counterflow Gradients. 
Theoretical and Practical Considerations. Anal. Chem. 1999; 71: 1621-1627. 
Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD. Protein microarray detection 
strategies: focus on direct detection technologies. J. Immunol. Methods 2004; 290: 
121-133. 
Fassina G, Ruvo M., Palombo G, Verdoliva A, Marino M. Novel ligands for the 
affinity-chromatographic purification of antibodies. J. Biochem. Biophys. Meth. 
2001; 49: 481-490. 
Fassina G, Verdoliva A, Odierna MR, Ruvo M, Cassini G. Protein A Mimetic Peptide 
Ligand for Affinity Purification of Antibodies. J. Mol. Recog. 1996; 9: 564-569.  
Fassina G, Verdoliva A, Palombo G, Ruvo M, Cassani G. Immunoglobulin specificity 
of TG19318: a novel synthetic ligand for antibody affinity purification. J. Mol. 
Recogn. 1998; 11: 128-133.  
Feng B, Dai Y, Wamg L, Tao N, Huang S, Zeng H. A novel affinity ligand for 
polystyrene surface from a phage display random library and its application in anti-
HIV-1 ELISA system. Biologicals 2009; 37: 48-54. 
Feng HQ, Jia LY, Li HL, Wang XC. Screening and chromatographic assessing of a 
novel IgG biomimetic ligand. Biomed. Chromatogr. 2006; 20: 1109-1115. 
Filippusson H, Erlendsson LS, Lowe CR. Design, synthesis and evaluation of 
biomimetic affinity ligands for elastases. J. Mol. Recognit. 2000; 13: 370-381. 
Forcic D, Cakanic KB, Ivancic J, Jug R, Barut M, Strancar A, Mazuran R. 
Chromatographic detection of residual cellular DNA on short monolithic columns. 
Anal. Biochem. 2005; 336: 273-278. 
Furka A, Sebestyen F, Asgedom M, Dibo G. General-Method for Rapid Synthesis Of 
Multicomponent Peptide Mixtures. Int. J. Pept. Protein Res. 1991; 37: 487-493. 
 157 
Furuya M, Tsushima Y, Tani S, Kamimura T. Development of affinity 
chromatography using a bioactive peptide as a ligand. Bioorg. Med. Chem. Lett. 
2006; 14: 5093-5098. 
Gagnon P, Hensel F, Lee S, Zaidi S. IgM Purification. 4th International Monolith 
Summer School & Symposium May 29-June 2, 2010. 
Gagnon P, Hensel F, Richieri R. Purification of IgM Monoclonal Antibodies. 
Biopharm International; Supplement Mar 2008; 26-36. 
Gaskin DJH, Starck K, Turner NA, Vulfson EN. Phage display combinatorial libraries 
of short peptides: ligand selection for protein purification. Enzy. Microb. Tech. 200; 
28: 766-772. 
Ghose S, Hubbard B, Cramer SM.  Evaluation and comparison of alternatives to 
Protein A chromatography- Mimetic and hydrophobic charge induction 
chromatographic stationary phases. J. Chrom. A. 2006; 1122: 144-152. 
Goldblum RM, Hanson LA, Brandtzaeg P. The mucosal defense system. In: Stiehm 
ER (Ed.) Immunologic Disorders in Infants & Children, W. B. Saunders Co., 
Philadelphia, 1996. 
Gonzalez MG, Bettinger S, Ott S, Olivier P, Kadouche J, Pouletty P. Purification of 
murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation. J. Immunol. 
Meth. 1988; 111: 17-23. 
Gupta G, Lowe CR. An artificial receptor for glycoproteins. J Mol. Recognit. 2004; 
17: 218-235. 
Gurgel PV, Carbonell RG, Swaisgood HE. Identification of peptide ligands generated 
by combinatorial chemistry that bind alpha-lactalbumin. Sep. Sci. Technol. 2001; 36: 
2411-2431. 
Gustavsson PE, Larsson PO. Continuous superporous agarose beds in radial flow 
columns. J. Chrom. A 2001; 925: 69-78. 
Gutierrez-Aguirre I, Banjac M, Steyer A, Poljsak-Prijatelj M, Peterka M, Strancar A, 
Ravnikar M. Concentrating rotaviruses from water samples using monolithic 
chromatographic supports. J. Chrom. A 2008; in press.  
 158 
Hai Si-Han, McMurry JA, Knopf PM, Martin W, Groot AS De. Immunogenicity 
Screening Using in silico Methods: Correlation between T Cell Epitope Content and 
Clinical Immunogenicity of Monoclonal Antibodies In: Zhiqiang An editor. 
Therapeutic Monoclonal Antibodies: From Bench to Clinic, Wiley; 2009: 417-438.   
Hamburger AE, West AP. Bjorkman PJ. Crystal Structure of a Polymeric 
Immunoglobulin Binding Fragment of the Human Polymeric Immunoglobulin 
Receptor. Structure 2004; 12: 1925-1935. 
Hamilton RG.  Human Immunoglobulins. In: Leffell MS, Donnenberg AD, Rose NR, 
editors. Handbook of Human Immunology. CRC Press; 1997. pp 63-74. 
Hamilton RG.  The Human IgG Subclasses. Calbiochem 1998. 
Hanora A, Savina I, Plieva FM, Izumrudov VA, Mattiasson B, Galaev IY. Direct 
capture of plasmid DNA from non-clarified bacterial lysate using polycation-grafted 
monoliths. J. Biotechnol. 2006; 123: 343-355. 
Harker EA, Daniels DS, Guarracino DA, Schepartz A. β-peptides with improved 
affinity for hDM2 and hDMX. Bioorg. Med. Chem. 2009; 17: 2038-2046. 
Harshman JS. Purification of Murine IgM Monoclonal Antibodies by Hydroxylapatite 
Chromatography. J. Tissue Cult. Meth. 1989; 12: 115-117. 
Harte PG, Cooke A, Playfair JHL. Specific monoclonal IgM is a potent adjuvant in 
murine malaria vaccination. Nature 1983; 302: 256-258.  
Heegaard NHH, Hansen BE, Svejgaard, Fugger LH. Interactions of the human class II 
major histocompatibility complex protein HLA-DR4 with a peptide ligand 
demonstrated by affinity capillary electrophoresis. J. Chrom. A. 1997; 26: 91-97. 
Hermanson GT. Bioconjugate Techniques, Academic Press, San Diego, 1996. 
Hibma MH, Griffin JFT. The purification and characterisation of cervine IgM and 
IgG. Vet. Immunol. Immunopathol. 1990; 26: 343-352. 
Houghten RA, Dooley CT. The use of synthetic peptide combinatorial libraries for the 
determination of peptide ligands in radio-receptor assays: opioid peptides. Bioorg. 
Med. Chem. Lett. 1993; 3: 405-412. 
 159 
Houghten RA, Pinilla C, Blondelle SE, Appel JR, Dooley CT, Cuervo JH. Generation 
and use of synthetic peptide combinatorial libraries for basic research and drug 
discovery. Nature 1991; 354: 84-86. 
Houghten RA. Soluble chemical combinatorial libraries: Current capabilities and 
future possibilities. In: Peptides-Synthesis, Structures and Applications; Gutte, B., 
Ed.; Academic Press: London, 1995.  
Hoven AVD, Conradie JD, Bubb M, Visser L. The Isolation of Immunogenically Pure 
IgM from Cohn Fraction III of Pooled Normal Human Plasma. Immunochemisry 
1973; 10: 107-114.   
Huang PY, Baumbach GA, Dadd CA, Buettner JA, Masecar BL, Hentsch M, 
Hammond DJ, Carbonell RG. Affinity Purification of von Willebrand Factor Using 
Ligands Derived from Peptide Libraries. Bioorg. Med. Chem. 1996; 4: 699-708.  
Huschka U, Maier J, Rauterberg EW, Doerr HW. Rapid Separation of 
Immunoglobulin M by Immunoaffinity Chromatography for Detection. of Specific 
Antibodies to Rubella and Treponema pallidum Eur. J. Clin. Microbiol. 1982; 1: 118-
121.  
Hutchens TW. Thiophilic adsorption chromatography. Methods Mol Biol. 1992; 11: 
1-15. 
Irie RF, Ollila DW, O'DAY S, Morton DL. Phase I pilot clinical trial of human IgM 
monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. 
Cancer Immunology, Immunotherapy 2004; 53: 110-117.  
Jacobsen B, Gardsvoll H, Funch GJ, Ostergaard S, Barkholt V, Ploug M. One-step 
affinity purification of recombinant urokinase-type plasminogen activator receptor 
using a synthetic peptide developed by combinatorial chemistry. Protein Expression 
and Purif. 2007; 52: 286-296.  
Jehanli A, Hough D. A Rapid Procedure for the Isolation of Human IgM Myeloma 
Proteins. J. Immunol. Meth. 1981; 44: 199-204. 
Jensena LB, Riisea E, Nielsenb LK, Dziegielb M, Fuggerc L, Engberga J. Efficient 
purification of unique antibodies using peptide affinity-matrix columns. J. Immunol. 
Meth. 2004; 284: 45-54. 
 160 
Johnson E, Miribel L, Arnaud P, Tsang KY. Purification of IgM monoclonal antibody 
from murine ascitic fluid by a two-step column chromatography procedure. Immunol. 
Lett. 1986/1987; 14: 159-165. 
Johnsson E, Andersson G, Lindahl G, Heden LO. Identification of the IgA-binding 
region in streptococcal protein Arp. J. Immunol. 153; 1994: 3557-3564. 
Jones CL, Georgiou GM, Fowler KJ, Wajngarten PI, Roberton DM. Purification of 
polymeric immunoglobulin from cell culture supernatants by affinity chromatography 
using secretory component. J. Immunol. Meth. 1987; 104: 237-243.  
Josic D, Lim YP. Analytical and Preparative Methods for Purification of Antibodies. 
Food Technol. Biotechnol. 2001; 39: 215-226. 
Josic D, Loster K, Kuhl R, Noll F, Reusch J. Purification of Monoclonal Antibodies 
by Hydroxylapatite HPLC and Size Exclusion HPLC. Biol. Chem. Hoppe-Seyler 
1991; 372: 149-156. 
Kaetzel CS. Polymeric Ig receptor: Defender of the fort or Trojan Horse? Current 
Biology 11; 2001: R35-R38. 
Kaplan H, Long BG, Young NM. Chemical properties of functional groups of 
immunoglobulins IgA, IgG2a, and IgM mouse myeloma proteins. Biochemistry, 
1980; 19: 2821-2827. 
Kaufmann DB, Hentsch ME, Baumbach GA, Buettner JA, Dadd CA, Huang PY, 
Hammond DJ, Carbonell RG. Affinity purification of fibrinogen using a ligand from a 
peptide library. Biotechnol. Bioeng. 2002; 77: 278-289. 
Kelley BD, Tannatt M, Magnusson R, Hagelberg S. James Booth1Development and 
Validation of an Affinity Chromatography Step Using a Peptide Ligand for cGMP 
Production of Factor VIII. Biotechnol. Bioeng. 2004; 87: 400-412. 
Knor S, Khrenov A, Laufer B, Benhida A, Grailly SC, Schwaab R, Oldenburg J, 
Beaufort N, Magdolen V, Saint-Remy JMR, Saenko EL, Hauser CAE, Kessler H. 
Efficient factor VIII affinity purification using a small synthetic ligand. J. Thromb. 
Haemost. 2008; 6: 470-477. 
Knudsen KL, Hansen MB, Henriksen LR, Andersen BK, Lihme A. Sulfone-Aromatic 
Ligands for Thiophilic Adsorption Chromatography: Purification of Human and 
Mouse lmmunoglobulins. Anal. Biochem. 1992; 201: 170-177. 
 161 
Knutson VP, Buck RA, Moreno RM. Purification of a murine monoclonal antibody of 
the IgM class. J. Immunol. Meth. 1991; 136: 151-157. 
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of 
predefined specificity. Nature 1975; 256: 495-497. 
Kornelia G. Emil von Behring: The Founder of Serum Therapy. 2001; 
http://nobelprize.org/nobel_prizes/medicine/articles/behring/index.html. 
Kramberger P, Peterka M, Boben J, Ravnikar M, Strancar A. Short monolithic 
columns-A breakthrough in purification and fast quantification of tomato mosaic 
virus. J. Chrom. A 2007; 1144: 143-149. 
Kramberger P, Petrovi N, Strancar A, Ravnikar M. Concentration of plant viruses 
using monolithic chromatographic supports. J. Virol. Meth. 2004; 120: 51-57.  
Kuyas C, Haeberli A, Walder P, Straub PW. Isolation of human fibrinogen and its 
derivatives by affinity chromatography on Gly-Pro-Arg-Pro-Lys-Fractogel. Thromb. 
Haemost. 1990; 63: 439-444.  
Labrou NE, Eliopoulos E, Clonis YD. Dye-affinity labelling of bovine heart 
mitochondrial malate dehydrogenase and study of the NADH-binding site. Biochem. 
J. 1996; 315: 687-693. 
Labrou NE, Eliopoulos E, Clonis YD. Molecular modelling for the design of 
chimaeric biomimetic dye–ligands and their interaction with bovine heart 
mitochondrial malate dehydrogenase. Biochem. J. 1996; 315: 695-703.  
Lam KS, Lebl M, Krchnak V. The ''one-bead-one-compound'' combinatorial library 
method. Chem. Rev. 1997; 97: 411-448. 
Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A New 
Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity. Nature. 
1991; 354: 82-84. 
Lan JCW, Ling TC, O'Sullivan DA, Lyddiatt A. Comparison of two matrices for 
selective recovery of C595 diabody fragment (dbFv) from Escherichia coli lysates. 
Process Biochemistry 2007; 42: 335-343. 
 162 
Lasonder E, Bloemhoff W, Welling GW. Interaction of lysozyme with synthetic anti-
lysozyme anti-body fragments studied by affinity chromatography surface Plasmon 
resonance. J. Chrom. A. 1994; 676: 91-98. 
Leinweber FC, Lubda D, Cabrera K, Tallarek U. Characterization of Silica-Based 
Monoliths with Bimodal Pore Size Distribution. Anal. Chem. 2002; 74: 2470-2477. 
Li PY, Lin B, Gerstenmaier J, Cinningham BT. A new method for label-free imaging 
of biomolecular interactions. Sens. Actuat. B 2004; 99: 6-13.  
Li R, Dowd V, Stewart DJ, Burton SJ, Lowe CR. Design, synthesis, and application 
of a protein A mimetic. Nat. Biotechnol. 1998; 16: 190-195. 
Lim PL. Isolation of Specific IgM Monoclonal Antibodies by Affinity 
Chromatography using Alkaline Buffers. Mol. Immunol. 1987; 24: 11-15. 
Limhe A, Hansen M, Olander M, Zafirakos E. Expanded bed adsorption in the 
purification of biomolecules. In: Desai MA.  (Ed) Downstream processing of proteins: 
methods and protocols. Humana Press, 2000. 
Lipinski CA. Samples in DMSO: What an end user needs to know LRIG, New Jersey 
2006. 
Liu FF, Dong XY, Wang T, Sun Y. Rational design of peptide ligand for affinity 
chromatography of tissue-type plasminogen activator by the combination of docking 
and molecular dynamics simulations. J. Chrom. A. 2007; 1175: 249-258. 
Lofas S, Johnsson B, Edstrom A, Hansson A, Lindquist G, Hillgren Rose-Marie M, 
Stigh L. Methods for site controlled coupling to carboxymethyl-dextran surfaces in 
surface plasmon resonance sensors, Biosens. Bioelectron. 1995; 10: 813-822.  
Lowe CR, Burton SJ, Burton NP, Alderton WK, Pitts JM, Thomas JA. Designer dyes 
biomimetic ligands for the purification of pharmaceutical proteins by affinity-
chromatography. Trends Biotechnol. 1992; 10: 442-448. 
Lowe CR, Lowe AR, Gupta G. New developments in affinity chromatography with 
potential application in the production of biopharmaceuticals. J. Biochem. Biophys. 
Meth. 2001; 49: 561-574. 
Lowe CR. Combinatorial approaches to affinity chromatography. Curr. Opin. Chem. 
Biol. 2001; 5: 248-256. 
 163 
Mahassni SH, Klapper DG, Hiskey RG. Purification of a Murine IgM Monoclonal 
Antibody. Hybridoma 2009; 28: 189-197. 
Makriyannis T, Clonis YD. Design and study of peptide-ligand affinity 
chromatography adsorbents: Application to the case of trypsin purification from 
bovine pancreas. Biotechnol. Bioeng. 1997; 53: 49-57. 
Mantzourani E, Laimou D, Matsoukas MT, Tselios T. Peptides as Therapeutic Agents 
or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases. 
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7: 294-306. 
Marino M, Campanile N,  Ippolito A, Scarallo A, Ruvo M, Fassina G, Peptides 98, 
Academia Kiado, Budapest, 1999, pp. 776. 
Maupetit J, Derreumaux P, Tufféry P. PEP-FOLD: an online resource for de novo 
peptide structure prediction. Nucleic Acids Res. 2009; 37: W498-503. 
McCarthy E, Vella G, Mhatre R, Lim YP. Rapid purification and monitoring of 
immunoglobulin M from ascites by perfusion ion-exchange chromatography. J. 
Chrom. A 1996; 743: 163-170. 
McMurry J, Begley TP. The organic chemistry of biological pathways. Roberts and 
Company, 2005. 
Morrill PR, Millington RB, Lowe CR. Imaging surface plasmon resonance system for 
screening affinity ligands. J Chrom. B Biomed Sci. Appl. 2003; 793: 229-251. 
Murray A, Sekowski M, Spencer DIR, Denton G, Price MR. Purification of 
monoclonal antibodies by epitope and mimotope affinity chromatography. J. Chrom. 
A. 1997; 782: 49-54. 
Murray A, Smith RG, Brady K, Williams S, Badley RA, Price MR. Generation and 
refinement of peptide mimetic ligands for paratope-specific purification of 
monoclonal antibodies. Anal. Biochem. 2001; 296: 9-17. 
Murray A, Spencer DIR, Missailidis S, Denton G, Price MR. Design of ligands for the 
purification of anti-MUC1 antibodies by peptide epitope affinity chromatography. J. 
Peptide Res. 1998; 52: 375-383. 
 164 
Musil LS, Baenziger JU. Cleavage of membrane secretory component to soluble 
secretory component occurs on the cell surface of rat hepatocyte monolayers. J. Cell 
Biol. 1987; 104: 1725-1733. 
Necina R, Amatschek A, Schallaun E, Schwinn H, Josic D, Jungbauer A. Peptide 
affinity chromatography of human clotting factor VIII Screening of the vWF-binding 
domain. J. Chrom. B 1998; 715: 191-201. 
Neoh SH, Gordon C, Potter A, Zola H. The purification of mouse monoclonal 
antibodies from ascitic fluid. J. Immunol. Meth. 1986; 91: 231-235. 
Nethery A, Raison RL, Smith SBE. Single-step purification of immunoglobulin M on 
Clq-Sepharose. J. Immunol. Meth. 1990; 126: 57-60. 
Nevens JR, Mallia AK, Wendt MW, Smith PK. Affinity chromatographic purification 
of immunoglobulin M antibodies utilizing immobilized mannan binding protein. J. 
Chrom. 1992; 597: 247-256. 
New World Encyclopedia; http://www.newworldencyclopedia.org/entry/Antibody. 
Newcombe AR, Cresswell C, Davies S, Watson K, Harris G, O'Donovan K, Francis 
R. Optimised affinity purification of polyclonal antibodies from hyperimmunised 
ovine serum using a synthetic Protein A adsorbent. J. Chromatogr. B. Biomed. Sci. 
Appl. 2005; 814: 209-215. 
Noppe W, Plieva FM, Galaev IY, Vanhoorelbeke K, Mattiasson B, Deckmyn H. 
Immobilised peptide displaying phages as affinity ligands Purification of lactoferrin 
from defatted milk. J. Chrom. A 2006; 1101: 79-85. 
Palanisamy UD, Hussain A, Iqbal S, Sproule K, Lowe CR. Design, synthesis and 
characterisation of affinity ligands for glycoproteins. J. Mol. Recognit. 1999; 12: 57-
66. 
Palanisamy UD, Winzor DJ, Lowe CR. Synthesis and evaluation of affinity 
adsorbents for glycoproteins: an artificial lectin. J. Chrom. B Biomed. Sci. Appl. 
2000; 746: 265-281. 
Palombo G, Falco SD, Tortora M, Cassani G, Fassina G. A synthetic ligand for IgA 
affinity purification. J. Mol. Recogn. 1998; 11: 243-246.  
 165 
Palombo G, Rossi M, Cassani G, Fassina G. Affinity purification of mouse 
monoclonal IgE using a protein A mimetic ligand (TG19318) immobilized on solid 
supports. J. Mol. Recogn. 1998; 11: 247-249. 
Palombo G, Verdoliva A, Fassina G. Affinity purification of immunoglobulin M 
using a novel synthetic ligand. J. Chrom. B 1998; 715: 137-145. 
Perkins SJ, Nealis AS, Sutton BJ, Feinstein A. Solution Structure of Human and 
Mouse Immunoglobulin M by Synchrotron X-ray Scattering and Molecular Graphics 
Modelling: A Possible Mechanism for Complement Activation.  J. Mol. Biol. 1991; 
221: 1345-1366. 
Pflegerl K, Podgornik A, Berger E, Jungbauer A. Direct Synthesis of Peptides on 
Convective Interaction Media Monolithic Columns for Affinity Chromatography. J. 
Comb. Chem. 2002; 4: 33-37. 
Pingali A, McGuinness B, Keshishian H, Jing FW, Varady L, Regnier F. Peptides as 
Affinity Surfaces for Protein Purification. J. Mol. Recognit.1996; 9: 426-432.  
Price MR, Hudecz F, Osullivan C, Baldwin RW, Edwards PM, Tendler SJB  
Immunological and Structural Features of The Protein Core of Human Polymorphic 
Epithelial Mucin. Mol. Immunol. 1990; 27: 795-802. 
Price MR, Sekowski M, Tendler SJ. Purification of anti-epithelial mucin monoclonal 
antibodies by epitope affinity chromatography. J. Immunol. Meth. 1991, 139, 83-90. 
Ray S, Mehta G, Srivastava S. Label-free detection techniques for protein 
microarrays: Prospects, merits and challenges. Proteomics 2010; 10: 731-748. 
Reed J, Reed TA. A Set of Constructed Type Spectra for the Practical Estimation of 
Peptide Secondary Structure from Circular Dichroism. Anal. Biochem. 1997; 254: 36-
40.  
Renou ENS, Gupta G, Young DS, Dear DV, Lowe CR. The design, synthesis and 
evaluation of affinity ligands for prion proteins. J. Mol. Recognit. 2004; 17: 248-261. 
Ribbeck K, Gorlich D. The permeability barriers of nuclear pore complexes appear to 
operate via hydrophobic exclusion. The EMBO Journal. 2002; 21: 2664-2671. 
Roche Applied Science. POROS Perfusion Chromatography Media. Biochemica No. 
1. 1996.  
 166 
Roe M, Norderhaug IN, Brandtzaeg P, Johansen Finn-Eirik. Fine Specificity of 
Ligand-Binding Domain 1 in the Polymeric Ig Receptor: Importance of the CDR2-
Containing Region for IgM Interaction.  J. Immunol. 1999; 162: 6046-6052. 
Roggenbuck D, Marx U, Kiessig ST, Schoenherr G, Jahn S, Porstmann T. Purification 
and immunochemical characterization of a natural human polyreactive monoclonal 
IgM antibody. J. Immunol. Meth. 1994; 167: 207-218.  
Roque ACA, Lowe CR, Taipa MA. Antibodies and Genetically Engineered Related 
Molecules: Production and Purification. Biotechnol. Prog. 2004; 20: 639-654. 
Roque ACA, Lowe CR. Advances and applications of de novo designed affinity 
ligands in proteomics. Biotechnol. Adv. 2006; 24: 17-26. 
Roque ACA, Silva CSO, Taipa MA. Affinity-based methodologies and ligands for 
antibody purification: Advances and perspectives, J. Chrom. A 2007; 1160: 44-55. 
Roque ACA, Taipa MA, Lowe CR. A new method for the screening of solid-phase 
combinatorial libraries for affinity chromatography. J. Mol. Recognit. 2004; 17: 262-
267. 
Roque ACA, Taipa MA, Lowe CR. An artificial protein L for the purification of 
immunoglobulins and Fab fragments by affinity chromatography. J. Chrom. A 2005a; 
1064: 157-167. 
Roque ACA, Taipa MA, Lowe CR. Synthesis and screening of a rationally designed 
combinatorial library of affinity ligands mimicking protein L from Peptostreptococcus 
magnus. J. Mol. Recognit. 2005b; 18: 213-224. 
Rudolf  MP, Vogel M, Kricek F, Ruf C, Zurcher AW, Reuschel R, Auer M, Miescher 
S, Stadler BM. Epitope-specific antibody response to IgE by mimotope immunization. 
J. Immunol. 1998; 160: 3315-3321.  
Rusmini F, Zhong Z, Feijen J. Protein Immobilization Strategies for Protein Biochips 
Biomacromolecules 2007; 8: 1775–1789. 
Sampson IA, Hodgen AN, Arthur IH. The Separation of Immunoglobulin M from 
Human Serum by Fast Protein Liquid Chromatography. J. Immunol. Meth. 1984; 69: 
9-15. 
 167 
Samra Z, Gadba R. Diagnosis of Mycoplasma Pneumoniae Infection by Specific IgM 
Antibodies Using a New Capture-Enzyme-Immunoassay. Eur. J. Epidemiol. 1993; 9: 
97-99. 
Sandin C, Linse S, Areschoug T, Woof JM, Reinholdt J, Lindahl G. Isolation and 
detection of human IgA using a streptococcal IgA-binding peptide. J. Immunol. 2002; 
169: 1357-1364. 
Sathish N, Vijayakumar TS, Abraham P, Sridharan G. Dengue Fever: Its Laboratory 
Diagnosis, with Special Emphasis on IgM Detection. Dengue Bulletin 2003; 27: 116-
125. 
Schaschke N, Garbrijelcic-Geiger D, Dominik A, Sommerhoff CP. Affinity 
Chromatography of Tryptases: Design, Synthesis and Characterization of a Novel 
Matrix-Bound Bivalent Inhibitor. Chem. BioChem. 2005; 6: 95-103. 
Schienfeld NS, Godwin JE. Intravenous Immunoglobulin. 2008; 
http://www.emedicine.com/med/topic3546.htm 
Shibuya N, Berry JE, Goldstein IJ. One-Step Purification of Murine IgM and Human 
α2-Macroglobulin by Affinity Chromatography on Immobilized Snowdrop Bulb 
Lectin. Arch. Biochem. Biophys. 1988; 267: 676-680. 
Skerra A, Schmidt TGM. Applications of a peptide ligand for streptavidin: the Strep-
tag. Biomol. Eng. 1999; 16: 79-86. 
Smrekar F, Ciringer M, Peterka M, Podgornik A, Strancar A. Purification and 
concentration of bacteriophage T4 using monolithic chromatographic supports. J. 
Chrom. B 2008; 861: 177-180. 
Socken DJ, Underdown BJ. Comparison of human, bovine and rabbit secretory 
component-immunoglobulin interactions. Immunochemistry 1978; 15: 499-506. 
Sousa F, Prazeres DMF, Queiroz JA. Affinity chromatography approaches to 
overcome the challenges of purifying plasmid DNA Trends Biotechnol. 2008; 26, 
518-525.  
Sproule K, Morrill P, Pearson JC, Burton SJ, Hejnaes KR, Valore H, Ludvigsen S, 
Lowe CR. New strategy for the design of ligands for the purification of 
pharmaceutical proteins by affinity chromatography. J. Chromatogr. B 2000; 740: 17-
33. 
 168 
Sproule K, Winzor D, Christensen J, Mollerup I. Rational combinatorial chemistry-
based selection, synthesis and evaluation of an affinity adsorbent for recombinant 
human clotting factor VII. J. Chrom. B Biomed. Sci. Appl. 2002; 774: 1-15. 
Stanker LH, Vanderlaan M, Juarez-Salinas H. One-Step Purification of Mouse 
Monoclonal Antibodies from Ascites Fluid by Hydroxylapatite Chromatography.  J. 
Immunol. Meth. 1985; 76: 157-169. 
Starncar A, Koselj P, Schwinn H, Josic D. Application of Compact Porous Disks for 
Fast Separations of Biopolymers and In-Process Control in Biotechnology. Anal. 
Chem. 1996; 68: 3483-3488. 
Strancar A, Barut M, Podgornik A, Koselj P, Schwinn H, Raspor P. Application of 
compact poros tubes for preparative isolation of clotting factor VIII from human 
plasma. J. Chrom. A 1997; 760: 117-123. 
Sun Shih-Wen, Lin Yi-Cheng, Weng Yih-Ming, Chen Min-Jane. Efficiency 
improvements on ninhydrin method for amino acid quantification. J. Food Compos. 
Anal. 2006; 19: 112-117. 
Tatum AH. Large scale recovery of biologically active IgM (95% pure) from human 
plasma obtained by therapeutic plasmapheresis. J. Immunol. Meth. 1993; 158: 1-4. 
Teng SF, Sproule K, Husain A, Lowe CR. Affinity chromatography on immobilized 
biomimetic Q ligands synthesis, immobilization and chromatographic assessment of 
an immunoglobulin G-binding ligand. J. Chrom. B Biomed. Sci. Appl. 2000; 740: 1-
15. 
Teng SF, Sproule K, Hussain A, Lowe CR. A strategy for the generation of 
biomimetic ligands for affinity chromatography Combinatorial synthesis and 
biological evaluation of an IgG binding ligand. J. Mol. Recognit. 1999; 12: 67-75. 
Thiele C, Fahrenholz F. Photocleavable biotinylated ligands for affinity 
chromatography. J. Anal. Biochem. 1994; 218: 330-337. 
Thomson S. Small-Molecule-Protein Conjugation Procedures In: Decker J, Reischl U, 
editors. Molecular diagnosis of infectious diseases. Humana Press, 2005.  
Tornoe I, Titlestad IL, Kejling K, Erb K, Ditzel HJ, Jensenius JC. Pilot scale 
purification of human monoclonal IgM (COU-1) for clinical trials. J. Immunol. Meth. 
1997; 205: 11-17.  
 169 
Tugyi R, Uray K, Iván D,
 
Fellinger E, Perkins A, Hudecz F. Partial D-amino acid 
substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 
epitope peptide. Proc. Natl. Acad. Sci. 2005; 102: 413-418. 
Turner MW. Structure and Function of Immunoglobulins. In: Glynn LE, Steward 
MW, editors. Structure and Function of Antibodies. Wiley; London; 1981. 
Underdown BJ, Switzer I, Jackson GD. Rat secretory component binds poorly to 
rodent IgM. J. Immunol. 1992; 149: 487-491. 
Urthaler J, Schlegl R, Podgornik A, Strancar A, Jungbauer A, Necina R. Application 
of monoliths for plasmid DNA purification Development and transfer to production. 
J. Chrom. A 2005; 1065: 93-106.  
Vene SL. Diagnosis of Rickettsial Infections in Swedish Patients: Detection of 
Specific IgM.  Eur. J. Epidemiol. 1989; 5: 436-437.  
Verdoliva A, Basile G, Fassina G. Affinity purification of immunoglobulins from 
chicken egg yolk using a new synthetic ligand. J. Chrom. B 2000; 749: 233-242.  
Verdoliva A, Cassani G, Fassina G. Affinity purification of polyclonal antibodies 
using immobilized multimeric peptides.  J. Chrom. B Biomed. Appl. 1995; 664: 175-
183.  
Verdoliva A, Marasco D, Capua AD, Saporito A, Bellofiore P, Manfredi V, 
Fattorusso R, Pedone C, Ruvo M. A new ligand for immunoglobulin G subdomains 
by screening of a synthetic peptide library. Chembiochem. 2005; 6: 1242-1253. 
Verdoliva A, Pannone F, Rossi M, Catello S, Manfredi V. Affinity purification of 
polyclonal antibodies using a new all-D synthetic peptide ligand: comparison with 
protein A and protein G. J. Immunol. Meth. 2002; 271: 77-88. 
Vlakh E, Ostryanina N, Jungbauer A, Tennikova T. Use of monolithic sorbents 
modified by directly synthesized peptides for affinity separation of recombinant tissue 
plasminogen activator (t-Pa). J. Biotech. 2004; 107: 275-284. 
Volkov VV, Lapuk VA, Kayushina RL, Shtykova EV, Yu E, Malfois VM, Svergun 
DI. Low-resolution structure of immunoglobulins IgG, IgM and rheumatoid factor 
IgM-RF from solution X-ray scattering data. J. Appl. Cryst. 2003; 36: 503-508. 
 170 
Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, 
Hermann R, Thiede A, Wilhelm M, Rückle-Lanz H, Reindl L, Müller-Hermelink HK. 
Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human 
monoclonal antibody SC-1: first clinical and histopathological results. Oncol. Rep. 
1998; 5: 549-552.  
Wang G,  De J,  Schoeniger JS, Roe DC, Carbonell RG. A hexamer peptide ligand 
that binds selectively to staphylococcal enterotoxin B: isolation from a solid phase 
combinatorial library.  J. Pept. Res. 2004; 64: 51-64. 
Weimer BC, Walsh MK, Wang X. Influence of a poly-ethylene glycol spacer on 
antigen capture by immobilized antibodies. J. Biochem. Biophys. Meth. 2000; 45: 
211-219. 
Welling GW, Geurts T, Gorkum JV, Damhof RA, Drijfhout JW. Synthetic antibody 
fragment as a ligand in immunoaffinity chromatography. J. Chrom. 1990; 512: 337-
343. 
Wichman A, Borg H. Purification of Human Immunoglobulin M by Affinity 
Chromatography on Protamine-Sepharose. Biochimica et Biophysica Acta 1977; 490: 
363-369. 
Wieland WH, Orzaez D, Lammers A, Parmentier HK, Verstegen MW, Schots A. A 
functional polymeric immunoglobulin receptor in chicken (Gallus gallus) indicates 
ancient role of secretory IgA in mucosal immunity. Biochem. J. 2004; 380: 669-676. 
Williams SL, Eccleston ME, Slater NKH. Affinity Capture of a Biotinylated 
Retrovirus on Macroporous Monolithic Adsorbents: Towards a Rapid Single-Step 
Purification Process. Biotechnol. Bioeng. 2005; 89: 783-787.  
Wittilin S, Rçsel J, Stover DR. One-step purification of Cathepsin-D by affinity 
chromatography using immobilized propeptide sequences. Eur. J. Biochem. 1998; 
252: 530-536. 
Wobbe L, Zimmermann D, Wibbrock M, Urman S, Sewald K, Malesevic M, Sewald 
N. Integrin α5β1: a new purification strategy based on immobilized peptides. J. Pep. 
Res. 2006, 66 (Suppl. 1): 22-29. 
 171 
Wong DWS, Robertson GH, Tillin SJ, Wong C. Identifying peptide ligands for barley 
α-amylase1 using combinatorial phage display libraries. J. Agr. Food Chem. 1998, 46; 
3852-3857. 
Xie S, Allington RW, Svec F, Frechet JMJ. Rapid reversed-phase separation of 
proteins and peptides using optimized „moulded‟ monolithic poly(styrene–co-
divinylbenzene) columns.  J. Chrom. A 1999; 865: 169-174. 
Yang H, Gurgel PV, Carbonell RGJ. Hexamer Peptide Affinity Resins that Bind the 
Fc Region of Human Immunoglobulin G. Peptide Res. 2005; 66: 120-137. 
Yang H, Gurgel PV, Carbonell RGJ. Purification of human Immunoglobin-G via Fc-
specific small peptide ligand affinity chromatography. J. Chrom. A. 2009; 1216: 910-
918. 
Yang Y, Chase HA, Liu G. Selection of affinity ligands for protein purification from 
proteolytic digests. Biotechnol. Tech. 1998; 12: 245-251. 
Yao ZJ, Kao MCC, Loh KC, Chung MCM. Antibody against branched epitope as an 
affinity ligand to separate the parent protein. J. Chrom. A 1994; 679: 190-194. 
Yu HQ, Dong XY, Sun Y. Affinity Chromatography of Insulin with a Heptapeptide 
Ligand Selected from Phage Display Library. Chromatographia 2004; 60: 379-383.  
Yu S, Geng J, Zhou P, Wang J, Chen X, Hu J. New hydroxyapatite monolithic 
column for DNA extraction and its application in the purification of Bacillus subtilis 
crude lysate. J. Chrom. A 2008; 1183: 29-37. 
Yu X, Xu D, Cheng Q. Label-free detection methods for protein microarrays. 
Proteomics 2006; 6: 5493-5503. 
Zimmerman SE, French ML, Allen SD, Wilson E, Kohler RB. Immunoglobulin M 





LIST OF PUBLICATIONS AND PRESENTATIONS 
1. S. Gautam and Kai-Chee Loh (2010) Immunoglobulin-M Purification- 
Challenges and Perspectives, submitted to Biotechnology Advances.  
2. S. Gautam and Kai-Chee Loh (2010) Human pIgR Mimetic Peptidic Ligand for 
Affinity Purification of IgM: Ligand Design and Binding Mechanism, submitted 
to Journal of Molecular Recognition.  
3. S. Gautam and Kai-Chee Loh (2010) Binding Characteristics of Polymeric 
Immunoglobulin Receptor-D1 Based Affinity Ligand for IgM Purification, 
submitted to Journal of Chromatography B.  
4. S. Gautam and Kai-Chee Loh (2010) Immobilization of Hydrophobic Peptidic 
Ligands to Hydrophilic Chromatographic Matrices, Analytical Biochemistry (in 
preparation).  
5. Rebecca L. Rich,  Giuseppe A. Papalia, Peter J. Flynn et al., S. Gautam (2009) 
A Global Benchmark Study using Affinity-based Biosensors, Analytical 
Biochemistry.  
6. S. Gautam and Kai-Chee Loh (2009) Strategies for the Immobilization of 
Hydrophobic Affinity Peptidic Ligands to Hydrophilic Surfaces, presented at the 
101st Annual AICHE Meeting, Nov 8-11, Nashville, TN, USA. 
7. S. Gautam and Kai-Chee Loh (2008) Polymeric Immunoglobulin Receptor-D1 
Based Affinity Ligand for IgM Purification, presented at the 100th Annual 
AICHE Meeting, Nov 16-21, Philadelphia, USA. 
8. S. Gautam and Kai-Chee Loh (2007) A Search for Affinity Ligands for IgM 
purification presented at the 99th Annual AICHE Meeting, Nov 4-9, Salt Lake 
City, Utah, USA. 
